Covid-19
Literature Update



A CURATED SELECTION AND OVERVIEW OF COVID-19 PUBLICATIONS

Update August 24 - August 30, 2020, **Dr. Peter J. Lansberg MD, PhD**

Weekly COVID-19 Literature Update
will keep you up-to-date with all recent PubMed publications
categorized by relevant topics

COVID-19 publications - Week 35 2020
792 Publications

PubMed based Covid-19 weekly literature update

For those interested in receiving weekly updates
click here

For questions and requests for topics to add send an e-mail
lansberg@gmail.com

Reliable on-line resources for Covid 19

WHO
Daily dashbord
Country Guidance
Travel restriction
Covid Counter
Covid forcasts
CDC
AHA
ESC
EMEA
Evidence EPPI
Wikipedia
Cardionerds - **COVID-19**
Genomic epidemiology
Oxygenation Ventilation toolkit

Cochrane
BMJ
The Lancet
New England Journal of Medicine
JAMA
Cell
Science
Oxford Universtiy Press
Cambridge Univeristy Press
Springer Nature
Elsevier
Wiley
PLOS
LitCovid NIH-NLM
SSRN (Pre-prints)

German (ICU) bed capacity

COVID reference (Steinhauser Verlag)

COVID-19 Projections tracker

AAN - Neurology resources

COVID-19 resources (Harvard)

COVID-19 resources (McMasters)

COVID-19 resources (NHLBI)

COVID-19 resources (MEDSCAPE)

COVID-19 Diabetes (JDRF)

COVID-19 TELEMEDICINE (BMJ)

Global Causes of death (Johns Hopkins)

COVID-19 calculators (Medscap)

Guidelines

NICE Guidelines Covid-19

Korean CDC Covid-19 guidelines

Flattening the curve - Korea

IDSA COVID-19 Guidelines

Airway Management Clinical Practice Guidelines (SIAARTI/EAMS, 2020)

ESICM Ventilation Guidelines

Performing Procedures on Patients With Known or Suspected COVID-19 (ASA, 2020)

OSHA Guidance on Preparing the Workplace for COVID-19 (2020)

Policy for Sterilizers, Disinfectant Devices, and Air Purifiers (FDA, 2020)

Breast Cancer Patient Triage Guidelines (CPBCC, 2020)

clinical guidance for adult Belgian patients with suspected or confirmed COVID-19

National Covid-19 Testing Action Plan (Rockefeller Foundation)

ASE issues Echo-cardiography guidance

Trials & Registries

CAPACITY European registry COVID 19 patients

WHO launches global megatrial

FDA launches Convalescent plasma trial

Lets Beat Covid-19 Survey to help plan hospital services

COVID IBD registry

Google mobility reports per country COVID 19

World's largest trial of potential coronavirus treatments rolled out across the UK

Pregnancy Registry (US)

ICNARC report on COVID-19 in critical care - NHS April 24

COVID-19 Human Genetics - Biobanks

COVID19 settings of transmission database

Mainstream Media

New York Times - Corona update

‘Here We Go Again’: A Second Virus Wave Grips Spain
C.D.C. Tells States How to Prepare for Covid-19 Vaccine by Early November
inexpensive steroid drugs can help critically sick people survive Covid-19.
‘Brace Yourself’: How Doctors in Italy Responded to Coronavirus
A New Coronavirus Adviser Roils the White House With Unorthodox Ideas
New Covid-19 Outbreaks Test South Korea’s Strategy
Coronavirus Vaccine Tracker
Coronavirus Drug and Treatment Tracker

Washington Post - Corona update

Coronavirus updates
Britain is promoting strict coronavirus quarantines but has issued hardly any fines
Universities can’t use privacy laws to withhold data on coronavirus outbreaks,
What I learned about contact tracing when the tracers came for me
Fauci debunks coronavirus death misinformation promoted by Trump
It’s time to talk about how toilets may be spreading covid-19
Students in France return to schools, even as covid-19 cases soar

Guardian - Corona update

Two types of steroid found to save lives of some Covid-19 patients
Claims of 99% accuracy for UK Covid antibody test ‘cannot be trusted’
Covid-19: ‘possible’ Oxford vaccine data will be put before regulators this year
UK to give emergency approval to any Covid vaccine breakthrough
Covid-19 ethics: digital contact tracing (part 1) – podcast
Nasal swab followed by antibody test may catch incorrect Covid-19 diagnoses

Key Articles

1. **Meta-analysis of Effectiveness of Statins in Patients with Severe COVID-19.** The American Journal of Cardiology 2020; Kow CS, Hasan SS.
   In this meta-analysis 4 studies, out of the 274 potential studies, were used to probe the harms or benefits of statins in Covid-19 infected patients. The pooled analysis of 8 990 patients included in the analysis showed a significantly reduced risk for developing fatal or severe disease compared to no statin use; HR: 0.70 (0.53-0.94). due to the observational nature of these retrospective studies, properly designed prospective studies are warranted to confirm these promising findings.

2. **Two metres or one: what is the evidence for physical distancing in covid-19?** BMJ 2020; 370:m3223Jones NR, Qureshi ZU, Temple RJ ***et al.***
   http://www.ncbi.nlm.nih.gov/pubmed/?term=32843355
   The authors question the validity of the globally advised uniform 2-meter distance rule to prevent spreading of the COVID-19 viral infection. They show that other factors such as ventilation, force of emission, and exposure time are unaccounted for but are indeed important risk modifiers. They present a more

nuanced and personalized distancing model that incorporates factors that affect spreading, and display this an easy to understand colored graph, depicting circumstances with low (green), medium (yellow), and high (red) risk for contamination from asymptomatic people.

3. **Emerging Pandemic Diseases: How We Got to COVID-19.** Cell 2020; Morens DM, Fauci AS. http://www.ncbi.nlm.nih.gov/pubmed/?term=32846157 Both authors, dr. Fauci and dr. Morens, are icons of the COVID-19 pandemic, working at the National Institute of Allergy & Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. Their 16-page review published in Cell provides an excellent summary of not only the origin and the pandemic consequences of the MERS-CoV2 virus but that new viral outbreaks, like the COVID-19, are very likely in the future. They reflect on past global outbreaks with devastating consequences; what was learned then as well as a detailed review on what we have learned this time. They underline the importance of using rigorous science to combat MERS-CoV2 but also warn us that humans need to strive for a more thoughtful, creative harmonious relationship with nature because if we fail to do so, new diseases will emerge with potentially similar or even worse consequences as the COVID-19 disease we are coming to grips with in 2020.

4. **SARS-CoV-2 Infectivity and Neurological Targets in the Brain.** Cell. Mol. Neurobiol. 2020; Lukiw WJ, Pogue A, Hill JM. http://www.ncbi.nlm.nih.gov/pubmed/?term=32840758

5. **Cardiogenic Shock and Hyperinflammatory Syndrome in Young Males with COVID-19.** Circ Heart Fail 2020; Chau VQ, Giustino G, Mahmood K ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32844662

6. **Unpuzzling COVID-19 Prothrombotic State: Are Preexisting Thrombophilic Risk Profiles Responsible for Heterogenous Thrombotic Events?** Clin. Appl. Thromb. Hemost. 2020; 26:1076029620952884Burlacu A, Genovesi S, Popa IV, Crisan-Dabija R. http://www.ncbi.nlm.nih.gov/pubmed/?term=32842771

7. **Comparison of qualitative and quantitative analyses of COVID-19 clinical samples.** Clin Chim Acta 2020; Dang Y, Liu N, Tan C ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32858058

8. **Patient Characteristics and Outcomes of 11,721 Patients with COVID19 Hospitalized Across the United States.** Clin Infect Dis 2020; Fried MW, Crawford JM, Mospan AR ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32856034

9. **Finding the Best Antiviral Regimen for COVID-19: A Double-Center Retrospective Cohort Study of 207 Cases in Hunan, China.** Dose Response 2020; 18:1559325820949740Hu X, Hu C, Zhong P ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32855629

10. **Renin-Angiotensin System and Coronavirus Disease 2019: A Narrative Review.** Front Cardiovasc Med 2020; 7:143Mascolo A, Scavone C, Rafaniello C ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32850989

11. **Incidence of Venous Thromboembolism in Hospitalized Coronavirus Disease 2019 Patients: A Systematic Review and Meta-Analysis.** Front Cardiovasc Med 2020; 7:151Zhang C, Shen L, Le KJ ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32850990

12. **Combination Therapy Using Inhalable GapmeR and Recombinant ACE2 for COVID-19.** Front Mol Biosci 2020; 7:197Verma NK, Fazil M, Duggan SP, Kelleher D. http://www.ncbi.nlm.nih.gov/pubmed/?term=32850978

13. **Coronavirus Disease 2019 (COVID-19) in Children: Prevalence, Diagnosis, Clinical Symptoms, and Treatment.** Int. J. Gen. Med. 2020; 13:477-482Zare-Zardini H, Soltaninejad H, Ferdosian F ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32848446

14. **Anticoagulation, Mortality, Bleeding and Pathology Among Patients Hospitalized with COVID-19: A Single Health System Study.** J Am Coll Cardiol 2020; Nadkarni GN, Lala A, Bagiella E ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32860872

15. **Clinical features of neonates born to mothers with coronavirus disease-2019: A systematic review of 105 neonates.** J Microbiol Immunol Infect 2020; Chi H, Chiu NC, Tai YL ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32847748

Basic Science (31 articles)

1. **Establishment and validation of a drug-target microarray for SARS-CoV-2.** Biochem. Biophys. Res. Commun. 2020; 530:4-9Chen P, Zeng Z, Du H. http://www.ncbi.nlm.nih.gov/pubmed/?term=32828312
2. **Virus-Receptor Interactions of Glycosylated SARS-CoV-2 Spike and Human ACE2 Receptor.** Cell Host Microbe 2020; Zhao P, Praissman JL, Grant OC ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32841605
3. **Nano-Vesicle (Mis)Communication in Senescence-Related Pathologies.** Cells 2020; 9Saheera S, Potnuri AG, Krishnamurthy P. http://www.ncbi.nlm.nih.gov/pubmed/?term=32859053
4. **COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing.** Clin Infect Dis 2020; To KK, Hung IF, Ip JD ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32840608
5. **The Antiviral and Antimalarial Drug Repurposing in Quest of Chemotherapeutics to Combat COVID-19 Utilizing Structure-Based Molecular Docking.** Comb. Chem. High Throughput Screen. 2020; Nandi S, Kumar M, Saxena M, Saxena AK. http://www.ncbi.nlm.nih.gov/pubmed/?term=32838713

6. **Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2.** Embo j 2020:e106275Klemm T, Ebert G, Calleja DJ ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32845033
7. **Viroinformatics approach to explore the inhibitory mechanism of existing drugs repurposed to fight against COVID-19.** Eur. J. Pharmacol. 2020:173496Bibi N, Gul S, Ali J, Kamal MA. http://www.ncbi.nlm.nih.gov/pubmed/?term=32841640
8. **Food proteins are a potential resource for mining cathepsin L inhibitory drugs to combat SARS-CoV-2.** Eur. J. Pharmacol. 2020:173499Madadlou A. http://www.ncbi.nlm.nih.gov/pubmed/?term=32841639
9. **Construction of SARS-CoV-2 Virus-Like Particles by Mammalian Expression System.** Front Bioeng Biotechnol 2020; 8:862Xu R, Shi M, Li J ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32850726
10. **Functional Pangenome Analysis Shows Key Features of E Protein Are Preserved in SARS and SARS-CoV-2.** Front Cell Infect Microbiol 2020; 10:405Alam I, Kamau AA, Kulmanov M ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32850499
11. **Genetic Analysis of the Coronavirus SARS-CoV-2 Host Protease TMPRSS2 in Different Populations.** Front Genet 2020; 11:872Russo R, Andolfo I, Lasorsa VA ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32849840
12. **Combating COVID-19: MVA Vector Vaccines Applied to the Respiratory Tract as Promising Approach Toward Protective Immunity in the Lung.** Front. Immunol. 2020; 11:1959Förster R, Fleige H, Sutter G. http://www.ncbi.nlm.nih.gov/pubmed/?term=32849655
13. **Crosstalk Between Platelets and Microbial Pathogens.** Front. Immunol. 2020; 11:1962Li C, Li J, Ni H. http://www.ncbi.nlm.nih.gov/pubmed/?term=32849656
14. **Understanding the Pathophysiology of COVID-19: Could the Contact System Be the Key?** Front. Immunol. 2020; 11:2014Meini S, Zanichelli A, Sbrojavacca R ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32849666
15. **CoronaVR: A Computational Resource and Analysis of Epitopes and Therapeutics for Severe Acute Respiratory Syndrome Coronavirus-2.** Front. Microbiol. 2020; 11:1858Gupta AK, Khan MS, Choudhury S ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32849449
16. **A survey of genetic variants in SARS-CoV-2 interacting domains of ACE2, TMPRSS2 and TLR3/7/8 across populations.** Infect Genet Evol 2020:104507Lee IH, Lee JW, Kong SW. http://www.ncbi.nlm.nih.gov/pubmed/?term=32858233
17. **Chemokine receptor gene polymorphisms and COVID-19: Could knowledge gained from HIV/AIDS be important?** Infect Genet Evol 2020:104512Mehlotra RK. http://www.ncbi.nlm.nih.gov/pubmed/?term=32858232
18. **Insights into the structural and dynamical changes of spike glycoprotein mutations associated with SARS-CoV-2 host receptor binding.** J Biomol Struct Dyn 2020:1-13Ahamad S, Kanipakam H, Gupta D. http://www.ncbi.nlm.nih.gov/pubmed/?term=32851910
19. **In silico screening of hundred phytocompounds of ten medicinal plants as potential inhibitors of nucleocapsid phosphoprotein of COVID-19: an approach to prevent virus assembly.** J Biomol Struct Dyn 2020:1-18Rolta R, Yadav R, Salaria D ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32851912
20. **Human angiotensin-converting enzyme 2 transgenic mice infected with SARS-CoV-2 develop severe and fatal respiratory disease.** JCI Insight 2020; Golden JW, Cline CR, Zeng X ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32841215

21. **COVID-19: Pathophysiology, treatment options, nanotechnology approaches, and research agenda to combating the SARS-CoV2 pandemic.** Life Sci 2020:118336Bhavana V, Thakor P, Singh SB, Mehra NK. http://www.ncbi.nlm.nih.gov/pubmed/?term=32846164
22. **Compartmentalized Replication of SARS-Cov-2 in Upper vs. Lower Respiratory Tract Assessed by Whole Genome Quasispecies Analysis.** Microorganisms 2020; 8Rueca M, Bartolini B, Gruber CEM ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32858978
23. **Drug Discovery by Drug Repurposing: Combating COVID-19 in the 21st Century.** Mini Rev. Med. Chem. 2020; Sanghai N, Shafiq K, Tranmer GK. http://www.ncbi.nlm.nih.gov/pubmed/?term=32838716
24. **In Silico Identification of Potential Natural Product Inhibitors of Human Proteases Key to SARS-CoV-2 Infection.** Molecules 2020; 25Vivek-Ananth RP, Rana A, Rajan N ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32842606
25. **Extending the identification of structural features responsible for anti-SARS-CoV activity of peptide-type compounds using QSAR modelling.** SAR QSAR Environ. Res. 2020:1-12Masand VH, Rastija V, Patil MK ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32847369
26. **Viral, host and environmental factors that favor anthropozoonotic spillover of coronaviruses: An opinionated review, focusing on SARS-CoV, MERS-CoV and SARS-CoV-2.** Sci Total Environ 2020; 750:141483da Silva PG, Mesquita JR, de São José Nascimento M, Ferreira VAM. http://www.ncbi.nlm.nih.gov/pubmed/?term=32829257
27. **Single-cell RNA expression profiling of ACE2 and TMPRSS2 in the human trophectoderm and placenta.** Ultrasound Obstet Gynecol 2020; Cui D, Liu Y, Jiang X ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32851697
28. **Characterization of accessory genes in coronavirus genomes.** Virol J 2020; 17:131Michel CJ, Mayer C, Poch O, Thompson JD. http://www.ncbi.nlm.nih.gov/pubmed/?term=32854725
29. **Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development.** Virus Res. 2020:198141Samrat SK, Tharappel AM, Li Z, Li H. http://www.ncbi.nlm.nih.gov/pubmed/?term=32846196
30. **Viral Vectors Applied for RNAi-Based Antiviral Therapy.** Viruses 2020; 12Lundstrom K. http://www.ncbi.nlm.nih.gov/pubmed/?term=32842491
31. **Optimization Rules for SARS-CoV-2 M(pro) Antivirals: Ensemble Docking and Exploration of the Coronavirus Protease Active Site.** Viruses 2020; 12Stoddard SV, Stoddard SD, Oelkers BK ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32859008

Biomarkers - Genetics (70 articles)

1. **Red Blood Cell Distribution Is a Significant Predictor of Severe Illness in Coronavirus Disease 2019.** Acta Haematol. 2020:1-5Lippi G, Henry BM, Sanchis-Gomar F. http://www.ncbi.nlm.nih.gov/pubmed/?term=32841949
2. **Early coagulation tests predict risk stratification and prognosis of COVID-19.** Aging (Albany NY) 2020; 12Luo L, Xu M, Du M ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32860672
3. **Systematic review with meta-analysis: SARS-CoV-2 stool testing and the potential for faecal-oral transmission.** Aliment. Pharmacol. Ther. 2020; van Doorn

AS, Meijer B, Frampton CMA ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32852082

4. **COVID-19 Testing.** Am J Clin Pathol 2020; Brooks ZC, Das S. http://www.ncbi.nlm.nih.gov/pubmed/?term=32857119
5. **Utility of D-dimer as a Prognostic Factor in SARS CoV2 Infection: A Review.** Am J Med Case Rep 2020; 8:337-340Kariyanna PT, Aurora L, Jayarangaiah A ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32851129
6. **The Importance of Redox Status in the Frame of Lifestyle Approaches and the Genetics of the Lung Innate Immune Molecules, SP-A1 and SP-A2, on Differential Outcomes of COVID-19 Infection.** Antioxidants (Basel) 2020; 9Tekos F, Skaperda Z, Goutzourelas N ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32854247
7. **The Role of Anxiety and Cortisol in Outcomes of Patients With Covid-19.** Basic Clin Neurosci 2020; 11:179-184Ramezani M, Simani L, Karimialavijeh E ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32855777
8. **ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19.** Biomed. Pharmacother. 2020; 131:110678Dong M, Zhang J, Ma X ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32861070
9. **Rapid establishment of a COVID-19 perinatal biorepository: early lessons from the first 100 women enrolled.** BMC Med. Res. Methodol. 2020; 20:215Shook LL, Shui JE, Boatin AA ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32842979
10. **Pre-procedural screening for COVID-19 with nasopharyngeal polymerase chain reaction testing.** Br J Anaesth 2020; Gershengorn HB, Warde PR, Nguyen DM ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32859362
11. **High clinical performance and quantitative assessment of antibody kinetics using a dual recognition assay for the detection of SARS-CoV-2 IgM and IgG antibodies.** Clin. Biochem. 2020; Mairesse A, Favresse J, Eucher C ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32858061
12. **Results of the first pilot external quality assessment (EQA) scheme for anti-SARS-CoV2-antibody testing.** Clin Chem Lab Med 2020; Haselmann V, Özçürümez MK, Klawonn F ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32853163
13. **SARS-CoV-2 serosurvey in health care workers of the Veneto Region.** Clin Chem Lab Med 2020; Plebani M, Padoan A, Fedeli U ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32845861
14. **Comparison of qualitative and quantitative analyses of COVID-19 clinical samples.** Clin Chim Acta 2020; Dang Y, Liu N, Tan C ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32858058
15. **Using Serologic Testing to Assess the Effectiveness of Outbreak Control Efforts, Serial PCR Testing, and Cohorting of Positive SARS-CoV-2 Patients in a Skilled Nursing Facility.** Clin Infect Dis 2020; Dora AV, Winnett A, Fulcher JA ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32857830
16. **SARS-CoV-2 RNA in serum as predictor of severe outcome in COVID-19: a retrospective cohort study.** Clin Infect Dis 2020; Hagman K, Hedenstierna M, Gille-Johnson P ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32856036
17. **COVID-19 patients in earlier stages exhaled millions of SARS-CoV-2 per hour.** Clin Infect Dis 2020; Ma J, Qi X, Chen H ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32857833

18. **Viral dynamics and immune correlates of COVID-19 disease severity.** Clin Infect Dis 2020; Young BE, Ong SWX, Ng LFP ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32856707
19. **High levels of anti-SSA/Ro antibodies in COVID-19 patients with severe respiratory failure: a case-based review : High levels of anti-SSA/Ro antibodies in COVID-19.** Clin Rheumatol 2020; Fujii H, Tsuji T, Yuba T ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32844364
20. **Predictive value of neutrophil to lymphocyte and platelet to lymphocyte ratio in COVID-19.** Crit Care 2020; 24:532Zhu S, Dong L, Cai W. http://www.ncbi.nlm.nih.gov/pubmed/?term=32859254
21. **Positive Chest CT Features in Patients With COVID-19 Pneumonia and Negative Real-Time Polymerase Chain Reaction Test.** Cureus 2020; 12:e9942Pakdemirli E, Mandalia U, Monib S. http://www.ncbi.nlm.nih.gov/pubmed/?term=32850265
22. **J-shaped Association Between Fasting Blood Glucose Levels and COVID-19 Severity in Patients without Diabetes.** Diabetes Res Clin Pract 2020:108381Zhu B, Jin S, Wu L ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32853687
23. **Clinical, immunological and virological characterization of COVID-19 patients that test re-positive for SARS-CoV-2 by RT-PCR.** EBioMedicine 2020; 59:102960Lu J, Peng J, Xiong Q ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32853988
24. **Monocyte activation in systemic Covid-19 infection: Assay and rationale.** EBioMedicine 2020; 59:102964Martinez FO, Combes TW, Orsenigo F, Gordon S. http://www.ncbi.nlm.nih.gov/pubmed/?term=32861199
25. **Antibody Profiles According to Mild or Severe SARS-CoV-2 Infection, Atlanta, Georgia, USA, 2020.** Emerg Infect Dis 2020; 26Hu WT, Howell JC, Ozturk T ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32857691
26. **Pooling Upper Respiratory Specimens for Rapid Mass Screening of COVID-19 by Real-Time RT-PCR.** Emerg Infect Dis 2020; 26Kim SY, Lee J, Sung H ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32844739
27. **Functional mapping of B-cell linear epitopes of SARS-CoV-2 in COVID-19 convalescent population.** Emerg Microbes Infect 2020:1-34Yi Z, Ling Y, Zhang X ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32844713
28. **Fasting Plasma Glucose Level Independently Predicts the Mortality of Patients with Coronavirus Disease 2019 Infection: A Multicenter, Retrospective Cohort Study.** Endocrinol Metab (Seoul) 2020; Chang MC, Hwang JM, Jeon JH ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32842719
29. **Children account for a small proportion of diagnoses of SARS-CoV-2 infection and do not exhibit greater viral loads than adults.** Eur J Clin Microbiol Infect Dis 2020; Colson P, Tissot-Dupont H, Morand A ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32845413
30. **The Diagnostic Methods in the COVID-19 Pandemic, Today and in the Future.** Expert Rev Mol Diagn 2020; Wu SY, Yau HS, Yu MY ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32845192
31. **Severity Detection for the Coronavirus Disease 2019 (COVID-19) Patients Using a Machine Learning Model Based on the Blood and Urine Tests.** Front Cell Dev Biol 2020; 8:683Yao H, Zhang N, Zhang R ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32850809

32. **Value of Viral Nucleic Acid in Sputum and Feces and Specific IgM/IgG in Serum for the Diagnosis of Coronavirus Disease 2019.** Front Cell Infect Microbiol 2020; 10:445He Y, Luo J, Yang J ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32850506
33. **Genetic Analysis of the Coronavirus SARS-CoV-2 Host Protease TMPRSS2 in Different Populations.** Front Genet 2020; 11:872Russo R, Andolfo I, Lasorsa VA ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32849840
34. **Contriving Multi-Epitope Subunit of Vaccine for COVID-19: Immunoinformatics Approaches.** Front. Immunol. 2020; 11:1784Dong R, Chu Z, Yu F, Zha Y. http://www.ncbi.nlm.nih.gov/pubmed/?term=32849643
35. **Longer Duration of SARS-CoV-2 Infection in a Case of Mild COVID-19 With Weak Production of the Specific IgM and IgG Antibodies.** Front. Immunol. 2020; 11:1936Guo X, Zeng L, Huang Z ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32849650
36. **Leptin levels in SARS-CoV-2 infection related respiratory failure: A cross-sectional study and a pathophysiological framework on the role of fat tissue.** Heliyon 2020; 6:e04696van der Voort PHJ, Moser J, Zandstra DF ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32844126
37. **Plasma Angiotensin Peptide Profiling and ACE2-Activity in COVID-19 Patients treated with Pharmacological Blockers of the Renin Angiotensin System.** Hypertension 2020; Kintscher U, Slagman A, Domenig O ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32851897
38. **Neutralizing antibody responses to SARS-CoV-2 in COVID-19 patients.** Indian J Med Res 2020; Deshpande GR, Sapkal GN, Tilekar BN ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32859866
39. **Chemokine receptor gene polymorphisms and COVID-19: Could knowledge gained from HIV/AIDS be important?** Infect Genet Evol 2020:104512Mehlotra RK. http://www.ncbi.nlm.nih.gov/pubmed/?term=32858232
40. **Differences of inflammatory and non-inflammatory indicators in Coronavirus disease-19 (COVID-19) with different severity.** Infect Genet Evol 2020:104511Wang M, Zhu Q, Fu J ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32858231
41. **Current approach in laboratory testing for SARS-CoV-2.** Int J Infect Dis 2020; Xu Y, Cheng M, Chen X, Zhu J. http://www.ncbi.nlm.nih.gov/pubmed/?term=32829053
42. **Insights into the structural and dynamical changes of spike glycoprotein mutations associated with SARS-CoV-2 host receptor binding.** J Biomol Struct Dyn 2020:1-13Ahamad S, Kanipakam H, Gupta D. http://www.ncbi.nlm.nih.gov/pubmed/?term=32851910
43. **Peripheral CD4+ T cell subsets and antibody response in COVID-19 convalescent individuals.** J. Clin. Invest. 2020; Gong F, Dai Y, Zheng T ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32841212
44. **Clinical characteristics and factors affecting the duration of positive nucleic acid test for patients of COVID-19 in XinYu, China.** J. Clin. Lab. Anal. 2020:e23534Lu J, Yin Q, Li Q ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32860649
45. **Positive RT-PCR nasopharyngeal swab in patients recovered from COVID-19 disease: When does quarantine really end?** J Infect 2020; Landi F, Gremese E, Rota E ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32853596

46. **Characterizing COVID-19 severity, epidemiology and SARS-CoV-2 genotypes in a regional business hub of China.** J Infect 2020; Yan Y, Liu B, Ding H ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32853601
47. **Are SARS-CoV-2 seroprevalence estimates biased?** J Infect Dis 2020; Takahashi S, Greenhouse B, Rodríguez-Barraquer I. http://www.ncbi.nlm.nih.gov/pubmed/?term=32856712
48. **A High Through-Put Assay For Circulating Antibodies Directed Against The S Protein Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2).** J Infect Dis 2020; Weiss S, Klingler J, Hioe C ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32860510
49. **The prognostic role of neopterin in COVID-19 patients.** J Med Virol 2020; Ozger HS, Dizbay M, Corbacioglu SK ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32860465
50. **Saliva sample pooling for the detection of SARS-CoV-2.** J Med Virol 2020; Pasomsub E, Watcharananan SP, Watthanachockchai T ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32841429
51. **Management of SARS-CoV-2 Pneumonia.** J Med Virol 2020; Sagnelli C, Celia B, Monari C ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32856728
52. **Investigating the potential antiviral activity drugs against SARS-CoV-2 by molecular docking simulation.** J. Mol. Liq. 2020; 318:113968El-Hoshoudy AN. http://www.ncbi.nlm.nih.gov/pubmed/?term=32839634
53. **Response to "Studies on hemostasis in COVID-19 deserve careful reporting of the laboratory methods, their significance and their limitation": don't throw the baby out with the bathwater.** J Thromb Haemost 2020; Nougier C, Benoit R, Dargaud Y. http://www.ncbi.nlm.nih.gov/pubmed/?term=32860301
54. **Assessing SARS-CoV-2 RNA levels and lymphocyte/T cell counts in COVID-19 patients revealed initial immune status as a major determinant of disease severity.** Med. Microbiol. Immunol. 2020; Han M, Xu M, Zhang Y ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32860073
55. **Development and Clinical Application of a Rapid and Sensitive Loop-Mediated Isothermal Amplification Test for SARS-CoV-2 Infection.** mSphere 2020; 5Hu X, Deng Q, Li J ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32848011
56. **Re-positive COVID-19 PCR test: could it be a reinfection?** New Microbes New Infect 2020:100748Osman AA, Al Daajani MM, Alsahafi AJ. http://www.ncbi.nlm.nih.gov/pubmed/?term=32843984
57. **Bi-stability of SUDR+K model of epidemics and test kits applied to COVID-19.** Nonlinear Dyn 2020:1-8Zlatić V, Barjašić I, Kadović A ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32839639
58. **Decreased prealbumin level is associated with increased risk for mortality in elderly hospitalized patients with COVID-19.** Nutrition 2020; 78:110930Zuo P, Tong S, Yan Q ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32854020
59. **The Correlation Between Clinical Features and Viral RNA Shedding in Outpatients With COVID-19.** Open Forum Infect Dis 2020; 7:ofaa331Liao T, Yin Z, Xu J ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32851112
60. **A Simple Algorithm for Return to Workplace Employer Antibody Testing.** Popul Health Manag 2020; Shrank WH, Caveney B, Miller S ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32857015
61. **A systematic review on recent trends in transmission, diagnosis, prevention and imaging features of COVID-19.** Process Biochem. 2020; Manigandan S, Wu

MT, Ponnusamy VK ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32843849
62. **The Interplay Between Coagulation and Inflammation Pathways in COVID-19-Associated Respiratory Failure: A Narrative Review.** Pulm Ther 2020; Bhattacharyya R, Iyer P, Phua GC, Lee JH. http://www.ncbi.nlm.nih.gov/pubmed/?term=32844302
63. **Microfluidic devices for detection of RNA viruses.** Rev Med Virol 2020:e2154Basiri A, Heidari A, Nadi MF ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32844526
64. **Interleukin-6 in Covid-19: A systematic review and meta-analysis.** Rev Med Virol 2020:e2141Coomes EA, Haghbayan H. http://www.ncbi.nlm.nih.gov/pubmed/?term=32845568
65. **Alpha-1-antitrypsin: A possible host protective factor against Covid-19.** Rev Med Virol 2020:e2157de Loyola MB, Dos Reis TTA, de Oliveira G ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32844538
66. **Detection of SARS-CoV-2 in raw and treated wastewater in Germany - Suitability for COVID-19 surveillance and potential transmission risks.** Sci Total Environ 2020; 751:141750Westhaus S, Weber FA, Schiwy S ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32861187
67. **Admission D-dimer levels, D-dimer trends, and outcomes in COVID-19.** Thromb Res 2020; 196:99-105Naymagon L, Zubizarreta N, Feld J ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32853982
68. **Single-cell RNA expression profiling of ACE2 and TMPRSS2 in the human trophectoderm and placenta.** Ultrasound Obstet Gynecol 2020; Cui D, Liu Y, Jiang X ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32851697
69. **COVID-19 surveillance in Southeastern Virginia using wastewater-based epidemiology.** Water Res 2020; 186:116296Gonzalez R, Curtis K, Bivins A ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32841929
70. **[Predictive value of neutrophil/lymphocyte ratio on myocardial injury in severe COVID-19 patients].** Zhonghua Xin Xue Guan Bing Za Zhi 2020; 48:572-579Chen Y, Wang KJ, Luo YC ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32842269

Children (27 articles)

1. **COVID-19 infection in children and adolescents.** Br. J. Hosp. Med. (Lond.) 2020; 81:1-10Naja M, Wedderburn L, Ciurtin C. http://www.ncbi.nlm.nih.gov/pubmed/?term=32845750
2. **Stress and parenting during the global COVID-19 pandemic.** Child Abuse Negl. 2020:104699Brown SM, Doom JR, Lechuga-Peña S ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32859394
3. **Do suicide rates in children and adolescents change during school closure in Japan? The acute effect of the first wave of COVID-19 pandemic on child and adolescent mental health.** Child Abuse Negl. 2020:104680Isumi A, Doi S, Yamaoka Y ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32847679
4. **Child safety, protection, and safeguarding in the time of COVID-19 in Great Britain: Proposing a conceptual framework.** Child Abuse Negl. 2020:104668Levine DT, Morton J, O'Reilly M. http://www.ncbi.nlm.nih.gov/pubmed/?term=32828561
5. **Telemental health for child trauma treatment during and post-COVID-19: Limitations and considerations.** Child Abuse Negl. 2020:104698Racine N,

Hartwick C, Collin-Vézina D, Madigan S. http://www.ncbi.nlm.nih.gov/pubmed/?term=32839022

6. **"Oh, this is actually okay": Understanding how one state child welfare training system adapted to the COVID-19 pandemic.** Child Abuse Negl. 2020:104697Schwab-Reese LM, Drury I, Allan H, Matz K. http://www.ncbi.nlm.nih.gov/pubmed/?term=32839023
7. **Material hardship and parenting stress among grandparent kinship providers during the COVID-19 pandemic: The mediating role of grandparents' mental health.** Child Abuse Negl. 2020:104700Xu Y, Wu Q, Levkoff SE, Jedwab M. http://www.ncbi.nlm.nih.gov/pubmed/?term=32854948
8. **Chronotypes and trauma reactions in children with ADHD in home confinement of COVID-19: full mediation effect of sleep problems.** Chronobiol. Int. 2020:1-8Çetin FH, Uçar HN, Türkoğlu S ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32856947
9. **COVID-19 issues related to pediatric neuropsychology and inpatient rehabilitation - challenges to usual care and solutions during the pandemic.** Clin. Neuropsychol. 2020:1-15Koterba CH, Baum KT, Hamner T ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32847476
10. **COVID-19 manifestations in children.** Curr Med Res Pract 2020; 10:186-188Kachru S, Kaul D. http://www.ncbi.nlm.nih.gov/pubmed/?term=32839729
11. **Caring for a Child with Type 1 Diabetes During COVID-19 lockdown in a developing country: Challenges and Parents' Perspectives on the Use of Telemedicine.** Diabetes Res Clin Pract 2020:108393Odeh R, Gharaibeh L, Daher A ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32858098
12. **Children account for a small proportion of diagnoses of SARS-CoV-2 infection and do not exhibit greater viral loads than adults.** Eur J Clin Microbiol Infect Dis 2020; Colson P, Tissot-Dupont H, Morand A ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32845413
13. **Clinical outcome of SARS-CoV-2 infection in immunosuppressed children in Spain.** Eur. J. Pediatr. 2020; Pérez-Martinez A, Guerra-García P, Melgosa M ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32860101
14. **Child Healthcare and Immunizations in Sub-Saharan Africa During the COVID-19 Pandemic.** Front Pediatr 2020; 8:517Buonsenso D, Cinicola B, Kallon MN, Iodice F. http://www.ncbi.nlm.nih.gov/pubmed/?term=32850565
15. **Case Report: Benign Infantile Seizures Temporally Associated With COVID-19.** Front Pediatr 2020; 8:507García-Howard M, Herranz-Aguirre M, Moreno-Galarraga L ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32850563
16. **CSANZ Position Statement on COVID-19 From the Paediatric and Congenital Council(☆).** Heart Lung Circ. 2020; Ayer J, Anderson B, Gentles TL, Cordina RL. http://www.ncbi.nlm.nih.gov/pubmed/?term=32839114
17. **Coronavirus Disease 2019 (COVID-19) in Children: Prevalence, Diagnosis, Clinical Symptoms, and Treatment.** Int. J. Gen. Med. 2020; 13:477-482Zare-Zardini H, Soltaninejad H, Ferdosian F ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32848446
18. **COVID-19 pandemic and adolescent health and well-being in sub-Saharan Africa: Who cares?** Int. J. Health Plann. Manage. 2020; Addae EA. http://www.ncbi.nlm.nih.gov/pubmed/?term=32856325
19. **Gastrointestinal bleeding in a newborn infant with congenital factor X deficiency and COVID-19-A common clinical feature between a rare disorder**

and a new, common infection. Int. J. Lab. Hematol. 2020; Dorgalaleh A, Baghaipour MR, Tabibian S ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32845081

20. **Immune dysregulation and Multisystem Inflammatory Syndrome in Children (MIS-C) in individuals with haploinsufficiency of SOCS1.** J Allergy Clin Immunol 2020; Lee PY, Platt CD, Weeks S ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32853638
21. **COVID-19: Impacts and Implications for Pediatric Practice.** J. Pediatr. Health Care 2020; Peck JL. http://www.ncbi.nlm.nih.gov/pubmed/?term=32859434
22. **SARS-CoV-2 Point Prevalence among Asymptomatic Hospitalized Children and Subsequent Healthcare Worker Evaluation.** J Pediatric Infect Dis Soc 2020; Patel AB, Clifford A, Creaden J ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32857134
23. **A Pediatric Infectious Disease Perspective of SARS-CoV-2 and COVID-19 in Children.** J Pediatric Infect Dis Soc 2020; Shane AL, Sato AI, Kao C ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32840614
24. **Lessons Learned: Pediatric Tele-Mental Health in a Rural Medical Center in the Age of SARS-CoV-2.** J Rural Health 2020; Satti K, Ojugbele O. http://www.ncbi.nlm.nih.gov/pubmed/?term=32845031
25. **Bi-stability of SUDR+K model of epidemics and test kits applied to COVID-19.** Nonlinear Dyn 2020:1-8Zlatić V, Barjašić I, Kadović A ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32839639
26. **Be aware of acute kidney injury in critically ill children with COVID-19.** Pediatr. Nephrol. 2020; Wang X, Chen X, Tang F ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32844290
27. **[Investigation of pathogenic agents causing acute respiratory tract infections in pediatric patients in a children's hospital assigned for case screening in Beijing during the outbreak of COVID-19].** Zhonghua Er Ke Za Zhi 2020; 58:635-639Zhao LQ, Deng L, Cao L ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32842383

Clinical Features (29 articles)

1. **Erythema nodosum-like rash in a COVID-19 patient: A case report.** Am J Emerg Med 2020; Sipfle DN, Bridwell Md RE, Roper DJ. http://www.ncbi.nlm.nih.gov/pubmed/?term=32828595
2. **Patient Characteristics and Outcomes of 11,721 Patients with COVID19 Hospitalized Across the United States.** Clin Infect Dis 2020; Fried MW, Crawford JM, Mospan AR ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32856034
3. **Morbilliform Rash: An Uncommon Herald of SARS-CoV-2.** Cureus 2020; 12:e9321Kulkarni RB, Lederman Y, Afiari A ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32850199
4. **Do we have serological evidences that chilblain-like lesions are related to SARS-CoV-2? A review of the literature.** Dermatol Ther 2020:e14229Balestri R, Magnano M, Rizzoli L, Rech G. http://www.ncbi.nlm.nih.gov/pubmed/?term=32844512
5. **Case report: SARS-CoV-2 induced urticaria or just a concomitance?** Dermatol Ther 2020; Fida M, Mala R, Pupo L ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32860461

6. **COVID-19: Variable symptoms in mild course: Olfactory loss and increased resting heart rate.** Deutsche Medizinische Wochenschrift 2020; 145:1095-1099Isenmann A, Isenmann S.
7. **Facial nerve palsy: an atypical clinical manifestation of COVID-19 infection in a family cluster.** Eur. J. Neurol. 2020; Derollez C, Alberto T, Leroi I ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32853484
8. **Clinical Characteristics and Short-Term Outcomes of Severe Patients With COVID-19 in Wuhan, China.** Front Med (Lausanne) 2020; 7:491Feng X, Li P, Ma L ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32850926
9. **Clinical Characteristics and Prognosis of 218 Patients With COVID-19: A Retrospective Study Based on Clinical Classification.** Front Med (Lausanne) 2020; 7:485Yan X, Han X, Peng D ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32850925
10. **Racial and Gender-Based Differences in COVID-19.** Front Public Health 2020; 8:418Kopel J, Perisetti A, Roghani A ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32850607
11. **Asymptomatic SARS-CoV-2 infection in patients with inflammatory bowel disease under biologic treatment.** Gastroenterology 2020; Norsa L, Cosimo P, Indriolo A ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32860790
12. **Conjunctivitis in COVID-19 patients: frequency and clinical presentation.** Graefes Arch Clin Exp Ophthalmol 2020; Güemes-Villahoz N, Burgos-Blasco B, García-Feijoó J ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32860573
13. **Clinical and radiological characteristics of COVID-19: a multicentre, retrospective, observational study.** Hong Kong Med. J. 2020; Wang Y, Luo S, Zhou CS ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32848097
14. **First report on clinical and radiological features of COVID-19 pneumonitis in a Caucasian population: factors predicting fibrotic evolution.** Int J Infect Dis 2020; Marvisi M, Ferrozzi F, Balzarini L ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32841688
15. **Comment on "Androgenetic alopecia present in the majority of patients hospitalized with COVID-19".** J Am Acad Dermatol 2020; Bukovac D, Makše U. http://www.ncbi.nlm.nih.gov/pubmed/?term=32860917
16. **Reply to "Comment on androgenetic alopecia present in the majority of patients hospitalized with COVID-19".** J Am Acad Dermatol 2020; Wambier CG. http://www.ncbi.nlm.nih.gov/pubmed/?term=32860919
17. **Immune Alterations in a Patient with SARS-CoV-2-Related Acute Respiratory Distress Syndrome.** J. Clin. Immunol. 2020:1-11Bouadma L, Wiedemann A, Patrier J ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32829467
18. **Clinical characteristics and factors affecting the duration of positive nucleic acid test for patients of COVID-19 in XinYu, China.** J. Clin. Lab. Anal. 2020:e23534Lu J, Yin Q, Li Q ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32860649
19. **An Atypical Presentation of COVID-19 in a Previously Healthy Young Male With a Rare Cause of Abdominal Pain.** J. Clin. Med. Res. 2020; 12:624-628Bashari DR, Peguero-Tejada JL, Shah JI. http://www.ncbi.nlm.nih.gov/pubmed/?term=32849952
20. **Understanding the epidemiology, pathophysiology, diagnosis and management of SARS-CoV-2.** J. Int. Med. Res. 2020; 48:300060520949077Fadaka AO, Sibuyi NRS, Adewale OB ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32842818

21. **Differentiation of COVID-19 from seasonal influenza: a multicenter comparative study.** J Med Virol 2020; Zhang J, Ding D, Huang X ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32856744
22. **Die COVID-19-Pandemie – wachsam bleiben!** JDDG - Journal of the German Society of Dermatology 2020; 18:787-788Emmert S.
23. **Evolving Consensus of International Uveitis Study Group, Intraocular Inflammation Society, and Foster Ocular Inflammation Society with Uveitis in the Time of COVID-19 Infection.** Klin. Monbl. Augenheilkd. 2020; Zierhut M, de MDS, Gupta V ***et al.***
24. **One-Seventh of Patients with COVID-19 Had Olfactory and Gustatory Abnormalities as Their Initial Symptoms: A Systematic Review and Meta-Analysis.** Life (Basel) 2020; 10Chi H, Chiu NC, Peng CC ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32842563
25. **Attaching clinical significance to COVID-19-associated diarrhea.** Life Sci 2020; 260:118312Wang F, Zheng S, Zheng C, Sun X. http://www.ncbi.nlm.nih.gov/pubmed/?term=32846165
26. **Non-aneurysmal subarachnoid haemorrhage in COVID-19.** Neuroradiology 2020; Harrogate S, Mortimer A, Burrows L ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32857213
27. **The Correlation Between Clinical Features and Viral RNA Shedding in Outpatients With COVID-19.** Open Forum Infect Dis 2020; 7:ofaa331Liao T, Yin Z, Xu J ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32851112
28. **Syncope and presyncope in patients with COVID-19.** Pacing Clin. Electrophysiol. 2020; Oates C, Turagam MK, Musikantow D ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32840325
29. **[Comparison of epidemic characteristics between severe acute respiratory syndrome and coronavirus disease 2019].** Zhonghua Yu Fang Yi Xue Za Zhi 2020; 54:726-730Cai WF, Yuan J, Huang LF ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32842293

CNS (23 articles)

1. **Central Nervous System Targets and Routes for SARS-CoV-2: Current Views and New Hypotheses.** ACS Chem Neurosci 2020; Barrantes FJ. http://www.ncbi.nlm.nih.gov/pubmed/?term=32845609
2. **Neuronophagia and microglial nodules in a SARS-CoV-2 patient with cerebellar hemorrhage.** Acta Neuropathol Commun 2020; 8:147Al-Dalahmah O, Thakur KT, Nordvig AS ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32847628
3. **Olfactory dysfunction in patients after recovering from COVID-19.** Acta Otolaryngol. 2020:1-4Otte MS, Eckel HNC, Poluschkin L ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32852240
4. **COVID-19 and Central Nervous System: Entry Routes And.** Basic Clin Neurosci 2020; 11:217-224Ahmadirad N, Ghasemi Z. http://www.ncbi.nlm.nih.gov/pubmed/?term=32855781
5. **Evaluation of the Opinion of Patients With Multiple Sclerosis on the Outcomes of Catching COVID-19 and Its Effects on the MS Symptoms.** Basic Clin Neurosci 2020; 11:201-206Rezaeimanesh N, Sahraian MA, Naser Moghadasi A. http://www.ncbi.nlm.nih.gov/pubmed/?term=32855779

6. **SARS-CoV-2 Infectivity and Neurological Targets in the Brain.** Cell. Mol. Neurobiol. 2020; Lukiw WJ, Pogue A, Hill JM. http://www.ncbi.nlm.nih.gov/pubmed/?term=32840758
7. **Management of new onset loss of sense of smell during the COVID-19 pandemic - BRS Consensus Guidelines.** Clin. Otolaryngol. 2020; Hopkins C, Alanin M, Philpott C ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32854169
8. **Seizures Related to Coronavirus Disease (COVID-19): Case Series and Literature Review.** Cureus 2020; 12:e9378Ashraf M, Sajed S. http://www.ncbi.nlm.nih.gov/pubmed/?term=32850246
9. **Chemosensory dysfunction in COVID-19 out-patients.** Eur Arch Otorhinolaryngol 2020; Rojas-Lechuga MJ, Izquierdo-Domínguez A, Chiesa-Estomba C ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32844305
10. **Facial nerve palsy: an atypical clinical manifestation of COVID-19 infection in a family cluster.** Eur. J. Neurol. 2020; Derollez C, Alberto T, Leroi I ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32853484
11. **Cytokine release syndrome-associated encephalopathy in patients with COVID-19.** Eur. J. Neurol. 2020; Perrin P, Collongues N, Baloglu S ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32853434
12. **Case Report: Benign Infantile Seizures Temporally Associated With COVID-19.** Front Pediatr 2020; 8:507García-Howard M, Herranz-Aguirre M, Moreno-Galarraga L ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32850563
13. **Neurological manifestations of COVID-19: A brief review.** Indian J Med Res 2020; Sachdev K, Agrawal S, Ish P ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32859864
14. **Olfactory disorder in patients infected with SARS-CoV-2.** J Microbiol Immunol Infect 2020; Yen YF, Lai HH, Chan SY ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32859529
15. **Guillain-Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases.** J. Neurol. 2020; Abu-Rumeileh S, Abdelhak A, Foschi M ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32840686
16. **COVID-19: dealing with a potential risk factor for chronic neurological disorders.** J. Neurol. 2020; Schirinzi T, Landi D, Liguori C. http://www.ncbi.nlm.nih.gov/pubmed/?term=32852580
17. **Neurological manifestations of COVID-19: available evidences and a new paradigm.** J. Neurovirol. 2020; Khatoon F, Prasad K, Kumar V. http://www.ncbi.nlm.nih.gov/pubmed/?term=32839951
18. **Implication of Aging Related Chronic Neuroinflammation on COVID-19 Pandemic.** J Pers Med 2020; 10Bossù P, Toppi E, Sterbini V, Spalletta G. http://www.ncbi.nlm.nih.gov/pubmed/?term=32858874
19. **Smell disorders at COVID-19 - The current level of knowledge.** Laryngo- Rhino-Otologie 2020; 99:531-535Otte MS, Kluβmann JP, Luers JC.
20. **One-Seventh of Patients with COVID-19 Had Olfactory and Gustatory Abnormalities as Their Initial Symptoms: A Systematic Review and Meta-Analysis.** Life (Basel) 2020; 10Chi H, Chiu NC, Peng CC ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32842563
21. **Fatal COVID-19 in an MS patient on natalizumab: A case report.** Mult Scler J Exp Transl Clin 2020; 6:2055217320942931Rimmer K, Farber R, Thakur K ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32850133

22. **Neurocovid: Pharmacological Recommendations for Delirium Associated With COVID-19.** Psychosomatics 2020; Baller EB, Hogan CS, Fusunyan MA ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32828569
23. **Status epilepticus and other EEG findings in patients with COVID-19: A case series.** Seizure 2020; 81:198-200Chen W, Toprani S, Werbaneth K, Falco-Walter J. http://www.ncbi.nlm.nih.gov/pubmed/?term=32861152

Coagulation (26 articles)

1. **Early coagulation tests predict risk stratification and prognosis of COVID-19.** Aging (Albany NY) 2020; 12Luo L, Xu M, Du M ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32860672
2. **Utility of D-dimer as a Prognostic Factor in SARS CoV2 Infection: A Review.** Am J Med Case Rep 2020; 8:337-340Kariyanna PT, Aurora L, Jayarangaiah A ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32851129
3. **Unpuzzling COVID-19 Prothrombotic State: Are Preexisting Thrombophilic Risk Profiles Responsible for Heterogenous Thrombotic Events?** Clin. Appl. Thromb. Hemost. 2020; 26:1076029620952884Burlacu A, Genovesi S, Popa IV, Crisan-Dabija R. http://www.ncbi.nlm.nih.gov/pubmed/?term=32842771
4. **Incidence and Risk Factors of Deep Vein Thrombosis in Hospitalized COVID-19 Patients.** Clin. Appl. Thromb. Hemost. 2020; 26:1076029620953217Yu Y, Tu J, Lei B ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32854513
5. **Reduced vitamin K status as a potentially modifiable risk factor of severe COVID-19.** Clin Infect Dis 2020; Dofferhoff ASM, Piscaer I, Schurgers LJ ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32852539
6. **Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients.** EBioMedicine 2020; 59:102969Buijsers B, Yanginlar C, Maciej-Hulme ML ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32853989
7. **Incidence of Venous Thromboembolism in Hospitalized Coronavirus Disease 2019 Patients: A Systematic Review and Meta-Analysis.** Front Cardiovasc Med 2020; 7:151Zhang C, Shen L, Le KJ ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32850990
8. **Hypercoagulopathy and Adipose Tissue Exacerbated Inflammation May Explain Higher Mortality in COVID-19 Patients With Obesity.** Front. Endocrinol. (Lausanne) 2020; 11:530Pasquarelli-do-Nascimento G, Braz-de-Melo HA, Faria SS ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32849309
9. **Crosstalk Between Platelets and Microbial Pathogens.** Front. Immunol. 2020; 11:1962Li C, Li J, Ni H. http://www.ncbi.nlm.nih.gov/pubmed/?term=32849656
10. **Preliminary Experience With Low Molecular Weight Heparin Strategy in COVID-19 Patients.** Front. Pharmacol. 2020; 11:1124Paolisso P, Bergamaschi L, D'Angelo EC ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32848743
11. **Hemostatic alterations in COVID-19.** Haematologica 2020; Peyvandi F, Artoni A, Novembrino C ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32855280
12. **Prevalence of asymptomatic deep vein thrombosis in patients hospitalized with SARS-CoV-2 pneumonia: a cross-sectional study.** Intern Emerg Med 2020; Giorgi-Pierfranceschi M, Paoletti O, Pan A ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32840805
13. **Anticoagulation, Mortality, Bleeding and Pathology Among Patients Hospitalized with COVID-19: A Single Health System Study.** J Am Coll Cardiol

2020; Nadkarni GN, Lala A, Bagiella E ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32860872

14. **A Case Series of Devastating Intracranial Hemorrhage During Venovenous Extracorporeal Membrane Oxygenation for COVID-19.** J Cardiothorac Vasc Anesth 2020; Usman AA, Han J, Acker A ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32828653
15. **Coronavirus disease associated immune thrombocytopenia: Causation or correlation?** J Microbiol Immunol Infect 2020; Pascolini S, Granito A, Muratori L ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32859531
16. **COVID-19 Coagulopathy in Pregnancy: Critical Review, Preliminary Recommendations and ISTH Registry - Communication from the ISTH SSC for Women's Health.** J Thromb Haemost 2020; Kadir RA, Kobayashi T, Iba T ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32846051
17. **Response to "Studies on hemostasis in COVID-19 deserve careful reporting of the laboratory methods, their significance and their limitation": don't throw the baby out with the bathwater.** J Thromb Haemost 2020; Nougier C, Benoit R, Dargaud Y. http://www.ncbi.nlm.nih.gov/pubmed/?term=32860301
18. **Anticoagulation use and Hemorrhagic Stroke in SARS-CoV-2 Patients Treated at a New York Healthcare System.** Neurocrit. Care 2020; Kvernland A, Kumar A, Yaghi S ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32839867
19. **A proof of evidence supporting abnormal immunothrombosis in severe COVID-19: naked megakaryocyte nuclei increase in the bone marrow and lungs of critically ill patients.** Platelets 2020:1-5Roncati L, Ligabue G, Nasillo V ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32857624
20. **The Interplay Between Coagulation and Inflammation Pathways in COVID-19-Associated Respiratory Failure: A Narrative Review.** Pulm Ther 2020; Bhattacharyya R, Iyer P, Phua GC, Lee JH. http://www.ncbi.nlm.nih.gov/pubmed/?term=32844302
21. **Anticoagulant protein S in COVID-19: low activity, and associated with outcome.** Rom. J. Intern. Med. 2020; Stoichitoiu LE, Pinte L, Balea MI ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32841167
22. **Concomitant calciphylaxis and COVID-19 associated thrombotic retiform purpura.** Skeletal Radiol. 2020; Rotman JA, Dean KE, Magro C ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32844243
23. **Labile PT-INR in a Covid-19 Patient Under Long-term Vitamin K Antagonist Therapy: a Case Report.** SN Compr Clin Med 2020:1-3Trevisan C, Miconi L, Barbierato E ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32839751
24. **Admission D-dimer levels, D-dimer trends, and outcomes in COVID-19.** Thromb Res 2020; 196:99-105Naymagon L, Zubizarreta N, Feld J ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32853982
25. **Venous thromboembolism in patients with COVID-19: Systematic review and meta-analysis.** Thromb Res 2020; 196:67-74Porfidia A, Valeriani E, Pola R ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32853978
26. **COVID-19 versus HIT hypercoagulability.** Thromb Res 2020; 196:38-51Warkentin TE, Kaatz S. http://www.ncbi.nlm.nih.gov/pubmed/?term=32841919

Complications (47 articles)

1. **Clinical characteristics of chronic liver disease with coronavirus disease 2019 (COVID-19): a cohort study in Wuhan, China.** Aging (Albany NY) 2020; 12Li C, Chen Q, Wang J ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32855361
2. **Disparity in HIV Service Interruption in the Outbreak of COVID-19 in South Carolina.** AIDS Behav. 2020; Qiao S, Li Z, Weissman S ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32856176
3. **Airway management guidance for the endemic phase of COVID-19.** Anaesthesia 2020; Cook TM, McGuire B, Mushambi M ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32839960
4. **A COVID-19 Airway Management Innovation with Pragmatic Efficacy Evaluation: The Patient Particle Containment Chamber.** Ann. Biomed. Eng. 2020; Maloney LM, Yang AH, Princi RA ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32856180
5. **A case of COVID-19 immediately after liver transplantation: Not only bad news.** Ann Hepatobiliary Pancreat Surg 2020; 24:314-318Prieto M, Gastaca M, Ruiz P ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32843598
6. **Evaluation of the Opinion of Patients With Multiple Sclerosis on the Outcomes of Catching COVID-19 and Its Effects on the MS Symptoms.** Basic Clin Neurosci 2020; 11:201-206Rezaeimanesh N, Sahraian MA, Naser Moghadasi A. http://www.ncbi.nlm.nih.gov/pubmed/?term=32855779
7. **Cardio-Cerebrovascular Disease is Associated With Severity and Mortality of COVID-19: A Systematic Review and Meta-Analysis.** Biol. Res. Nurs. 2020:1099800420951984Yu JN, Wu BB, Yang J ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32851851
8. **Intraoperative coagulopathy during cesarean section as an unsuspected initial presentation of COVID-19: a case report.** BMC Pregnancy Childbirth 2020; 20:481Kinsey KE, Ganz E, Khalil S, Brustman L. http://www.ncbi.nlm.nih.gov/pubmed/?term=32838744
9. **COVID-19 and Cancer: Lessons Learnt from a Michigan Hotspot.** Cancers (Basel) 2020; 12Singh SRK, Thanikachalam K, Jabbour-Aida H ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32842584
10. **Incidence and Risk Factors of Deep Vein Thrombosis in Hospitalized COVID-19 Patients.** Clin. Appl. Thromb. Hemost. 2020; 26:1076029620953217Yu Y, Tu J, Lei B ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32854513
11. **Patient Characteristics and Outcomes of 11,721 Patients with COVID19 Hospitalized Across the United States.** Clin Infect Dis 2020; Fried MW, Crawford JM, Mospan AR ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32856034
12. **Antibody Responses and Clinical Outcomes in Adults Hospitalized with Severe COVID-19: A Post hoc Analysis of LOTUS China Trial.** Clin Infect Dis 2020; Ren L, Fan G, Wu W ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32840287
13. **A national strategy to diagnose COVID-19 associated invasive fungal disease in the ICU.** Clin Infect Dis 2020; White PL, Dhillon R, Cordey A ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32860682
14. **Overwhelming COVID-19 Sepsis in a Patient With Idiopathic Pulmonary Fibrosis.** Cureus 2020; 12:e9320Akram A. http://www.ncbi.nlm.nih.gov/pubmed/?term=32850198
15. **Characterization of Critically Ill COVID-19 Patients at a Brooklyn Safety-Net Hospital.** Cureus 2020; 12:e9809Capone S, Abramyan S, Ross B ***et al.***

http://www.ncbi.nlm.nih.gov/pubmed/?term=32850261
16. **Clinical profile and outcomes in COVID-19 patients with diabetic ketoacidosis: A systematic review of literature.** Diabetes Metab Syndr 2020; 14:1563-1569Pal R, Banerjee M, Yadav U, Bhattacharjee S. http://www.ncbi.nlm.nih.gov/pubmed/?term=32853901
17. **Reversible cardiac dysfunction in severe COVID-19 infection, mechanisms and case report.** Echocardiography 2020; Chao CJ, DeValeria PA, Sen A ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32856328
18. **Multidrug-Resistant Candida auris Infections in Critically Ill Coronavirus Disease Patients, India, April-July 2020.** Emerg Infect Dis 2020; 26Chowdhary A, Tarai B, Singh A, Sharma A. http://www.ncbi.nlm.nih.gov/pubmed/?term=32852265
19. **Clinical outcome of SARS-CoV-2 infection in immunosuppressed children in Spain.** Eur. J. Pediatr. 2020; Pérez-Martinez A, Guerra-García P, Melgosa M ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32860101
20. **Clinical Characteristics and Short-Term Outcomes of Severe Patients With COVID-19 in Wuhan, China.** Front Med (Lausanne) 2020; 7:491Feng X, Li P, Ma L ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32850926
21. **Secondary Bacterial Infections in Patients With Viral Pneumonia.** Front Med (Lausanne) 2020; 7:420Manohar P, Loh B, Nachimuthu R ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32850912
22. **Care for Critical Ill Patients With COVID-19: Establishment of a Temporary Intensive Care Unit in an Isolated Hospital.** Front Med (Lausanne) 2020; 7:519Peng M, Qian Z, Zhang L. http://www.ncbi.nlm.nih.gov/pubmed/?term=32850928
23. **Special Issues Encountered When Cancer Patients Confront COVID-19.** Front. Oncol. 2020; 10:1380Qi L, Wang K, Ye C, Zheng S. http://www.ncbi.nlm.nih.gov/pubmed/?term=32850443
24. **Disease progression patterns and risk factors associated with mortality in deceased patients with COVID-19 in Hubei Province, China.** Immun Inflamm Dis 2020; Chen L, Liu S, Tian J ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32857453
25. **Gastrointestinal bleeding in a newborn infant with congenital factor X deficiency and COVID-19-A common clinical feature between a rare disorder and a new, common infection.** Int. J. Lab. Hematol. 2020; Dorgalaleh A, Baghaipour MR, Tabibian S ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32845081
26. **COVID-19: effect on patients with gastrointestinal cancer and surgery.** Int J Surg 2020; Ghidinelli F, De Pascale S, Romario UF. http://www.ncbi.nlm.nih.gov/pubmed/?term=32858211
27. **Prevalence of asymptomatic deep vein thrombosis in patients hospitalized with SARS-CoV-2 pneumonia: a cross-sectional study.** Intern Emerg Med 2020; Giorgi-Pierfranceschi M, Paoletti O, Pan A ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32840805
28. **Anticoagulation, Mortality, Bleeding and Pathology Among Patients Hospitalized with COVID-19: A Single Health System Study.** J Am Coll Cardiol 2020; Nadkarni GN, Lala A, Bagiella E ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32860872
29. **ECMO-Challenges, strategies, and preparation from Spain.** J. Card. Surg. 2020; Pérez de la Sota E, Eixerés-Esteve A. http://www.ncbi.nlm.nih.gov/pubmed/?

term=32845030

30. **A Case Series of Devastating Intracranial Hemorrhage During Venovenous Extracorporeal Membrane Oxygenation for COVID-19.** J Cardiothorac Vasc Anesth 2020; Usman AA, Han J, Acker A ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32828653
31. **Severe Coronavirus disease 2019 pneumonia patients showed signs of aggravated renal impairment.** J. Clin. Lab. Anal. 2020:e23535Gao M, Wang Q, Wei J ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32840917
32. **Clinical features and potential risk factors for discerning the critical cases and predicting the outcome of patients with COVID-19.** J. Clin. Lab. Anal. 2020:e23547Wang W, Zhao Z, Liu X ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32860454
33. **SARS-CoV-2 seroprevalence in a Belgian cohort of patients with cystic fibrosis.** J Cyst Fibros 2020; Berardis S, Verroken A, Vetillart A ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32828701
34. **The FIB-4 Index Is Associated with Need for Mechanical Ventilation and 30-day Mortality in Patients Admitted with COVID-19.** J Infect Dis 2020; Sterling RK, Oakes T, Gal TS ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32856702
35. **Adrenal insufficiency in coronavirus disease 2019: a case report.** J Med Case Rep 2020; 14:134Heidarpour M, Vakhshoori M, Abbasi S ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32838801
36. **Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors.** J. Oncol. Pharm. Pract. 2020:1078155220953198Başcı S, Ata N, Altuntaş F ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32854573
37. **IgA Vasculitis with Nephritis (Henoch-Schönlein purpura) in a COVID-19 patient.** Kidney Int Rep 2020; Suso AS, Mon C, Alonso IO ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32839743
38. **Clinical characteristics, therapeutic management, and prognostic factors of adult COVID-19 inpatients with hematological malignancies.** Leuk. Lymphoma 2020:1-11Wu Y, Chen W, Li W ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32840399
39. **Acute pancreatitis and nosocomial COVID-19: Cause specific host responses may determine lung injury.** Pancreatology 2020; Elhence A, Mahapatra SJ, Vajpai T, Garg PK. http://www.ncbi.nlm.nih.gov/pubmed/?term=32859545
40. **ECMO Therapy in a Case of Severe ARDS Related to COVID-19.** Pneumologie 2020; 74:423-428Schmauss M, Müller E, Schwamborn M ***et al.***
41. **[Emergency and intensive care medicine aspects of COVID-19 infections].** Radiologe 2020; Dodt C, Schneider N. http://www.ncbi.nlm.nih.gov/pubmed/?term=32840663
42. **COVID-19 versus HIT hypercoagulability.** Thromb Res 2020; 196:38-51Warkentin TE, Kaatz S. http://www.ncbi.nlm.nih.gov/pubmed/?term=32841919
43. **SARS CoV 2 infection in chronic myelogenous leukemia: Severe hematological presentation.** Transfus. Apher. Sci. 2020:102881Sorà F, Chiusolo P, Laurenti L ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32828694
44. **Coinfection by SARS-CoV-2 and dengue virus in a dual viral circulation setting.** Travel Med Infect Dis 2020:101862Pontes RL, de Brito BB, da Silva FAF ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32858249
45. **The effect of prostacyclin (Iloprost) infusion at a dose of 1 ng/kg/min for 72 hours compared to placebo in mechanically ventilated patients with COVID-19:**

A structured summary of a study protocol for a randomized controlled trial. Trials 2020; 21:746Johansson PI, Bestle M, Søe-Jensen P ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32847626

46. **[Predictive value of neutrophil/lymphocyte ratio on myocardial injury in severe COVID-19 patients].** Zhonghua Xin Xue Guan Bing Za Zhi 2020; 48:572-579Chen Y, Wang KJ, Luo YC ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32842269
47. **[Analysis on the efficacy and safety of fibrinolytic therapy in patients with acute ST-segment elevation myocardial infarction during the COVID-19 epidemic].** Zhonghua Xin Xue Guan Bing Za Zhi 2020; 48:472-476Wei F, Shuai XX, Chen ZJ ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32842256

Cured – Recovered (3 articles)

1. **Pulmonary Rehabilitation: Time for an Upgrade.** J Clin Med 2020; 9Sebio-García R. http://www.ncbi.nlm.nih.gov/pubmed/?term=32854317
2. **Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19.** J Infect 2020; Garrigues E, Janvier P, Kherabi Y ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32853602
3. **Assessment of the Need for Early Initiation of Rehabilitation Treatments in Patients with Coronavirus Disease 2019.** Prog Rehabil Med 2020; 5:20200018Suzuki E, Sakai T, Hoshino C ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32844131

Cardiovascular disease (50 articles)

1. **Neuronophagia and microglial nodules in a SARS-CoV-2 patient with cerebellar hemorrhage.** Acta Neuropathol Commun 2020; 8:147Al-Dalahmah O, Thakur KT, Nordvig AS ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32847628
2. **Utility of D-dimer as a Prognostic Factor in SARS CoV2 Infection: A Review.** Am J Med Case Rep 2020; 8:337-340Kariyanna PT, Aurora L, Jayarangaiah A ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32851129
3. **An adult with COVID-19 kawasaki-like syndrome and ocular manifestations.** Am J Ophthalmol Case Rep 2020; 20:100875Lidder AK, Pandit SA, Lazzaro DR. http://www.ncbi.nlm.nih.gov/pubmed/?term=32839740
4. **Cardio-Cerebrovascular Disease is Associated With Severity and Mortality of COVID-19: A Systematic Review and Meta-Analysis.** Biol. Res. Nurs. 2020:1099800420951984Yu JN, Wu BB, Yang J ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32851851
5. **Reverse takotsubo cardiomyopathy in fulminant COVID-19 associated with cytokine release syndrome and resolution following therapeutic plasma exchange: a case-report.** BMC Cardiovasc. Disord. 2020; 20:389Faqihi F, Alharthy A, Alshaya R ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32842957
6. **Systematic review of COVID-19 related myocarditis: Insights on management and outcome.** Cardiovasc. Revasc. Med. 2020; Sawalha K, Abozenah M, Kadado AJ ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32847728
7. **Cardiogenic Shock and Hyperinflammatory Syndrome in Young Males with COVID-19.** Circ Heart Fail 2020; Chau VQ, Giustino G, Mahmood K ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32844662
8. **Unpuzzling COVID-19 Prothrombotic State: Are Preexisting Thrombophilic Risk Profiles Responsible for Heterogenous Thrombotic Events?** Clin. Appl.

Thromb. Hemost. 2020; 26:1076029620952884Burlacu A, Genovesi S, Popa IV, Crisan-Dabija R. http://www.ncbi.nlm.nih.gov/pubmed/?term=32842771

9. **Incidence and Risk Factors of Deep Vein Thrombosis in Hospitalized COVID-19 Patients.** Clin. Appl. Thromb. Hemost. 2020; 26:1076029620953217Yu Y, Tu J, Lei B ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32854513
10. **Covid-19 Presenting as Acute Limb Ischemia.** Cureus 2020; 12:e9344Singh B, Kaur P, Ajdir N ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32850218
11. **Endothelial Dysfunction in COVID-19: Lessons Learned from Coronaviruses.** Curr. Hypertens. Rep. 2020; 22:63Gavriilaki E, Anyfanti P, Gavriilaki M ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32852642
12. **Reversible cardiac dysfunction in severe COVID-19 infection, mechanisms and case report.** Echocardiography 2020; Chao CJ, DeValeria PA, Sen A ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32856328
13. **COVID-19 and Renin-Angiotensin System Modulators: What Do We Know So Far?** Expert Rev. Cardiovasc. Ther. 2020; de la Cruz A, Ashraf S, Vittorio TJ, Bella JN. http://www.ncbi.nlm.nih.gov/pubmed/?term=32842817
14. **Renin-Angiotensin System and Coronavirus Disease 2019: A Narrative Review.** Front Cardiovasc Med 2020; 7:143Mascolo A, Scavone C, Rafaniello C ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32850989
15. **Incidence of Venous Thromboembolism in Hospitalized Coronavirus Disease 2019 Patients: A Systematic Review and Meta-Analysis.** Front Cardiovasc Med 2020; 7:151Zhang C, Shen L, Le KJ ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32850990
16. **Coronavirus Disease-2019 Conundrum: RAS Blockade and Geriatric-Associated Neuropsychiatric Disorders.** Front Med (Lausanne) 2020; 7:515de Miranda AS, Teixeira AL. http://www.ncbi.nlm.nih.gov/pubmed/?term=32850927
17. **Stroke Care Services in Singapore During COVID-19 Pandemic-A National Perspective.** Front. Neurol. 2020; 11:780Venketasubramanian N. http://www.ncbi.nlm.nih.gov/pubmed/?term=32849231
18. **DPP4 and ACE2 in Diabetes and COVID-19: Therapeutic Targets for Cardiovascular Complications?** Front. Pharmacol. 2020; 11:1161Valencia I, Peiró C, Lorenzo Ó ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32848769
19. **Angiotensin-converting enzyme 2: a double-edged sword in COVID-19 patients with an increased risk of heart failure.** Heart Fail. Rev. 2020; Razeghian-Jahromi I, Zibaeenezhad MJ, Lu Z ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32844337
20. **Plasma Angiotensin Peptide Profiling and ACE2-Activity in COVID-19 Patients treated with Pharmacological Blockers of the Renin Angiotensin System.** Hypertension 2020; Kintscher U, Slagman A, Domenig O ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32851897
21. **Predictive factors for cardiac conduction abnormalities with hydroxychloroquine-containing combinations for COVID-19.** Int J Antimicrob Agents 2020:106142Padilla S, Telenti G, Guillén L ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32853675
22. **Catheterization laboratory activity before and during COVID-19 spread: A comparative analysis in Piedmont, Italy, by the Italian Society of Interventional Cardiology (GISE).** Int J Cardiol 2020; Quadri G, Rognoni A, Cerrato E ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32858138

23. **Prevalence of asymptomatic deep vein thrombosis in patients hospitalized with SARS-CoV-2 pneumonia: a cross-sectional study.** Intern Emerg Med 2020; Giorgi-Pierfranceschi M, Paoletti O, Pan A ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32840805
24. **Management and Outcomes of Patients With STEMI During the COVID-19 Pandemic in China.** J Am Coll Cardiol 2020; Xiang D, Xiang X, Zhang W ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32828614
25. **COVID-19 and cardiac surgery: Do outcomes differ?** J. Card. Surg. 2020; Harky A, Poole G, Axiaq A, Kirmani BH. http://www.ncbi.nlm.nih.gov/pubmed/?term=32845078
26. **Adult cardiac surgery in Trinidad and Tobago during the COVID-19 pandemic: Lessons from a developing country.** J. Card. Surg. 2020; Ramsingh RAE, Duval JL, Rahaman NC ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32845035
27. **Knowledge, perception, and level of confidence regarding COVID-19 care among healthcare workers involved in cardiovascular medicine: a web-based cross-sectional survey in Japan.** J. Cardiol. 2020; Kadoya Y, Zen K, Wakana N ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32859452
28. **A Case Series of Devastating Intracranial Hemorrhage During Venovenous Extracorporeal Membrane Oxygenation for COVID-19.** J Cardiothorac Vasc Anesth 2020; Usman AA, Han J, Acker A ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32828653
29. **Inpatient Cardiac Monitoring Using a Patch-Based Mobile Cardiac Telemetry System During the COVID-19 Pandemic.** J Cardiovasc Electrophysiol 2020; Braunstein ED, Reynbakh O, Krumerman A ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32852868
30. **Prolonged QT Interval in SARS-CoV-2 Infection: Prevalence and Prognosis.** J Clin Med 2020; 9Farré N, Mojón D, Llagostera M ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32839385
31. **Coronavirus disease associated immune thrombocytopenia: Causation or correlation?** J Microbiol Immunol Infect 2020; Pascolini S, Granito A, Muratori L ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32859531
32. **Environmental Factors and Hyperacute Stroke Care Activity During the COVID-19 Pandemic: An Interrupted Time-Series Analysis.** J. Stroke Cerebrovasc. Dis. 2020:105229Gittins M, Ashton C, Holden N ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32828638
33. **COVID-19 Coagulopathy in Pregnancy: Critical Review, Preliminary Recommendations and ISTH Registry - Communication from the ISTH SSC for Women's Health.** J Thromb Haemost 2020; Kadir RA, Kobayashi T, Iba T ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32846051
34. **Response to "Studies on hemostasis in COVID-19 deserve careful reporting of the laboratory methods, their significance and their limitation": don't throw the baby out with the bathwater.** J Thromb Haemost 2020; Nougier C, Benoit R, Dargaud Y. http://www.ncbi.nlm.nih.gov/pubmed/?term=32860301
35. **Acute Upper Limb Ischemia as the First Manifestation in a Patient with COVID-19.** J Vasc Surg Cases Innov Tech 2020; Shao T, In-Bok Lee C, Jabori S ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32844136
36. **Delayed Presentation of STEMI Complicated by Ventricular Septal Rupture in the Era of COVID-19 Pandemic.** JACC Case Rep 2020; 2:1599-1602Ahmed T,

Nautiyal A, Kapadia S, Nissen SE. http://www.ncbi.nlm.nih.gov/pubmed/?term=32839758

37. **Acute Myocardial Infarction and Papillary Muscle Rupture in the COVID-19 Era.** JACC Case Rep 2020; 2:1637-1641Atreya AR, Kawamoto K, Yelavarthy P ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32839759
38. **Surge in Delayed Myocardial Infarction Presentations: An Inadvertent Consequence of Social Distancing During the COVID-19 Pandemic.** JACC Case Rep 2020; 2:1642-1647Shah K, Tang D, Ibrahim F ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32839760
39. **Cardiovascular Diseases (CVDs) in COVID-19 Pandemic Era.** Mater Sociomed 2020; 32:158-164Gerc V, Masic I, Salihefendic N, Zildzic M. http://www.ncbi.nlm.nih.gov/pubmed/?term=32843866
40. **Anticoagulation use and Hemorrhagic Stroke in SARS-CoV-2 Patients Treated at a New York Healthcare System.** Neurocrit. Care 2020; Kvernland A, Kumar A, Yaghi S ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32839867
41. **Non-aneurysmal subarachnoid haemorrhage in COVID-19.** Neuroradiology 2020; Harrogate S, Mortimer A, Burrows L ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32857213
42. **A proof of evidence supporting abnormal immunothrombosis in severe COVID-19: naked megakaryocyte nuclei increase in the bone marrow and lungs of critically ill patients.** Platelets 2020:1-5Roncati L, Ligabue G, Nasillo V ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32857624
43. **COVID-19 and Comorbid Hypertension: Is ACE2 the Culprit?** Prehosp. Disaster Med. 2020:1-6Zhang T, Zhong S, Cao W. http://www.ncbi.nlm.nih.gov/pubmed/?term=32838828
44. **Anticoagulant protein S in COVID-19: low activity, and associated with outcome.** Rom. J. Intern. Med. 2020; Stoichitoiu LE, Pinte L, Balea MI ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32841167
45. **Labile PT-INR in a Covid-19 Patient Under Long-term Vitamin K Antagonist Therapy: a Case Report.** SN Compr Clin Med 2020:1-3Trevisan C, Miconi L, Barbierato E ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32839751
46. **Venous thromboembolism in patients with COVID-19: Systematic review and meta-analysis.** Thromb Res 2020; 196:67-74Porfidia A, Valeriani E, Pola R ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32853978
47. **COVID-19 versus HIT hypercoagulability.** Thromb Res 2020; 196:38-51Warkentin TE, Kaatz S. http://www.ncbi.nlm.nih.gov/pubmed/?term=32841919
48. **[Predictive value of neutrophil/lymphocyte ratio on myocardial injury in severe COVID-19 patients].** Zhonghua Xin Xue Guan Bing Za Zhi 2020; 48:572-579Chen Y, Wang KJ, Luo YC ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32842269
49. **[Prognostic value of myocardial injury in patients with COVID-19].** Zhonghua Xin Xue Guan Bing Za Zhi 2020; 48:461-466Wang L, He WB, Yu XM ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32842255
50. **[Analysis on the efficacy and safety of fibrinolytic therapy in patients with acute ST-segment elevation myocardial infarction during the COVID-19 epidemic].** Zhonghua Xin Xue Guan Bing Za Zhi 2020; 48:472-476Wei F, Shuai XX, Chen ZJ ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32842256

Diagnosis (3 articles)

1. **Profiling cases with non-respiratory symptoms and asymptomatic SARS-CoV-2 infections in Mexico City.** Clin Infect Dis 2020; Bello-Chavolla OY, Antonio-Villa NE, Vargas-Vázquez A ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32857829
2. **The Diagnostic Methods in the COVID-19 Pandemic, Today and in the Future.** Expert Rev Mol Diagn 2020; Wu SY, Yau HS, Yu MY ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32845192
3. **AI4COVID-19: AI enabled preliminary diagnosis for COVID-19 from cough samples via an app.** Inform Med Unlocked 2020; 20:100378Imran A, Posokhova I, Qureshi HN ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32839734

DM-MS-Obesity (18 articles)

1. **Association between Body Mass Index and Risk of COVID-19: A Nationwide Case-Control Study in South Korea.** Clin Infect Dis 2020; Jung CY, Park H, Kim DW ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32841322
2. **Hemoglobin A1C is a Predictor of COVID-19 Severity in Patients with Diabetes.** Diabetes Metab Res Rev 2020:e3398Merzon E, Green I, Shpigelman M ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32852883
3. **A cross sectional study reveals severe disruption in glycemic control in people with diabetes during and after lockdown in India.** Diabetes Metab Syndr 2020; 14:1579-1584Khader MA, Jabeen T, Namoju R. http://www.ncbi.nlm.nih.gov/pubmed/?term=32858476
4. **Observational study on Effect of Lock Down due to COVID 19 on glycemic control in patients with Diabetes: Experience from Central India.** Diabetes Metab Syndr 2020; 14:1571-1574Khare J, Jindal S. http://www.ncbi.nlm.nih.gov/pubmed/?term=32858474
5. **Clinical profile and outcomes in COVID-19 patients with diabetic ketoacidosis: A systematic review of literature.** Diabetes Metab Syndr 2020; 14:1563-1569Pal R, Banerjee M, Yadav U, Bhattacharjee S. http://www.ncbi.nlm.nih.gov/pubmed/?term=32853901
6. **Hyperglycemia and COVID-19: what was known and what is really new?** Diabetes Res Clin Pract 2020:108383Ceriello A. http://www.ncbi.nlm.nih.gov/pubmed/?term=32853690
7. **The challenge of diabetes home control in COVID-19 times: proof is in the pudding.** Diabetes Res Clin Pract 2020:108379Cotovad-Bellas L, Tejera-Pérez C, Prieto-Tenreiro A ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32853692
8. **Hyperglycemia without Diabetes and New-Onset Diabetes are both associated with Poorer Outcomes in COVID-19.** Diabetes Res Clin Pract 2020:108382Kumar Singh A, Singh R. http://www.ncbi.nlm.nih.gov/pubmed/?term=32853686
9. **The association of diabetes and the prognosis of COVID-19 patients: a retrospective study.** Diabetes Res Clin Pract 2020:108386Liu Z, Bai X, Han X ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32853685
10. **Caring for a Child with Type 1 Diabetes During COVID-19 lockdown in a developing country: Challenges and Parents' Perspectives on the Use of Telemedicine.** Diabetes Res Clin Pract 2020:108393Odeh R, Gharaibeh L, Daher A ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32858098
11. **J-shaped Association Between Fasting Blood Glucose Levels and COVID-19 Severity in Patients without Diabetes.** Diabetes Res Clin Pract 2020:108381Zhu B, Jin S, Wu L ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32853687

12. **Fasting Plasma Glucose Level Independently Predicts the Mortality of Patients with Coronavirus Disease 2019 Infection: A Multicenter, Retrospective Cohort Study.** Endocrinol Metab (Seoul) 2020; Chang MC, Hwang JM, Jeon JH ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32842719
13. **Hypercoagulopathy and Adipose Tissue Exacerbated Inflammation May Explain Higher Mortality in COVID-19 Patients With Obesity.** Front. Endocrinol. (Lausanne) 2020; 11:530Pasquarelli-do-Nascimento G, Braz-de-Melo HA, Faria SS ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32849309
14. **DPP-4 Inhibitors in the Prevention/Treatment of Pulmonary Fibrosis, Heart and Kidney Injury Caused by COVID-19-A Therapeutic Approach of Choice in Type 2 Diabetic Patients?** Front. Pharmacol. 2020; 11:1185Smelcerovic A, Kocic G, Gajic M ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32848788
15. **DPP4 and ACE2 in Diabetes and COVID-19: Therapeutic Targets for Cardiovascular Complications?** Front. Pharmacol. 2020; 11:1161Valencia I, Peiró C, Lorenzo Ó ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32848769
16. **Immune dysregulation and Multisystem Inflammatory Syndrome in Children (MIS-C) in individuals with haploinsufficiency of SOCS1.** J Allergy Clin Immunol 2020; Lee PY, Platt CD, Weeks S ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32853638
17. **Successful Initiation of Hybrid Closed-Loop System Using Virtual Pump Training Program in a Teenager With Type 1 Diabetes Previously Treated with Multiple Daily Injections.** J. Diabetes Sci. Technol. 2020:1932296820950753Petrovski G, Campbell J, Almajali D ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32840120
18. **Individuals with obesity and COVID-19: A global perspective on the epidemiology and biological relationships.** Obes Rev 2020; Popkin BM, Du S, Green WD ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32845580

Education and training and science (24 articles)

1. **Managing Resident Workforce and Residency Training During COVID-19 Pandemic: Scoping Review of Adaptive Approaches.** Adv Med Educ Pract 2020; 11:527-535Tolu LB, Feyissa GT, Ezeh A, Gudu W. http://www.ncbi.nlm.nih.gov/pubmed/?term=32848492
2. **Fear, Loss, Social Isolation, and Incomplete Grief Due to COVID-19: A Recipe for a Psychiatric Pandemic.** Basic Clin Neurosci 2020; 11:225-232Mortazavi SS, Assari S, Alimohamadi A ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32855782
3. **Facing COVID-19, Jumping From In-Person Training To Virtual Learning: A Review on Educational and Clinical Activities in a Neurology Department.** Basic Clin Neurosci 2020; 11:151-154Zeinali M, Almasi-Doghaee M, Haghi-Ashtiani B. http://www.ncbi.nlm.nih.gov/pubmed/?term=32855773
4. **The sudden transition to synchronized online learning during the COVID-19 pandemic in Saudi Arabia: a qualitative study exploring medical students' perspectives.** BMC Med. Educ. 2020; 20:285Khalil R, Mansour AE, Fadda WA ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32859188
5. **A cross-sectional survey of knowledge, attitude and practice associated with COVID-19 among undergraduate students in China.** BMC Public Health 2020;

20:1292Peng Y, Pei C, Zheng Y ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32847554

6. **Maintaining education and professional development for anaesthesia trainees during the COVID-19 pandemic: the Self-isolAting Virtual Education (SAVEd) project.** Br J Anaesth 2020; Eusuf DV, England EL, Charlesworth M ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32859361
7. **The use of knowledge management tools in viroinformatics. Example study of a highly conserved sequence motif in Nsp3 of SARS-CoV-2 as a therapeutic target.** Comput. Biol. Med. 2020; 125:103963Robson B. http://www.ncbi.nlm.nih.gov/pubmed/?term=32828990
8. **Novel 4W (When-Where-What-What) Approach of Training Point-of-Care Ultrasound (POCUS) Application in Resuscitation With High-Fidelity Simulator.** Cureus 2020; 12:e9353Wang H, Uraco AM, Stover J, Hollis N. http://www.ncbi.nlm.nih.gov/pubmed/?term=32850225
9. **Effectiveness and influencing factors of online education for caregivers of patients with eating disorders during COVID-19 pandemic in China.** Eur Eat Disord Rev 2020; Guo L, Wu M, Zhu Z ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32852142
10. **Data sharing during COVID-19 pandemic: what to take away.** Expert Rev. Gastroenterol. Hepatol. 2020; Rios RS, Zheng KI, Zheng MH. http://www.ncbi.nlm.nih.gov/pubmed/?term=32842793
11. **Open Access of COVID-19-related publications in the first quarter of 2020: a preliminary study based in PubMed.** F1000Res 2020; 9:649Arrizabalaga O, Otaegui D, Vergara I ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32850121
12. **COVID-19 Related Experience, Knowledge, Attitude, and Behaviors Among 2,669 Orthodontists, Orthodontic Residents, and Nurses in China: A Cross-Sectional Survey.** Front Med (Lausanne) 2020; 7:481Hua F, Qin D, Yan J ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32850923
13. **Misconceptions on COVID-19 Risk Among Ugandan Men: Results From a Rapid Exploratory Survey, April 2020.** Front Public Health 2020; 8:416Kasozi KI, MacLeod E, Ssempijja F ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32850606
14. **The scale of COVID-19 graphs affects understanding, attitudes, and policy preferences.** Health Econ. 2020; Romano A, Sotis C, Dominioni G, Guidi S. http://www.ncbi.nlm.nih.gov/pubmed/?term=32844495
15. **Ethical Considerations for safeguarding human participants in pandemic research: a rapid review protocol.** HRB Open Res 2020; 3:22O'Sullivan L, Killeen RP, Doran P, Crowley RK. http://www.ncbi.nlm.nih.gov/pubmed/?term=32832851
16. **Gaining "The Quarantine 15:" Perceived versus observed weight changes in college students in the wake of COVID-19.** Int. J. Eat. Disord. 2020; Keel PK, Gomez MM, Harris L ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32856752
17. **Strategies for Effective Medical Student Education in Dermatology During the COVID-19 Pandemic.** J Am Acad Dermatol 2020; Ashrafzadeh S, Imadojemu SE, Vleugels RA, Buzney EA. http://www.ncbi.nlm.nih.gov/pubmed/?term=32828857
18. **Knowledge, perception, and level of confidence regarding COVID-19 care among healthcare workers involved in cardiovascular medicine: a web-based cross-sectional survey in Japan.** J. Cardiol. 2020; Kadoya Y, Zen K, Wakana N ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32859452

19. **Stress assessment among internal medicine residents in a level-3 hospital versus a level-2 hospital with only emergency room service for COVID-19.** J Community Hosp Intern Med Perspect 2020; 10:301-305Milgrom Y, Richter V. http://www.ncbi.nlm.nih.gov/pubmed/?term=32850084
20. **Nursing Home Social Workers Perceptions of Preparedness and Coping for COVID-19.** J. Gerontol. B Psychol. Sci. Soc. Sci. 2020; Miller VJ, Fields NL, Anderson KA ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32861215
21. **Interprofessional education and collaborative practice research during the COVID-19 pandemic: Considerations to advance the field.** J Interprof Care 2020:1-4Lackie K, Najjar G, El-Awaisi A ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32838595
22. **Perception and attitudes of medical students on clinical clerkship in the era of the Coronavirus Disease 2019 pandemic.** Med. Educ. Online 2020; 25:1809929Kim SM, Park SG, Jee YK, Song IH. http://www.ncbi.nlm.nih.gov/pubmed/?term=32840462
23. **Factors determining the knowledge and prevention practice of healthcare workers towards COVID-19 in Amhara region, Ethiopia: a cross-sectional survey.** Trop Med Health 2020; 48:72Asemahagn MA. http://www.ncbi.nlm.nih.gov/pubmed/?term=32839649
24. **Impact of COVID-19 on medical education: introducing homo digitalis.** World J. Urol. 2020; Gravas S, Ahmad M, Hernández-Porras A ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32860535

Elderly (8 articles)

1. **Respiratory epidemics and older people.** Age Ageing 2020; Doraiswamy S, Mamtani R, Ameduri M ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32857159
2. **Material hardship and parenting stress among grandparent kinship providers during the COVID-19 pandemic: The mediating role of grandparents' mental health.** Child Abuse Negl. 2020:104700Xu Y, Wu Q, Levkoff SE, Jedwab M. http://www.ncbi.nlm.nih.gov/pubmed/?term=32854948
3. **Remodeling of the Immune Response With Aging: Immunosenescence and Its Potential Impact on COVID-19 Immune Response.** Front. Immunol. 2020; 11:1748Cunha LL, Perazzio SF, Azzi J ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32849623
4. **A public health perspective of aging: do hyper-inflammatory syndromes such as COVID-19, SARS, ARDS, cytokine storm syndrome, and post-ICU syndrome accelerate short- and long-term inflammaging?** Immun. Ageing 2020; 17:23Bektas A, Schurman SH, Franceschi C, Ferrucci L. http://www.ncbi.nlm.nih.gov/pubmed/?term=32849908
5. **Underlying Vulnerabilities to the Cytokine Storm and Adverse COVID-19 Outcomes in the Aging Immune System.** J Gerontol A Biol Sci Med Sci 2020; Nidadavolu L, Walston J. http://www.ncbi.nlm.nih.gov/pubmed/?term=32841329
6. **Clinical Characteristics and Outcomes of 821 Older Patients with SARS-Cov-2 Infection Admitted to Acute Care Geriatric Wards.** J Gerontol A Biol Sci Med Sci 2020; Zerah L, Baudouin É, Pépin M ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32845301
7. **Implication of Aging Related Chronic Neuroinflammation on COVID-19 Pandemic.** J Pers Med 2020; 10Bossù P, Toppi E, Sterbini V, Spalletta G.

http://www.ncbi.nlm.nih.gov/pubmed/?term=32858874

8. **Decreased prealbumin level is associated with increased risk for mortality in elderly hospitalized patients with COVID-19.** Nutrition 2020; 78:110930Zuo P, Tong S, Yan Q ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32854020

Epidemiology (62 articles)

1. **Distanced-based dynamic behaviour of aerosol particles during aerosol-generating medical procedures.** Br J Anaesth 2020; Tsui BCH, Pan S. http://www.ncbi.nlm.nih.gov/pubmed/?term=32828494
2. **Triage tool for suspected COVID-19 patients in the emergency room: AIFELL score.** Braz. J. Infect. Dis. 2020; Levenfus I, Ullmann E, Battegay E, Schuurmans MM. http://www.ncbi.nlm.nih.gov/pubmed/?term=32828735
3. **Population density, a factor in the spread of COVID-19 in Algeria: statistic study.** Bull Natl Res Cent 2020; 44:138Kadi N, Khelfaoui M. http://www.ncbi.nlm.nih.gov/pubmed/?term=32843835
4. **COVID-19 in sub-Saharan Africa: impacts on vulnerable populations and sustaining home-grown solutions.** Can. J. Public Health. 2020; Wallace LJ, Nouvet E, Bortolussi R ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32845460
5. **Emerging Pandemic Diseases: How We Got to COVID-19.** Cell 2020; Morens DM, Fauci AS. http://www.ncbi.nlm.nih.gov/pubmed/?term=32846157
6. **Deep learning models for forecasting and analyzing the implications of COVID-19 spread on some commodities markets volatilities.** Chaos Solitons Fractals 2020; 140:110215Sadefo Kamdem J, Bandolo Essomba R, Njong Berinyuy J. http://www.ncbi.nlm.nih.gov/pubmed/?term=32839644
7. **Predictions for COVID-19 with deep learning models of LSTM, GRU and Bi-LSTM.** Chaos Solitons Fractals 2020; 140:110212Shahid F, Zameer A, Muneeb M. http://www.ncbi.nlm.nih.gov/pubmed/?term=32839642
8. **Time series forecasting of Covid-19 using deep learning models: India-USA comparative case study.** Chaos Solitons Fractals 2020; 140:110227Shastri S, Singh K, Kumar S ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32843824
9. **Time series prediction for the epidemic trends of COVID-19 using the improved LSTM deep learning method: Case studies in Russia, Peru and Iran.** Chaos Solitons Fractals 2020; 140:110214Wang P, Zheng X, Ai G ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32839643
10. **Spatio-temporal estimation of the daily cases of COVID-19 in worldwide using random forest machine learning algorithm.** Chaos Solitons Fractals 2020; 140:110210YeŞİlkanat CM. http://www.ncbi.nlm.nih.gov/pubmed/?term=32843823
11. **Existing Data Sources in Clinical Epidemiology: The Danish COVID-19 Cohort.** Clin. Epidemiol. 2020; 12:875-881Pottegård A, Kristensen KB, Reilev M ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32848476
12. **The basic reproduction number of the new coronavirus pandemic with mortality for India, the Syrian Arab Republic, the United States, Yemen, China, France, Nigeria and Russia with different rate of cases.** Clin Epidemiol Glob Health 2020; Al-Raeei M. http://www.ncbi.nlm.nih.gov/pubmed/?term=32844133
13. **Using Serologic Testing to Assess the Effectiveness of Outbreak Control Efforts, Serial PCR Testing, and Cohorting of Positive SARS-CoV-2 Patients in a Skilled Nursing Facility.** Clin Infect Dis 2020; Dora AV, Winnett A, Fulcher JA ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32857830

14. **Viewpoint of a WHO Advisory Group Tasked to Consider Establishing a Closely-Monitored Challenge Model of COVID-19 in Healthy Volunteers.** Clin Infect Dis 2020; Levine MM, Abdullah S, Arabi YM ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32857836
15. **COVID-19 patients in earlier stages exhaled millions of SARS-CoV-2 per hour.** Clin Infect Dis 2020; Ma J, Qi X, Chen H ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32857833
16. **Concomitant marked decline in prevalence of SARS-CoV-2 and other respiratory viruses among symptomatic patients following public health interventions in Australia: data from St Vincent's Hospital and associated screening clinics, Sydney, NSW.** Clin Infect Dis 2020; Marriott D, Beresford R, Mirdad F ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32841316
17. **COVID-19, Australia: Epidemiology Report 23 (Fortnightly reporting period ending 16 August 2020).** Commun Dis Intell (2018) 2020; 44. http://www.ncbi.nlm.nih.gov/pubmed/?term=32847492
18. **Global COVID-19 Efforts as the Platform to Achieving the Sustainable Development Goals.** Curr Trop Med Rep 2020:1-5Mejia R, Hotez P, Bottazzi ME. http://www.ncbi.nlm.nih.gov/pubmed/?term=32844081
19. **Covid-19 Dataset: Worldwide spread log including countries first case and first death.** Data Brief 2020; 32:106173Ali H, Hossain MF, Hasan MM, Abujar S. http://www.ncbi.nlm.nih.gov/pubmed/?term=32844105
20. **Generated Time-series Prediction Data of COVID-19's Daily Infections in Brazil by Using Recurrent Neural Networks.** Data Brief 2020; 32:106175Hawas M. http://www.ncbi.nlm.nih.gov/pubmed/?term=32839733
21. **Socio-demographic heterogeneity in the prevalence of COVID-19 during lockdown is associated with ethnicity and household size: Results from an observational cohort study.** EClinicalMedicine 2020:100466Martin CA, Jenkins DR, Minhas JS ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32840492
22. **Spread of SARS-CoV-2 through Latin America and the Caribbean region: A look from its economic conditions, climate and air pollution indicators.** Environ. Res. 2020; 191:109938Bolaño-Ortiz TR, Camargo-Caicedo Y, Puliafito SE ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32858479
23. **Population-level COVID-19 mortality risk for non-elderly individuals overall and for non-elderly individuals without underlying diseases in pandemic epicenters.** Environ. Res. 2020; 188:109890Ioannidis JPA, Axfors C, Contopoulos-Ioannidis DG. http://www.ncbi.nlm.nih.gov/pubmed/?term=32846654
24. **[Not Available].** Ethics Med Public Health 2020:100580Etteh CC, Adoga MP, Ogbaga CC. http://www.ncbi.nlm.nih.gov/pubmed/?term=32844107
25. **The Enigma of Low COVID-19 Fatality Rate in India.** Front Genet 2020; 11:854Samaddar A, Gadepalli R, Nag VL, Misra S. http://www.ncbi.nlm.nih.gov/pubmed/?term=32849833
26. **Global and Temporal COVID-19 Risk Evaluation.** Front Public Health 2020; 8:440Arsalan M, Mubin O, Alnajjar F ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32850611
27. **Evaluation of the effect of the state of emergency for the first wave of COVID-19 in Japan.** Infect Dis Model 2020; 5:580-587Kuniya T. http://www.ncbi.nlm.nih.gov/pubmed/?term=32844135
28. **Mathematical modelling on diffusion and control of COVID-19.** Infect Dis Model 2020; 5:588-597Veera Krishna M. http://www.ncbi.nlm.nih.gov/pubmed/?

term=32844134
29. **The first months of COVID-19 in Madagascar.** Infect Genet Evol 2020; 85:104506Narison S. http://www.ncbi.nlm.nih.gov/pubmed/?term=32828939
30. **Big Data Analytics in the Fight against Major Public Health Incidents (Including COVID-19): A Conceptual Framework.** Int J Environ Res Public Health 2020; 17Jia Q, Guo Y, Wang G, Barnes SJ. http://www.ncbi.nlm.nih.gov/pubmed/?term=32854265
31. **COVID-19 Experience: Taking the Right Steps at the Right Time to Prevent Avoidable Morbidity and Mortality in Nigeria and Other Nations of the World.** Int. J. Gen. Med. 2020; 13:491-495Oleribe OO, Osita-Oleribe P, Salako BL ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32848447
32. **Clusters of COVID-19 associated with Purim celebration in the Jewish community in Marseille, France, March 2020.** Int J Infect Dis 2020; Aherfi S, Gautret P, Chaudet H ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32829043
33. **COVID-19 epidemic monitoring after non-pharmaceutical interventions: the use of time-varying reproduction number in a country with a large migrant population.** Int J Infect Dis 2020; Al Wahaibi A, Al Manji A, Al Maani A ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32829052
34. **Airborne Transmission of Covid-19: Implications for Irish Hospitals.** Ir Med J 2020; 113:126Humphreys H, Fitzpatrick F. http://www.ncbi.nlm.nih.gov/pubmed/?term=32846080
35. **Long-Term Care, Residential Facilities, and COVID-19: An Overview of Federal and State Policy Responses.** J. Am. Med. Dir. Assoc. 2020; 21:1186-1190Chen AT, Ryskina KL, Jung HY. http://www.ncbi.nlm.nih.gov/pubmed/?term=32859298
36. **Nosocomial Coronavirus Disease 2019 (COVID-19): Experience from a large Acute NHS Trust in South-West London.** J Hosp Infect 2020; Taylor J, Rangaiah J, Narasimhan S ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32841703
37. **Preventing COVID-19 from the perspective of industrial information integration: Evaluation and continuous improvement of information networks for sustainable epidemic prevention.** J Ind Inf Integr 2020; 19:100157Yin S, Zhang N, Dong H. http://www.ncbi.nlm.nih.gov/pubmed/?term=32839741
38. **Findings from a probability-based survey of U.S. households about prevention measures based on race, ethnicity, and age in response to SARS-CoV-2.** J Infect Dis 2020; Sauceda JA, Neilands TB, Lightfoot M, Saberi P. http://www.ncbi.nlm.nih.gov/pubmed/?term=32860499
39. **Cluster of SARS-CoV-2 infections linked to music clubs in Osaka, Japan: asymptomatically infected persons can transmit the virus as soon as 2 days after infection.** J Infect Dis 2020; Sugano N, Ando W, Fukushima W. http://www.ncbi.nlm.nih.gov/pubmed/?term=32840606
40. **Epidemiologic surveillance for controlling Covid-19 pandemic: types, Challenges and implications.** J Infect Public Health 2020; Ibrahim NK. http://www.ncbi.nlm.nih.gov/pubmed/?term=32855090
41. **Understanding the epidemiology, pathophysiology, diagnosis and management of SARS-CoV-2.** J. Int. Med. Res. 2020; 48:300060520949077Fadaka AO, Sibuyi NRS, Adewale OB ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32842818
42. **Palestinian Health Care Workers' Stress and Stressors During COVID-19 Pandemic: A Cross-Sectional Study.** J. Prim. Care Community Health 2020;

11:2150132720955026Maraqa B, Nazzal Z, Zink T. http://www.ncbi.nlm.nih.gov/pubmed/?term=32847464
43. **COVID-19 After Effects: Concerns for Singers.** J. Voice 2020; Helding L, Carroll TL, Nix J ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32839055
44. **Four Challenges Associated With Current Mathematical Modeling Paradigm of Infectious Diseases and Call for a Shift.** Open Forum Infect Dis 2020; 7:ofaa333Chen S, Robinson P, Janies D, Dulin M. http://www.ncbi.nlm.nih.gov/pubmed/?term=32851113
45. **Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a newly emerged pathogen: an overview.** Pathog Dis 2020; Rathore JS, Ghosh C. http://www.ncbi.nlm.nih.gov/pubmed/?term=32840560
46. **Reduction of West Nile virus infections in Italy during 2020 early summer: a secondary 'COVID-19' effect?** Pathog Glob Health 2020:1-2Zuin M, Rigatelli G, Roncon L. http://www.ncbi.nlm.nih.gov/pubmed/?term=32845819
47. **A note on the effects of epidemic forecasts on epidemic dynamics.** PeerJ 2020; 8:e9649Record NR, Pershing A. http://www.ncbi.nlm.nih.gov/pubmed/?term=32844061
48. **A Simple Algorithm for Return to Workplace Employer Antibody Testing.** Popul Health Manag 2020; Shrank WH, Caveney B, Miller S ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32857015
49. **The Essential Role of Technology in the Public Health Battle Against COVID-19.** Popul Health Manag 2020; Uohara MY, Weinstein JN, Rhew DC. http://www.ncbi.nlm.nih.gov/pubmed/?term=32857014
50. **Revealing regional disparities in the transmission potential of SARS-CoV-2 from interventions in Southeast Asia.** Proc. Biol. Sci. 2020; 287:20201173Lim JT, Dickens BSL, Choo ELW ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32842911
51. **A network-based explanation of why most COVID-19 infection curves are linear.** Proc Natl Acad Sci U S A 2020; Thurner S, Klimek P, Hanel R. http://www.ncbi.nlm.nih.gov/pubmed/?term=32839315
52. **Implications for border containment strategies when COVID-19 presents atypically.** Public Health 2020; 186:193-196Teo WY. http://www.ncbi.nlm.nih.gov/pubmed/?term=32861084
53. **Outbreak and Regression of COVID-19 Epidemic Among Chinese Medical Staff.** Risk Manag. Healthc. Policy 2020; 13:1095-1102Li N, Yu X. http://www.ncbi.nlm.nih.gov/pubmed/?term=32848486
54. **Interventions to suppress the coronavirus pandemic will increase unemployment and lead to many premature deaths.** Scand J Public Health 2020:1403494820947974Rosén M, Stenbeck M. http://www.ncbi.nlm.nih.gov/pubmed/?term=32842900
55. **Modeling Return of the Epidemic: Impact of Population Structure, Asymptomatic Infection, Case Importation and Personal Contacts.** Travel Med Infect Dis 2020:101858Yu X. http://www.ncbi.nlm.nih.gov/pubmed/?term=32860959
56. **A dashboard for monitoring preventive measures in response to COVID-19 outbreak in the Democratic Republic of Congo.** Trop Med Health 2020; 48:74Wimba PM, Bazeboso JA, Katchunga PB ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32855618
57. **COVID-19 surveillance in Southeastern Virginia using wastewater-based epidemiology.** Water Res 2020; 186:116296Gonzalez R, Curtis K, Bivins A ***et al.***

http://www.ncbi.nlm.nih.gov/pubmed/?term=32841929

58. **[Comparison of epidemic characteristics between severe acute respiratory syndrome and coronavirus disease 2019].** Zhonghua Yu Fang Yi Xue Za Zhi 2020; 54:726-730Cai WF, Yuan J, Huang LF ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32842293
59. **[Expanding the pandemic influenza preparedness framework to the epidemic of COVID-19].** Zhonghua Yu Fang Yi Xue Za Zhi 2020; 54:597-601Li BZ, Li MS, Huang JY ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32842276
60. **[Construction of urban scale-free network model and its epidemiological significance in the prevention and control of COVID-19].** Zhonghua Yu Fang Yi Xue Za Zhi 2020; 54:817-821Song WY, Ding ZX, Hu JL ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32842308
61. **[Principles of dynamics model and its application in forecasting the epidemics and evaluation the efforts of prevention and control interventions].** Zhonghua Yu Fang Yi Xue Za Zhi 2020; 54:602-607Wei YY, Zhao Y, Chen F, Shen HB. http://www.ncbi.nlm.nih.gov/pubmed/?term=32842277
62. **[Analysis on the cluster epidemic of coronavirus disease 2019 in Guangdong Province].** Zhonghua Yu Fang Yi Xue Za Zhi 2020; 54:720-725Zhuang YL, Zhang YT, Li M ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32842292

Gastro-enterology (10 articles)

1. **Clinical characteristics of chronic liver disease with coronavirus disease 2019 (COVID-19): a cohort study in Wuhan, China.** Aging (Albany NY) 2020; 12Li C, Chen Q, Wang J ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32855361
2. **Systematic review with meta-analysis: SARS-CoV-2 stool testing and the potential for faecal-oral transmission.** Aliment. Pharmacol. Ther. 2020; van Doorn AS, Meijer B, Frampton CMA ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32852082
3. **A case of COVID-19 immediately after liver transplantation: Not only bad news.** Ann Hepatobiliary Pancreat Surg 2020; 24:314-318Prieto M, Gastaca M, Ruiz P ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32843598
4. **SARS-CoV-2 another kind of liver aggressor, how does it do that?** Ann. Hepatol. 2020; Lozano-Sepulveda SA, Galan-Huerta K, Martínez-Acuña N ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32858226
5. **COVID-19 in patients with Inflammatory Bowel Disease.** Expert Rev. Gastroenterol. Hepatol. 2020; Anikhindi SA, Kumar A, Arora A. http://www.ncbi.nlm.nih.gov/pubmed/?term=32856955
6. **Involvement of the digestive system in covid-19. A review.** Gastroenterol. Hepatol. 2020; Sanz Segura P, Arguedas Lázaro Y, Mostacero Tapia S ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32859408
7. **Asymptomatic SARS-CoV-2 infection in patients with inflammatory bowel disease under biologic treatment.** Gastroenterology 2020; Norsa L, Cosimo P, Indriolo A ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32860790
8. **Gastrointestinal bleeding in a newborn infant with congenital factor X deficiency and COVID-19-A common clinical feature between a rare disorder and a new, common infection.** Int. J. Lab. Hematol. 2020; Dorgalaleh A, Baghaipour MR, Tabibian S ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32845081

9. **An Atypical Presentation of COVID-19 in a Previously Healthy Young Male With a Rare Cause of Abdominal Pain.** J. Clin. Med. Res. 2020; 12:624-628Bashari DR, Peguero-Tejada JL, Shah JI. http://www.ncbi.nlm.nih.gov/pubmed/?term=32849952
10. **Attaching clinical significance to COVID-19-associated diarrhea.** Life Sci 2020; 260:118312Wang F, Zheng S, Zheng C, Sun X. http://www.ncbi.nlm.nih.gov/pubmed/?term=32846165

Guidelines (8 articles)

1. **COVID-19 and Substance Use Disorders: Recommendations to a Comprehensive Healthcare Response. An International Society of Addiction Medicine Practice and Policy Interest Group Position Paper.** Basic Clin Neurosci 2020; 11:133-150Farhoudian A, Baldacchino A, Clark N ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32855772
2. **Management of new onset loss of sense of smell during the COVID-19 pandemic - BRS Consensus Guidelines.** Clin. Otolaryngol. 2020; Hopkins C, Alanin M, Philpott C ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32854169
3. **CSANZ Position Statement on COVID-19 From the Paediatric and Congenital Council(☆).** Heart Lung Circ. 2020; Ayer J, Anderson B, Gentles TL, Cordina RL. http://www.ncbi.nlm.nih.gov/pubmed/?term=32839114
4. **CSANZ COVID-19 Cardiovascular Nursing Care Consensus Statement: Executive Summary.** Heart Lung Circ. 2020; Inglis SC, Naismith C, White K ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32859539
5. **Evolving Consensus of International Uveitis Study Group, Intraocular Inflammation Society, and Foster Ocular Inflammation Society with Uveitis in the Time of COVID-19 Infection.** Klin. Monbl. Augenheilkd. 2020; Zierhut M, de MDS, Gupta V ***et al.***
6. **Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI-AeDA-GPA-DGAKI Position Paper (Pocket-Guide).** Laryngo- rhino-otologie 2020; Pfaar O, Klimek L, Worm M ***et al.***
7. **ISNO Position Statement on Treatment Guidance in Neuro-oncology During Pandemics.** Neurol. India 2020; 68:769-773Gupta T, Singh VP, Balasubramian A ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32859812
8. **Obesity and Metabolic Surgery Society of India (OSSI) Recommendations for Bariatric and Metabolic Surgery Practice During the COVID-19 Pandemic.** Obes. Surg. 2020:1-7Aggarwal S, Mahawar K, Khaitan M ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32829450

Imaging (21 articles)

1. **Multiinstitutional U.S. Academic Radiology Perspectives on Inpatient Diagnostic Imaging of Patients With Coronavirus Disease (COVID-19) and Persons Under Investigation.** AJR Am J Roentgenol 2020:1-7C CM, J WA, Dighe M ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32845160
2. **HSMA_WOA: A hybrid novel Slime mould algorithm with whale optimization algorithm for tackling the image segmentation problem of chest X-ray images.** Appl Soft Comput 2020:106642Abdel-Basset M, Chang V, Mohamed R. http://www.ncbi.nlm.nih.gov/pubmed/?term=32843887

3. **Recording COVID-19 consultations: review of symptoms, risk factors, and proposed SNOMED CT terms.** BJGP Open 2020; Jani BD, Pell JP, McGagh D ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32843331
4. **The bullseye sign: A variant of the reverse halo sign in COVID-19 pneumonia.** Clin Imaging 2020; 68:191-196McLaren TA, Gruden JF, Green DB. http://www.ncbi.nlm.nih.gov/pubmed/?term=32853842
5. **An Analysis of High-Resolution Computed Tomography Chest Manifestations of COVID-19 Patients in Pakistan.** Cureus 2020; 12:e9373Khaliq M, Raja R, Khan N, Hanif H. http://www.ncbi.nlm.nih.gov/pubmed/?term=32850241
6. **Novel 4W (When-Where-What-What) Approach of Training Point-of-Care Ultrasound (POCUS) Application in Resuscitation With High-Fidelity Simulator.** Cureus 2020; 12:e9353Wang H, Uraco AM, Stover J, Hollis N. http://www.ncbi.nlm.nih.gov/pubmed/?term=32850225
7. **Postmortem imaging of the lung in cases of COVID-19 deaths.** Der Radiologe 2020; Kniep I, Lutter M, Ron A ***et al.***
8. **Incidental findings suggestive of COVID-19 in asymptomatic cancer patients undergoing 18F-FDG PET/CT in a low prevalence region.** Eur J Nucl Med Mol Imaging 2020; Pallardy A, Rousseau C, Labbe C ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32860074
9. **Multimodality imaging of COVID-19 pneumonia: from diagnosis to follow-up. Acomprehensive review.** Eur J Radiol 2020; 131:109217Larici AR, Cicchetti G, Marano R ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32861174
10. **Lung and kidney perfusion deficits diagnosed by dual-energy computed tomography in patients with COVID-19-related systemic microangiopathy.** Eur Radiol 2020; Idilman IS, Telli Dizman G, Ardali Duzgun S ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32860146
11. **2019 novel coronavirus (COVID-19) pneumonia: CT manifestations and pattern of evolution in 110 patients in Jiangxi, China.** Eur Radiol 2020; Zhan J, Li H, Yu H ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32852587
12. **Development and Validation of a Deep Learning-Based Model Using Computed Tomography Imaging for Predicting Disease Severity of Coronavirus Disease 2019.** Front Bioeng Biotechnol 2020; 8:898Xiao LS, Li P, Sun F ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32850746
13. **Clinical and radiological characteristics of COVID-19: a multicentre, retrospective, observational study.** Hong Kong Med. J. 2020; Wang Y, Luo S, Zhou CS ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32848097
14. **First report on clinical and radiological features of COVID-19 pneumonitis in a Caucasian population: factors predicting fibrotic evolution.** Int J Infect Dis 2020; Marvisi M, Ferrozzi F, Balzarini L ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32841688
15. **Lung ultrasound predicts clinical course and outcomes in COVID-19 patients.** Intensive Care Med 2020; Lichter Y, Topilsky Y, Taieb P ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32860069
16. **Quantitative-analysis of computed tomography in COVID-19 and non COVID-19 ARDS patients: A case-control study.** J Crit Care 2020; 60:169-176Chauvelot L, Bitker L, Dhelft F ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32854088
17. **Lung ultrasound artifacts in COVID-19 patients.** J Ultrasound 2020; McElyea C, Do C, Killu K. http://www.ncbi.nlm.nih.gov/pubmed/?term=32844375

18. **Usefulness of Lung Ultrasound Examinations Performed by Primary Care Physicians in Patients With Suspected COVID-19.** J Ultrasound Med 2020; Calvo-Cebrián A, Alonso-Roca R, Rodriguez-Contreras FJ ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32852112
19. **A systematic review on recent trends in transmission, diagnosis, prevention and imaging features of COVID-19.** Process Biochem. 2020; Manigandan S, Wu MT, Ponnusamy VK ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32843849
20. **Modifications to mobile chest radiography technique during the COVID-19 pandemic - implications of X-raying through side room windows.** Radiography (Lond) 2020; England A, Littler E, Romani S, Cosson P. http://www.ncbi.nlm.nih.gov/pubmed/?term=32855021
21. **Lung Ultrasound Score in Evaluating the Severity of Coronavirus Disease 2019 (COVID-19) Pneumonia.** Ultrasound Med. Biol. 2020; Zhao L, Yu K, Zhao Q ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32828577

Immune response (37 articles)

1. **An adult with COVID-19 kawasaki-like syndrome and ocular manifestations.** Am J Ophthalmol Case Rep 2020; 20:100875Lidder AK, Pandit SA, Lazzaro DR. http://www.ncbi.nlm.nih.gov/pubmed/?term=32839740
2. **Azithromycin Downregulates Gene Expression of IL-1β and Pathways Involving TMPRSS2 and TMPRSS11D Required by SARS-CoV-2.** Am. J. Respir. Cell Mol. Biol. 2020; Renteria AE, Endam Mfuna L, Adam D ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32857620
3. **Immune Dysfunction and Multiple Treatment Modalities for the SARS-CoV-2 Pandemic: Races of Uncontrolled Running Sweat?** Biology (Basel) 2020; 9Kothari A, Singh V, Nath UK ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32846906
4. **Cardiogenic Shock and Hyperinflammatory Syndrome in Young Males with COVID-19.** Circ Heart Fail 2020; Chau VQ, Giustino G, Mahmood K ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32844662
5. **High clinical performance and quantitative assessment of antibody kinetics using a dual recognition assay for the detection of SARS-CoV-2 IgM and IgG antibodies.** Clin. Biochem. 2020; Mairesse A, Favresse J, Eucher C ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32858061
6. **Antibody Responses and Clinical Outcomes in Adults Hospitalized with Severe COVID-19: A Post hoc Analysis of LOTUS China Trial.** Clin Infect Dis 2020; Ren L, Fan G, Wu W ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32840287
7. **Viral dynamics and immune correlates of COVID-19 disease severity.** Clin Infect Dis 2020; Young BE, Ong SWX, Ng LFP ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32856707
8. **Longitudinal changes of inflammatory parameters and their correlation with disease severity and outcomes in patients with COVID-19 from Wuhan, China.** Crit Care 2020; 24:525Zeng Z, Yu H, Chen H ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32854750
9. **Positive Chest CT Features in Patients With COVID-19 Pneumonia and Negative Real-Time Polymerase Chain Reaction Test.** Cureus 2020; 12:e9942Pakdemirli E, Mandalia U, Monib S. http://www.ncbi.nlm.nih.gov/pubmed/?term=32850265

10. **Endothelial Dysfunction in COVID-19: Lessons Learned from Coronaviruses.** Curr. Hypertens. Rep. 2020; 22:63Gavriilaki E, Anyfanti P, Gavriilaki M ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32852642
11. **Clinical, immunological and virological characterization of COVID-19 patients that test re-positive for SARS-CoV-2 by RT-PCR.** EBioMedicine 2020; 59:102960Lu J, Peng J, Xiong Q ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32853988
12. **Monocyte activation in systemic Covid-19 infection: Assay and rationale.** EBioMedicine 2020; 59:102964Martinez FO, Combes TW, Orsenigo F, Gordon S. http://www.ncbi.nlm.nih.gov/pubmed/?term=32861199
13. **Antibody Profiles According to Mild or Severe SARS-CoV-2 Infection, Atlanta, Georgia, USA, 2020.** Emerg Infect Dis 2020; 26Hu WT, Howell JC, Ozturk T ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32857691
14. **Functional mapping of B-cell linear epitopes of SARS-CoV-2 in COVID-19 convalescent population.** Emerg Microbes Infect 2020:1-34Yi Z, Ling Y, Zhang X ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32844713
15. **Cytokine release syndrome-associated encephalopathy in patients with COVID-19.** Eur. J. Neurol. 2020; Perrin P, Collongues N, Baloglu S ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32853434
16. **Mucosal-Associated Invariant T Cells as a Possible Target to Suppress Secondary Infections at COVID-19.** Front. Immunol. 2020; 11:1896Akasov RA, Khaydukov EV. http://www.ncbi.nlm.nih.gov/pubmed/?term=32849648
17. **Remodeling of the Immune Response With Aging: Immunosenescence and Its Potential Impact on COVID-19 Immune Response.** Front. Immunol. 2020; 11:1748Cunha LL, Perazzio SF, Azzi J ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32849623
18. **Impact of Hydroxychloroquine on Antibody Responses to the SARS-CoV-2 Coronavirus.** Front. Immunol. 2020; 11:1739de Miranda Santos IKF, Costa CHN. http://www.ncbi.nlm.nih.gov/pubmed/?term=32849619
19. **Longer Duration of SARS-CoV-2 Infection in a Case of Mild COVID-19 With Weak Production of the Specific IgM and IgG Antibodies.** Front. Immunol. 2020; 11:1936Guo X, Zeng L, Huang Z ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32849650
20. **Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past.** Front. Immunol. 2020; 11:1949Shah VK, Firmal P, Alam A ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32849654
21. **Molecular Pathogenesis, Immunopathogenesis and Novel Therapeutic Strategy Against COVID-19.** Front Mol Biosci 2020; 7:196Chatterjee SK, Saha S, Munoz MNM. http://www.ncbi.nlm.nih.gov/pubmed/?term=32850977
22. **Improving Non-specific Immunity to Coronavirus Disease (COVID-19) by the Novelty, Diversity, and Quantity of Antigen.** Front Public Health 2020; 8:393Boucher P, Boucher R. http://www.ncbi.nlm.nih.gov/pubmed/?term=32850603
23. **Cytokines and COVID-19: friends or foes?** Hum Vaccin Immunother 2020:1-3Rokni M, Hamblin MR, Rezaei N. http://www.ncbi.nlm.nih.gov/pubmed/?term=32841579
24. **A public health perspective of aging: do hyper-inflammatory syndromes such as COVID-19, SARS, ARDS, cytokine storm syndrome, and post-ICU syndrome accelerate short- and long-term inflammaging?** Immun. Ageing 2020;

17:23Bektas A, Schurman SH, Franceschi C, Ferrucci L. http://www.ncbi.nlm.nih.gov/pubmed/?term=32849908
25. **Implications of Sex Differences in Immunity for SARS-CoV-2 Pathogenesis and Design of Therapeutic Interventions.** Immunity 2020; Bunders MJ, Altfeld M. http://www.ncbi.nlm.nih.gov/pubmed/?term=32853545
26. **Neutralizing antibody responses to SARS-CoV-2 in COVID-19 patients.** Indian J Med Res 2020; Deshpande GR, Sapkal GN, Tilekar BN ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32859866
27. **Differences of inflammatory and non-inflammatory indicators in Coronavirus disease-19 (COVID-19) with different severity.** Infect Genet Evol 2020:104511Wang M, Zhu Q, Fu J ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32858231
28. **Immune dysregulation and Multisystem Inflammatory Syndrome in Children (MIS-C) in individuals with haploinsufficiency of SOCS1.** J Allergy Clin Immunol 2020; Lee PY, Platt CD, Weeks S ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32853638
29. **Peripheral CD4+ T cell subsets and antibody response in COVID-19 convalescent individuals.** J. Clin. Invest. 2020; Gong F, Dai Y, Zheng T ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32841212
30. **A Controllable Inflammatory Response and Temporary Abnormal Coagulation in Moderate Disease of COVID-19 in Wuhan, China.** J. Clin. Med. Res. 2020; 12:590-597Liu Y, Zhang X, Qiao J ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32849947
31. **Underlying Vulnerabilities to the Cytokine Storm and Adverse COVID-19 Outcomes in the Aging Immune System.** J Gerontol A Biol Sci Med Sci 2020; Nidadavolu L, Walston J. http://www.ncbi.nlm.nih.gov/pubmed/?term=32841329
32. **COVID-19 patients display distinct SARS-CoV-2 specific T-cell responses according to disease severity.** J Infect 2020; Kroemer M, Spehner L, Vettoretti L ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32853599
33. **Coronavirus disease associated immune thrombocytopenia: Causation or correlation?** J Microbiol Immunol Infect 2020; Pascolini S, Granito A, Muratori L ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32859531
34. **COVID-19 und Immunregulation – von grundlegenden und translationalen Aspekten zu klinischen Implikationen.** JDDG - Journal of the German Society of Dermatology 2020; 18:795-809Schön MP, Berking C, Biedermann T ***et al.***
35. **Assessing SARS-CoV-2 RNA levels and lymphocyte/T cell counts in COVID-19 patients revealed initial immune status as a major determinant of disease severity.** Med. Microbiol. Immunol. 2020; Han M, Xu M, Zhang Y ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32860073
36. **A proof of evidence supporting abnormal immunothrombosis in severe COVID-19: naked megakaryocyte nuclei increase in the bone marrow and lungs of critically ill patients.** Platelets 2020:1-5Roncati L, Ligabue G, Nasillo V ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32857624
37. **The Interplay Between Coagulation and Inflammation Pathways in COVID-19-Associated Respiratory Failure: A Narrative Review.** Pulm Ther 2020; Bhattacharyya R, Iyer P, Phua GC, Lee JH. http://www.ncbi.nlm.nih.gov/pubmed/?term=32844302

Management miscellaneous diseases (64 articles)

1. **[Management of Rheumatic Diseases during the COVID-19 Pandemic: Beyond Telehealth Services].** Acta Med Port 2020; Fernandes AL, Silva C, Miranda LC. http://www.ncbi.nlm.nih.gov/pubmed/?term=32840207
2. **Management of the ENT consultation during the COVID-19 pandemic alert. Are ENT telephone consultations useful?** Acta Otorrinolaringol. Esp. 2020; Gómez González MDR, Piqueras Pérez FM, Guillamón Vivancos L ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32859357
3. **What has changed during the state of emergency due to COVID-19 on an Academic Urology Department of a Tertiary Hospital in Portugal.** Actas Urol. Esp. 2020; Bernardino R, Gil M, Andrade V ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32843150
4. **Use of biologicals in allergic and type 2 inflammatory diseases in the current COVID-19 pandemic.** Allergologie 2020; 43:255-271Klimek L, Pfaar O, Worm M ***et al.***
5. **Local spikes in COVID-19 cases: Recommendations for maintaining otolaryngology clinic operations.** Am. J. Otolaryngol. 2020; 41:102688Benito DA, Pasick L, Mulcahy CF ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32854044
6. **Proficiency of virtual follow-up amongst tinnitus patients who underwent intratympanic steroid therapy amidst COVID 19 pandemic.** Am. J. Otolaryngol. 2020; 41:102680Vijayasundaram S, Karthikeyan P, Mehta SD. http://www.ncbi.nlm.nih.gov/pubmed/?term=32861124
7. **Our experiences of resuming services in ENT departments in Wuhan, once a COVID-19 epicenter.** Am. J. Otolaryngol. 2020; 41:102678Xu K, Lu X, Liu Z. http://www.ncbi.nlm.nih.gov/pubmed/?term=32846406
8. **Trends in Top Cancer Diagnosis and Challenges Related to COVID-19 Pandemic.** Am. Surg. 2020:3134820949522Ehrlich H, Sen-Crowe B, McKenney M, Elkbuli A. http://www.ncbi.nlm.nih.gov/pubmed/?term=32856936
9. **Analysis of operation procedure and effect for emergency surgery in general hospital during novel coronavirus pneumonia period.** BMC Surg. 2020; 20:190Liu Y, Wang M, Shen Y, Chen J. http://www.ncbi.nlm.nih.gov/pubmed/?term=32847559
10. **Emergency schedule management for COVID-19.** Br J Anaesth 2020; Hardy B, Marshall C. http://www.ncbi.nlm.nih.gov/pubmed/?term=32828492
11. **OMFS moving into the recovery phase of the COVID-19 pandemic - a survey on general practice for elective local anaesthetic procedures.** Br. J. Oral Maxillofac. Surg. 2020; Graham C, Mizen KD. http://www.ncbi.nlm.nih.gov/pubmed/?term=32828571
12. **Collateral Impact of the Covid-19 Pandemic on Tuberculosis Control in Jiangsu Province, China.** Clin Infect Dis 2020; Liu Q, Lu P, Shen Y ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32857838
13. **Operationalizing HIV cure-related trials with analytic treatment interruptions during the SARS-CoV-2 pandemic: A collaborative approach.** Clin Infect Dis 2020; Peluso MJ, Dee L, Shao S ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32841311
14. **COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series.** Clin Rheumatol 2020; Ferri C, Giuggioli D, Raimondo V ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32852623
15. **The Attend Study: A Retrospective Observational Study of Emergency Department Attendances During the Early Stages of the COVID-19 Pandemic.**

Cureus 2020; 12:e9328Leow SH, Dean W, MacDonald-Nethercott M ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32850205

16. **Facial Trauma Management during the COVID-19 era: a primer for surgeons.** Curr Med Res Pract 2020; 10:169-173Ghai S. http://www.ncbi.nlm.nih.gov/pubmed/?term=32839727
17. **Management of patients with hidradenitis suppurativa during the Covid-19 pandemic: risk and benefit of immunomodulatory therapy.** Dermatol Ther 2020; Molinelli E, Diotallevi F, Simonetti O ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32860474
18. **COVID-19 in GP Practice and Emergency Rooms.** Deutsche Medizinische Wochenschrift 2020; 145:1080-1085Herold T, Wörnle M, Schelling J.
19. **Catching our breath: reshaping rehabilitation services for COVID-19.** Disabil. Rehabil. 2020:1-6Khoo TC, Jesudason E, FitzGerald A. http://www.ncbi.nlm.nih.gov/pubmed/?term=32853046
20. **A "Forward Triage" Model in Telemedicine for Head and Neck Oncological Patients During the COVID-19 Era.** Ear Nose Throat J 2020:145561320948995Lambertoni A, Gravante G, Battaglia P ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32845737
21. **Epilepsy course during COVID-19 pandemic in three Italian epilepsy centers.** Epilepsy Behav. 2020; 112:107375Cabona C, Deleo F, Marinelli L ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32858368
22. **Optimal multiparametric set-up modelled for best survival outcomes in palliative treatment of liver malignancies: unsupervised machine learning and 3 PM recommendations.** Epma j 2020; 11:505-515Goldstein E, Yeghiazaryan K, Ahmad A ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32839667
23. **Oncological care organisation during COVID-19 outbreak.** ESMO Open 2020; 5Onesti CE, Rugo HS, Generali D ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32847836
24. **Effects of the first month of lockdown for COVID-19 in Italy: A preliminary analysis on the eyecare system from six centers.** Eur. J. Ophthalmol. 2020:1120672120953074dell'Omo R, Filippelli M, Semeraro F ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32838559
25. **COVID-19 Emergency and Post-Emergency in Italian Cancer Patients: How Can Patients Be Assisted?** Front. Oncol. 2020; 10:1571Crispo A, Montagnese C, Perri F ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32850461
26. **Plastic Surgery in times of COVID-19 in a maximum care hospital in Berlin - Description of the situation and approaches to action for resumption of regular operation.** Handchirurgie, Mikrochirurgie, plastische Chirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Handchirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Mikrochirurgie der Peripheren Nerven und Gefasse : Organ der V.. 2020; 52:265-271Kricheldorff J, Strempel M, Hetmank C ***et al.***
27. **The impact of COVID-19 in medical practice. A review focused on Urology.** Int Braz J Urol 2020; 46Mazzucchi E, Torricelli FCM, Vicentini FC ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32840335
28. **Antimicrobial stewardship program, a vital resource for hospitals during the global outbreak of Coronavirus Disease 2019 (COVID-19).** Int J Antimicrob Agents 2020:106145Liew Y, Lee WHL, Tan L ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32860880

29. **Where did all the trauma go? A rapid review of the demands on orthopaedic services at a U.K. Major Trauma Centre during the COVID-19 pandemic.** Int J Clin Pract 2020:e13690Greenhalgh M, Dupley L, Unsworth R, Boden R. http://www.ncbi.nlm.nih.gov/pubmed/?term=32852851
30. **The Impact and Consequences of SARS-CoV-2 Pandemic on a Single University Dermatology Outpatient Clinic in Germany.** Int J Environ Res Public Health 2020; 17Wang R, Helf C, Tizek L ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32858870
31. **Urological service provision during the COVID-19 period: the experience from an Irish tertiary centre.** Ir. J. Med. Sci. 2020; Collins PM, Madden A, O'Connell C ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32856269
32. **Initial Impact of Coronavirus Disease 2019 (COVID-19) on Radiology Practices: An ACR/RBMA Survey.** J Am Coll Radiol 2020; Malhotra A, Wu X, Fleishon HB ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32853538
33. **Children's Dental Anxiety during the COVID-19 Pandemic: Polish Experience.** J Clin Med 2020; 9Olszewska A, Rzymski P. http://www.ncbi.nlm.nih.gov/pubmed/?term=32854401
34. **Influence of the Pandemic Dissemination of COVID-19 on Facial Rejuvenation: A Survey of Twitter.** J Cosmet Dermatol 2020; Pang R, Wei Z, Liu W ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32852146
35. **To Drill or Not to Drill: Management of Endodontic Emergencies and In-Process Patients during the COVID-19 Pandemic.** J Endod 2020; Patel B, Eskander MA, Ruparel NB. http://www.ncbi.nlm.nih.gov/pubmed/?term=32841654
36. **Breast cancer surgery during the Covid-19 pandemic: a monocentre experience from the Regina Elena National Cancer Institute of Rome.** J. Exp. Clin. Cancer Res. 2020; 39:171Pelle F, Cappelli S, Graziano F ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32854728
37. **The Art of Surgery: Balancing Compassionate With Virtual Care.** J Med Internet Res 2020; 22:e22417Nemetz ETA, Urbach DR, Devon KM. http://www.ncbi.nlm.nih.gov/pubmed/?term=32852276
38. **Deep Brain Stimulation Battery Exhaustion during the COVID-19 Pandemic: Crisis within a Crisis.** J Mov Disord 2020; Holla VV, Neeraja K, Surisetti BK ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32854480
39. **The effective use of an e-dentistry service during the COVID-19 crisis.** J. Orthod. 2020:1465312520949557Crawford E, Taylor N. http://www.ncbi.nlm.nih.gov/pubmed/?term=32854562
40. **COVID-19: Impacts and Implications for Pediatric Practice.** J. Pediatr. Health Care 2020; Peck JL. http://www.ncbi.nlm.nih.gov/pubmed/?term=32859434
41. **Mandatory preoperative COVID-19 testing for cancer patients-Is it justified?** J. Surg. Oncol. 2020; Nekkanti SS, Vasudevan Nair S, Parmar V ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32841386
42. **Preparedness of the cancer hospitals and changes in oncosurgical practices during COVID-19 pandemic in India: A cross-sectional study.** J. Surg. Oncol. 2020; Singh HK, Patil V, Ganne C, Nair D. http://www.ncbi.nlm.nih.gov/pubmed/?term=32841395
43. **COVID-19 und Auswirkungen auf dermatologische und allergologische Erkrankungen.** JDDG - Journal of the German Society of Dermatology 2020; 18:815-825Buhl T, Beissert S, Gaffal E ***et al.***

44. **Systemische Immunsuppression in Zeiten von COVID-19: Müssen wir umdenken?** JDDG - Journal of the German Society of Dermatology 2020; 18:810-814Grabbe S, Beissert S, Enk A.
45. **Resuming elective hip and knee arthroplasty after the first phase of the SARS-CoV-2 pandemic: the European Hip Society and European Knee Associates recommendations.** Knee Surg. Sports Traumatol. Arthrosc. 2020; Kort NP, Barrena EG, Bédard M ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32844246
46. **Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI-AeDA-GPA-DGAKI Position Paper (Pocket-Guide).** Laryngo- rhino-otologie 2020; Pfaar O, Klimek L, Worm M ***et al.***
47. **Clinical characteristics, therapeutic management, and prognostic factors of adult COVID-19 inpatients with hematological malignancies.** Leuk. Lymphoma 2020:1-11Wu Y, Chen W, Li W ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32840399
48. **Fetal Surgery in the era of SARS-CoV-2 pandemic: A single institution review.** Mayo Clin Proc Innov Qual Outcomes 2020; Narang K, Elrefaei A, Wyatt MA ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32839753
49. **The impact of COVID-19 on access to Parkinson's disease medication.** Mov Disord 2020; Cheong JLY, Goh ZHK, Marras C ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32860226
50. **ISNO Position Statement on Treatment Guidance in Neuro-oncology During Pandemics.** Neurol. India 2020; 68:769-773Gupta T, Singh VP, Balasubramian A ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32859812
51. **Impact of Prolonged Lockdown due to COVID-19 in Patients with Parkinson's Disease.** Neurol. India 2020; 68:792-795Prasad S, Holla VV, Neeraja K ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32859814
52. **Obesity and Metabolic Surgery Society of India (OSSI) Recommendations for Bariatric and Metabolic Surgery Practice During the COVID-19 Pandemic.** Obes. Surg. 2020:1-7Aggarwal S, Mahawar K, Khaitan M ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32829450
53. **Does the COVID-19 Pandemic Spell the End for the Direct Ophthalmoscope?** Ophthalmol Ther 2020; Shih KC, Chau CYC, Chan JCH ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32860621
54. **[Impacts of the SARS-CoV-2 pandemic on ophthalmic care in Germany].** Ophthalmologe 2020; Hattenbach LO, Heinz P, Feltgen N ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32845384
55. **The impact of the COVID-19 pandemic on oral biopsies in the Brazilian National Health System.** Oral Dis 2020; da Cunha AR, Antunes JLF, Martins MD ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32852882
56. **Pain Management During the COVID-19 Pandemic.** Pain Ther 2020; El-Tallawy SN, Nalamasu R, Pergolizzi JV, Gharibo C. http://www.ncbi.nlm.nih.gov/pubmed/?term=32840756
57. **[Anaesthesia during COVID-19 epidemic].** Prat Anesth Reanim 2020; Faddoul A, de la Jonquière C. http://www.ncbi.nlm.nih.gov/pubmed/?term=32843845
58. **Impact of SARS-CoV-2 infection in patients with cystic fibrosis in Spain: Incidence and results of the national CF-COVID19-Spain survey.** Respir. Med. 2020; 170:106062Mondejar-Lopez P, Quintana-Gallego E, Giron-Moreno RM ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32843180

59. **Management of sleep apnea in New York City during the COVID-19 pandemic.** Sleep Med. 2020; 74:86-90Thorpy M, Figuera-Losada M, Ahmed I ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32841850
60. **Strategic use of obturator prostheses for the rehabilitation of oral cancer patients during the COVID-19 pandemic.** Support. Care Cancer 2020; Brandão TB, Migliorati CA, Vechiato-Filho AJ ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32856215
61. **Laparoscopic Surgery and the debate on its safety during COVID-19 pandemic: A systematic review of recommendations.** Surgeon 2020; El Boghdady M, Ewalds-Kvist BM. http://www.ncbi.nlm.nih.gov/pubmed/?term=32855070
62. **Urinary stone management during the COVID-19 pandemic: a suggested approach and review of literature.** Ther. Adv. Urol. 2020; 12:1756287220939513Fakhr Yasseri A, Aghamir SMK. http://www.ncbi.nlm.nih.gov/pubmed/?term=32849913
63. **Supply and demand for plasma-derived medicinal products - a critical re-assessment amidst the COVID-19 pandemic.** Transfusion 2020; Hartmann J, Klein HG. http://www.ncbi.nlm.nih.gov/pubmed/?term=32856742
64. **[SARS-CoV-2 & rheumatic disease : Consequences of the SARS-CoV-2 pandemic for patients with inflammatory rheumatic diseases. A comparison of the recommendations for action of rheumatological societies and risk assessment of different antirheumatic treatments].** Z. Rheumatol. 2020; Leipe J, Hoyer BF, Iking-Konert C ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32845393

Management (53 articles)

1. **Airway management guidance for the endemic phase of COVID-19.** Anaesthesia 2020; Cook TM, McGuire B, Mushambi M ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32839960
2. **Clean and Contain: Initial Development of a Measure of Infection Prevention Behaviors During the COVID-19 Pandemic.** Ann. Behav. Med. 2020; Toussaint LL, Cheadle AD, Fox J, Williams DR. http://www.ncbi.nlm.nih.gov/pubmed/?term=32856691
3. **A COVID-19 Airway Management Innovation with Pragmatic Efficacy Evaluation: The Patient Particle Containment Chamber.** Ann. Biomed. Eng. 2020; Maloney LM, Yang AH, Princi RA ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32856180
4. **Can a gluten-free diet be partly protective for covid-19 infection?** APMIS 2020; Haupt-Jorgensen M, Buschard K. http://www.ncbi.nlm.nih.gov/pubmed/?term=32854147
5. **Oesophageal manometry and gas exchange in patients with COVID-19 acute respiratory distress syndrome.** Br J Anaesth 2020; Coppola S, Pozzi T, Busana M ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32859365
6. **Epigenetic susceptibility to severe respiratory viral infections: pathogenic and therapeutic implications: a narrative review.** Br J Anaesth 2020; Crimi E, Benincasa G, Figueroa-Marrero N ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32828489

7. **Bedside monitoring of lung perfusion by electrical impedance tomography in the time of COVID-19.** Br J Anaesth 2020; Safaee Fakhr B, Araujo Morais CC, De Santis Santiago RR ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32859359
8. **Triage tool for suspected COVID-19 patients in the emergency room: AIFELL score.** Braz. J. Infect. Dis. 2020; Levenfus I, Ullmann E, Battegay E, Schuurmans MM. http://www.ncbi.nlm.nih.gov/pubmed/?term=32828735
9. **Easy-to-prescribe nutrition support in the intensive care in the era of COVID-19.** Clin Nutr ESPEN 2020; 39:74-78de Watteville A, Genton L, Barcelos GK ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32859332
10. **Ketanserin as potential additive drug to improve V/Q mismatch in COVID-19?** Crit Care 2020; 24:526Kuindersma M, Spronk PE. http://www.ncbi.nlm.nih.gov/pubmed/?term=32859243
11. **Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients.** EBioMedicine 2020; 59:102969Buijsers B, Yanginlar C, Maciej-Hulme ML ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32853989
12. **COVID-19 what have we learned? The rise of social machines and connected devices in pandemic management following the concepts of predictive, preventive and personalized medicine.** Epma j 2020; 11:311-332Radanliev P, De Roure D, Walton R ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32839666
13. **Hospital At Home Units In The Post-Covid 19 ERA.** Eur. J. Clin. Invest. 2020:e13390Coloma E, Nicolás D. http://www.ncbi.nlm.nih.gov/pubmed/?term=32852794
14. **Redeployment of ophthalmologists in the United Kingdom during the Coronavirus Disease Pandemic.** Eur. J. Ophthalmol. 2020:1120672120953339Lim C, De Silva I, Moussa G ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32854520
15. **Application of methylene blue -vitamin C -N-acetyl cysteine for treatment of critically ill COVID-19 patients, report of a phase-I clinical trial.** Eur. J. Pharmacol. 2020:173494Alamdari DH, Moghaddam AB, Amini S ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32828741
16. **COVID-19 and Renin-Angiotensin System Modulators: What Do We Know So Far?** Expert Rev. Cardiovasc. Ther. 2020; de la Cruz A, Ashraf S, Vittorio TJ, Bella JN. http://www.ncbi.nlm.nih.gov/pubmed/?term=32842817
17. **The Diagnostic Methods in the COVID-19 Pandemic, Today and in the Future.** Expert Rev Mol Diagn 2020; Wu SY, Yau HS, Yu MY ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32845192
18. **Synergistic effects of anionic surfactants on coronavirus (SARS-CoV-2) virucidal efficiency of sanitizing fluids to fight COVID-19.** Food Chem. Toxicol. 2020:111702Jahromi R, Mogharab V, Jahromi H, Avazpour A. http://www.ncbi.nlm.nih.gov/pubmed/?term=32860861
19. **Resilient agri-food systems for nutrition amidst COVID-19: evidence and lessons from food-based approaches to overcome micronutrient deficiency and rebuild livelihoods after crises.** Food Secur 2020; 12:823-830Heck S, Campos H, Barker I ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32839664
20. **Care for Critical Ill Patients With COVID-19: Establishment of a Temporary Intensive Care Unit in an Isolated Hospital.** Front Med (Lausanne) 2020; 7:519Peng M, Qian Z, Zhang L. http://www.ncbi.nlm.nih.gov/pubmed/?term=32850928
21. **Preliminary Experience With Low Molecular Weight Heparin Strategy in COVID-19 Patients.** Front. Pharmacol. 2020; 11:1124Paolisso P, Bergamaschi L,

D'Angelo EC ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32848743

22. **DPP-4 Inhibitors in the Prevention/Treatment of Pulmonary Fibrosis, Heart and Kidney Injury Caused by COVID-19-A Therapeutic Approach of Choice in Type 2 Diabetic Patients?** Front. Pharmacol. 2020; 11:1185Smelcerovic A, Kocic G, Gajic M ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32848788
23. **DPP4 and ACE2 in Diabetes and COVID-19: Therapeutic Targets for Cardiovascular Complications?** Front. Pharmacol. 2020; 11:1161Valencia I, Peiró C, Lorenzo Ó ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32848769
24. **COVID-19: A Multidisciplinary Review.** Front Public Health 2020; 8:383Chams N, Chams S, Badran R ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32850602
25. **Transforming a General Hospital to an Infectious Disease Hospital for COVID-19 Over 2 Weeks.** Front Public Health 2020; 8:382Pandey N, Kaushal V, Puri GD ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32850601
26. **Assessment of Healthcare System Capabilities and Preparedness in Yemen to Confront the Novel Coronavirus 2019 (COVID-19) Outbreak: A Perspective of Healthcare Workers.** Front Public Health 2020; 8:419Zawiah M, Al-Ashwal FY, Saeed RM ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32850608
27. **It's Time to Resolve the Direct Care Workforce Crisis in Long-Term Care.** Gerontologist 2020; Scales K. http://www.ncbi.nlm.nih.gov/pubmed/?term=32853357
28. **Impact of COVID-19-pandemic on Clinical Care, Work Flows and Staff at a University Hospital: Results of an Interview-study at the UKE.** Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)) 2020; Härter M, Bremer D, Scherer M ***et al.***
29. **CSANZ COVID-19 Cardiovascular Nursing Care Consensus Statement: Executive Summary.** Heart Lung Circ. 2020; Inglis SC, Naismith C, White K ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32859539
30. **Uninterrupted Continuous and Intermittent Nebulizer Therapy in a COVID-19 Patient Using Sequential Vibratory Mesh Nebulizers: A Case Report.** J. Aerosol Med. Pulm. Drug Deliv. 2020; Elnadoury O, Beattie J, Lubinsky AS. http://www.ncbi.nlm.nih.gov/pubmed/?term=32852238
31. **Anticoagulation, Mortality, Bleeding and Pathology Among Patients Hospitalized with COVID-19: A Single Health System Study.** J Am Coll Cardiol 2020; Nadkarni GN, Lala A, Bagiella E ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32860872
32. **ECMO-Challenges, strategies, and preparation from Spain.** J. Card. Surg. 2020; Pérez de la Sota E, Eixerés-Esteve A. http://www.ncbi.nlm.nih.gov/pubmed/?term=32845030
33. **Antimicrobial Stewardship Program, COVID-19, and Infection Control: Spread of Carbapenem-Resistant Klebsiella Pneumoniae Colonization in ICU COVID-19 Patients. What Did Not Work?** J Clin Med 2020; 9Tiri B, Sensi E, Marsiliani V ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32854334
34. **A Controllable Inflammatory Response and Temporary Abnormal Coagulation in Moderate Disease of COVID-19 in Wuhan, China.** J. Clin. Med. Res. 2020; 12:590-597Liu Y, Zhang X, Qiao J ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32849947
35. **Coronavirus disease (COVID-19): observations and lessons from primary medical care at a German community hospital.** J Community Hosp Intern Med Perspect 2020; 10:81-87Schiller M, Fisahn J, Huebner U ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32850041

36. **What we have to know about corticosteroids use during Sars-Cov-2 infection.** J. Endocrinol. Invest. 2020; Ferraù F, Ceccato F, Cannavò S, Scaroni C. http://www.ncbi.nlm.nih.gov/pubmed/?term=32860209
37. **The FIB-4 Index Is Associated with Need for Mechanical Ventilation and 30-day Mortality in Patients Admitted with COVID-19.** J Infect Dis 2020; Sterling RK, Oakes T, Gal TS ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32856702
38. **Understanding the epidemiology, pathophysiology, diagnosis and management of SARS-CoV-2.** J. Int. Med. Res. 2020; 48:300060520949077Fadaka AO, Sibuyi NRS, Adewale OB ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32842818
39. **Treatment of the novel COVID-19: why Costa Rica's proposal for the creation of a global pooling mechanism deserves serious consideration?** J Law Biosci 2020; 7:lsaa049Abbas MZ. http://www.ncbi.nlm.nih.gov/pubmed/?term=32855814
40. **Could Vitamins Help in the Fight Against COVID-19?** Nutrients 2020; 12Jovic TH, Ali SR, Ibrahim N ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32842513
41. **The Antiviral, Anti-Inflammatory Effects of Natural Medicinal Herbs and Mushrooms and SARS-CoV-2 Infection.** Nutrients 2020; 12Shahzad F, Anderson D, Najafzadeh M. http://www.ncbi.nlm.nih.gov/pubmed/?term=32854262
42. **A Case of Steroid-Responsive, COVID-19 Immune Reconstitution Inflammatory Syndrome Following the Use of Granulocyte Colony-Stimulating Factor.** Open Forum Infect Dis 2020; 7:ofaa326Mertens J, Laghrib Y, Kenyon C. http://www.ncbi.nlm.nih.gov/pubmed/?term=32855992
43. **Balancing Scientific Rigor With Urgency in the Coronavirus Disease 2019 Pandemic.** Open Forum Infect Dis 2020; 7:ofaa304Spec A, Schwartz IS. http://www.ncbi.nlm.nih.gov/pubmed/?term=32855988
44. **Addressing Palliative Care Needs of COVID-19 Patients in New Orleans, LA: A Team-Based Reflective Analysis.** Palliat Med Rep 2020; 1:124-128Burke RV, Rome R, Constanza K ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32856024
45. **Physical exercise as a tool to minimize the consequences of the Covid-19 quarantine: an overview for cystic fibrosis.** Pediatr Pulmonol 2020; Fernandez-Del-Valle M, Donadio MVF, Pérez-Ruiz M. http://www.ncbi.nlm.nih.gov/pubmed/?term=32841519
46. **ECMO Therapy in a Case of Severe ARDS Related to COVID-19.** Pneumologie 2020; 74:423-428Schmauss M, Müller E, Schwamborn M ***et al.***
47. **48-Year-Old Triathlete with Severe COVID-19 Pneumonia: Successful and Safe Treatment with Oxygen and CPAP.** Pneumologie 2020; 74:417-422Stais P, Salloum O, Kühle D ***et al.***
48. **[Emergency and intensive care medicine aspects of COVID-19 infections].** Radiologe 2020; Dodt C, Schneider N. http://www.ncbi.nlm.nih.gov/pubmed/?term=32840663
49. **Medical Overuse in the Iranian Healthcare System: A Systematic Scoping Review and Practical Recommendations for Decreasing Medical Overuse During Unexpected COVID-19 Pandemic Opportunity.** Risk Manag. Healthc. Policy 2020; 13:1103-1110Pezeshki MZ, Janati A, Arab-Zozani M. http://www.ncbi.nlm.nih.gov/pubmed/?term=32848487
50. **Labile PT-INR in a Covid-19 Patient Under Long-term Vitamin K Antagonist Therapy: a Case Report.** SN Compr Clin Med 2020:1-3Trevisan C, Miconi L, Barbierato E ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32839751

51. **A COVID-19 screening tool for oncology telephone triage.** Support. Care Cancer 2020; Elkin E, Viele C, Schumacher K ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32856214
52. **The effect of prostacyclin (Iloprost) infusion at a dose of 1 ng/kg/min for 72 hours compared to placebo in mechanically ventilated patients with COVID-19: A structured summary of a study protocol for a randomized controlled trial.** Trials 2020; 21:746Johansson PI, Bestle M, Søe-Jensen P ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32847626
53. **[Analysis on the efficacy and safety of fibrinolytic therapy in patients with acute ST-segment elevation myocardial infarction during the COVID-19 epidemic].** Zhonghua Xin Xue Guan Bing Za Zhi 2020; 48:472-476Wei F, Shuai XX, Chen ZJ ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32842256

Mental – public health (84 articles)

1. **[Coronavirus and the Mental Health Law: New Challenges, Old Problems].** Acta Med Port 2020; Carvalheiro AM, Martinho S. http://www.ncbi.nlm.nih.gov/pubmed/?term=32860367
2. **Mental health among head and neck surgeons in Brazil during the COVID-19 pandemic: A national study.** Am. J. Otolaryngol. 2020; 41:102694Civantos AM, Bertelli A, Gonçalves A ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32854041
3. **The Impact of COVID-19 on Individuals With Intellectual and Developmental Disabilities: Clinical and Scientific Priorities.** Am. J. Psychiatry 2020:appiajp202020060780Constantino JN, Sahin M, Piven J ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32854530
4. **U.S. Public Health Resources for COVID-19 That Are Relevant to Allergy/Immunology.** Ann. Allergy. Asthma. Immunol. 2020; Hsu J. http://www.ncbi.nlm.nih.gov/pubmed/?term=32858238
5. **[À sharp drop in psychiatric emergency admissions during lockdown].** Ann. Med. Psychol. (Paris) 2020; Flevaud L, Pham A, Gourevitch R. http://www.ncbi.nlm.nih.gov/pubmed/?term=32843772
6. **The Relationship between Risk Event Involvement and Risk Perception during the COVID-19 Outbreak in China.** Appl Psychol Health Well Being 2020; Qian D, Li O. http://www.ncbi.nlm.nih.gov/pubmed/?term=32829535
7. **COVID-19 and Substance Use Disorder: Study Protocol for the International Society of Addiction Medicine Practice and Policy Interest Group Global Survey.** Basic Clin Neurosci 2020; 11:155-162Baldacchino A, Radfar SR, De Jong C ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32855774
8. **Psychological Impact of the Acute COVID-19 Period on Patients With Substance Use Disorders: We are all in this Together.** Basic Clin Neurosci 2020; 11:207-216DeJong CAJ, DeJong Verhagen JG, Pols R ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32855780
9. **COVID-19 and Substance Use Disorders: Recommendations to a Comprehensive Healthcare Response. An International Society of Addiction Medicine Practice and Policy Interest Group Position Paper.** Basic Clin Neurosci 2020; 11:133-150Farhoudian A, Baldacchino A, Clark N ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32855772
10. **Stress, Anxiety, and Depression Levels Among Healthcare Staff During the COVID-19 Epidemic.** Basic Clin Neurosci 2020; 11:163-170Hosseinzadeh-Shanjani

Z, Hajimiri K, Rostami B ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32855775
11. **Drug Interactions of Psychiatric and COVID-19 Medications.** Basic Clin Neurosci 2020; 11:185-200Mohebbi N, Talebi A, Moghadamnia M ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32855778
12. **Fear, Loss, Social Isolation, and Incomplete Grief Due to COVID-19: A Recipe for a Psychiatric Pandemic.** Basic Clin Neurosci 2020; 11:225-232Mortazavi SS, Assari S, Alimohamadi A ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32855782
13. **The Role of Anxiety and Cortisol in Outcomes of Patients With Covid-19.** Basic Clin Neurosci 2020; 11:179-184Ramezani M, Simani L, Karimialavijeh E ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32855777
14. **Coping style, social support and psychological distress in the general Chinese population in the early stages of the COVID-19 epidemic.** BMC Psychiatry 2020; 20:426Yu H, Li M, Li Z ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32854656
15. **Demographic and health factors associated with pandemic anxiety in the context of COVID-19.** Br. J. Health Psychol. 2020; McElroy E, Patalay P, Moltrecht B ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32860334
16. **Stress and parenting during the global COVID-19 pandemic.** Child Abuse Negl. 2020:104699Brown SM, Doom JR, Lechuga-Peña S ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32859394
17. **Is the psychological impact of exposure to COVID-19 stronger in adolescents with pre-pandemic maltreatment experiences? A survey of rural Chinese adolescents.** Child Abuse Negl. 2020:104667Guo J, Fu M, Liu D ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32859393
18. **Do suicide rates in children and adolescents change during school closure in Japan? The acute effect of the first wave of COVID-19 pandemic on child and adolescent mental health.** Child Abuse Negl. 2020:104680Isumi A, Doi S, Yamaoka Y ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32847679
19. **Telemental health for child trauma treatment during and post-COVID-19: Limitations and considerations.** Child Abuse Negl. 2020:104698Racine N, Hartwick C, Collin-Vézina D, Madigan S. http://www.ncbi.nlm.nih.gov/pubmed/?term=32839022
20. **"Oh, this is actually okay": Understanding how one state child welfare training system adapted to the COVID-19 pandemic.** Child Abuse Negl. 2020:104697Schwab-Reese LM, Drury I, Allan H, Matz K. http://www.ncbi.nlm.nih.gov/pubmed/?term=32839023
21. **Material hardship and parenting stress among grandparent kinship providers during the COVID-19 pandemic: The mediating role of grandparents' mental health.** Child Abuse Negl. 2020:104700Xu Y, Wu Q, Levkoff SE, Jedwab M. http://www.ncbi.nlm.nih.gov/pubmed/?term=32854948
22. **Chronotypes and trauma reactions in children with ADHD in home confinement of COVID-19: full mediation effect of sleep problems.** Chronobiol. Int. 2020:1-8Çetin FH, Uçar HN, Türkoğlu S ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32856947
23. **Concomitant marked decline in prevalence of SARS-CoV-2 and other respiratory viruses among symptomatic patients following public health interventions in Australia: data from St Vincent's Hospital and associated**

screening clinics, Sydney, NSW. Clin Infect Dis 2020; Marriott D, Beresford R, Mirdad F ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32841316

24. **2020 COVID-19 American Academy of Clinical Neuropsychology (AACN) Student Affairs Committee survey of neuropsychology trainees.** Clin. Neuropsychol. 2020:1-30Guidotti Breting LM, Towns SJ, Butts AM ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32842877
25. **Post-traumatic stress disorder: a differential diagnostic consideration for COVID-19 survivors.** Clin. Neuropsychol. 2020:1-17Kaseda ET, Levine AJ. http://www.ncbi.nlm.nih.gov/pubmed/?term=32847484
26. **COVID-19 issues related to pediatric neuropsychology and inpatient rehabilitation - challenges to usual care and solutions during the pandemic.** Clin. Neuropsychol. 2020:1-15Koterba CH, Baum KT, Hamner T ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32847476
27. **COVID-19 induced psychosocial stressors during gestation: possible maternal and neonatal consequences.** Curr. Med. Res. Opin. 2020:1Nabi G, Siddique R, Xiaoyan W ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32844690
28. **Psychological impact of COVID-19 on older adults.** Curr Med Res Pract 2020; 10:201-202Mukhtar S. http://www.ncbi.nlm.nih.gov/pubmed/?term=32839732
29. **The psychological impact of COVID-19 pandemic on patients included in a bariatric surgery program.** Eat Weight Disord 2020; Sisto A, Vicinanza F, Tuccinardi D ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32857287
30. **Socio-demographic heterogeneity in the prevalence of COVID-19 during lockdown is associated with ethnicity and household size: Results from an observational cohort study.** EClinicalMedicine 2020:100466Martin CA, Jenkins DR, Minhas JS ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32840492
31. **Economic, social and political issues raised by the COVID-19 pandemic.** Econ Anal Policy 2020; Tisdell CA. http://www.ncbi.nlm.nih.gov/pubmed/?term=32843816
32. **Psychological impact of COVID-19 in the Swedish Population: Depression, Anxiety, and Insomnia and their Associations to Risk and Vulnerability factors.** Eur. Psychiatry 2020:1-30McCracken LM, Badinlou F, Buhrman M, Brocki KC. http://www.ncbi.nlm.nih.gov/pubmed/?term=32843115
33. **Psychological distress and sleep problems when people are under interpersonal isolation during an epidemic: A nationwide multicenter cross-sectional study.** Eur. Psychiatry 2020; 63:e77Wang S, Zhang Y, Ding W ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32854786
34. **Coronavirus Disease-2019 Conundrum: RAS Blockade and Geriatric-Associated Neuropsychiatric Disorders.** Front Med (Lausanne) 2020; 7:515de Miranda AS, Teixeira AL. http://www.ncbi.nlm.nih.gov/pubmed/?term=32850927
35. **Prevalence and Psychosocial Correlates of Mental Health Outcomes Among Chinese College Students During the Coronavirus Disease (COVID-19) Pandemic.** Front Psychiatry 2020; 11:803Chi X, Becker B, Yu Q ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32848958
36. **COVID-19: The Hidden Impact on Mental Health and Drug Addiction.** Front Psychiatry 2020; 11:767Chiappini S, Guirguis A, John A ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32848937
37. **Substance Use Disorders and COVID-19: Multi-Faceted Problems Which Require Multi-Pronged Solutions.** Front Psychiatry 2020; 11:714Jemberie WB, Stewart Williams J, Eriksson M ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32848907

38. **COVID-19 Pandemic and Lockdown Measures Impact on Mental Health Among the General Population in Italy.** Front Psychiatry 2020; 11:790Rossi R, Socci V, Talevi D ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32848952
39. **Multidimensional Assessment of COVID-19-Related Fears (MAC-RF): A Theory-Based Instrument for the Assessment of Clinically Relevant Fears During Pandemics.** Front Psychiatry 2020; 11:748Schimmenti A, Starcevic V, Giardina A ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32848926
40. **Validation of the Impact of Event Scale With Modifications for COVID-19 (IES-COVID19).** Front Psychiatry 2020; 11:738Vanaken L, Scheveneels S, Belmans E, Hermans D. http://www.ncbi.nlm.nih.gov/pubmed/?term=32848918
41. **How and When Does Inclusive Leadership Curb Psychological Distress During a Crisis? Evidence From the COVID-19 Outbreak.** Front. Psychol. 2020; 11:1898Ahmed F, Zhao F, Faraz NA. http://www.ncbi.nlm.nih.gov/pubmed/?term=32849111
42. **Don't Walk So Close to Me: Physical Distancing and Adult Physical Activity in Canada.** Front. Psychol. 2020; 11:1895Di Sebastiano KM, Chulak-Bozzer T, Vanderloo LM, Faulkner G. http://www.ncbi.nlm.nih.gov/pubmed/?term=32849110
43. **Emotional Responses and Self-Protective Behavior Within Days of the COVID-19 Outbreak: The Promoting Role of Information Credibility.** Front. Psychol. 2020; 11:1846Lep Ž, Babnik K, Hacin Beyazoglu K. http://www.ncbi.nlm.nih.gov/pubmed/?term=32849087
44. **The Relationship Between Physical Activity and Quality of Life During the Confinement Induced by COVID-19 Outbreak: A Pilot Study in Tunisia.** Front. Psychol. 2020; 11:1882Slimani M, Paravlic A, Mbarek F ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32849104
45. **Social Distancing and Stigma: Association Between Compliance With Behavioral Recommendations, Risk Perception, and Stigmatizing Attitudes During the COVID-19 Outbreak.** Front. Psychol. 2020; 11:1821Tomczyk S, Rahn M, Schmidt S. http://www.ncbi.nlm.nih.gov/pubmed/?term=32849073
46. **Psychosocial Support for Healthcare Workers During the COVID-19 Pandemic.** Front. Psychol. 2020; 11:1960Tomlin J, Dalgleish-Warburton B, Lamph G. http://www.ncbi.nlm.nih.gov/pubmed/?term=32849149
47. **Psychological Status and Influencing Factors of Hospital Medical Staff During the COVID-19 Outbreak.** Front. Psychol. 2020; 11:1841Yao Y, Tian Y, Zhou J ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32849083
48. **Factors Associated With Job Satisfaction of Frontline Medical Staff Fighting Against COVID-19: A Cross-Sectional Study in China.** Front Public Health 2020; 8:426Yu X, Zhao Y, Li Y ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32850610
49. **COVID-19 in China: Power, Transparency and Governance in Public Health Crisis.** Healthcare (Basel) 2020; 8Zhang J, Zhang R. http://www.ncbi.nlm.nih.gov/pubmed/?term=32842607
50. **A public health perspective of aging: do hyper-inflammatory syndromes such as COVID-19, SARS, ARDS, cytokine storm syndrome, and post-ICU syndrome accelerate short- and long-term inflammaging?** Immun. Ageing 2020; 17:23Bektas A, Schurman SH, Franceschi C, Ferrucci L. http://www.ncbi.nlm.nih.gov/pubmed/?term=32849908
51. **The impact of COVID-19 epidemic on eating disorders: A longitudinal observation of pre versus post psychopathological features in a sample of patients with eating disorders and a group of healthy controls.** Int. J. Eat.

Disord. 2020; Castellini G, Cassioli E, Rossi E ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32856333

52. **Eating disorders in times of the COVID-19 pandemic-Results from an online survey of patients with anorexia nervosa.** Int. J. Eat. Disord. 2020; Schlegl S, Maier J, Meule A, Voderholzer U. http://www.ncbi.nlm.nih.gov/pubmed/?term=32841413
53. **Professional Quality of Life and Mental Health Outcomes among Health Care Workers Exposed to Sars-Cov-2 (Covid-19).** Int J Environ Res Public Health 2020; 17Buselli R, Corsi M, Baldanzi S ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32858810
54. **The Asia Pacific Disaster Mental Health Network: Setting a Mental Health Agenda for the Region.** Int J Environ Res Public Health 2020; 17Newnham EA, Dzidic PL, Mergelsberg ELP ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32847057
55. **Impact of COVID-19 on access to healthcare in low- and middle-income countries: Current evidence and future recommendations.** Int. J. Health Plann. Manage. 2020; Okereke M, Ukor NA, Adebisi YA ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32857892
56. **Fear and avoidance of healthcare workers: An important, under-recognized form of stigmatization during the COVID-19 pandemic.** J. Anxiety Disord. 2020; 75:102289Taylor S, Landry CA, Rachor GS ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32853884
57. **COVID-19 Pandemic Outbreak and its Psychological Impact on Patients with Rare Lysosomal Diseases.** J Clin Med 2020; 9Fiumara A, Lanzafame G, Arena A ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32842622
58. **The Effect of Environmental Stressors on Tinnitus: A Prospective Longitudinal Study on the Impact of the COVID-19 Pandemic.** J Clin Med 2020; 9Schlee W, Hølleland S, Bulla J ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32858835
59. **Compassion fatigue, burnout, compassion satisfaction, and perceived stress in healthcare professionals during the COVID-19 health crisis in Spain.** J. Clin. Nurs. 2020; Ruiz-Fernández MD, Ramos-Pichardo JD, Ibáñez-Masero O ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32860287
60. **Stress assessment among internal medicine residents in a level-3 hospital versus a level-2 hospital with only emergency room service for COVID-19.** J Community Hosp Intern Med Perspect 2020; 10:301-305Milgrom Y, Richter V. http://www.ncbi.nlm.nih.gov/pubmed/?term=32850084
61. **Anxiety and depression symptoms after virological clearance of COVID-19: a cross-sectional study in Milan, Italy.** J Med Virol 2020; Tomasoni D, Bai F, Castoldi R ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32841387
62. **Evaluation of Depression and Anxiety Levels and Related Factors Among Operating Theater Workers During the Novel Coronavirus (COVID-19) Pandemic.** J. Perianesth. Nurs. 2020; Koksal E, Dost B, Terzi Ö ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32855053
63. **Psychometric properties of the Pandemic-Related Pregnancy Stress Scale (PREPS).** J. Psychosom. Obstet. Gynaecol. 2020; 41:191-197Preis H, Mahaffey B, Lobel M. http://www.ncbi.nlm.nih.gov/pubmed/?term=32838629
64. **Lessons Learned: Pediatric Tele-Mental Health in a Rural Medical Center in the Age of SARS-CoV-2.** J Rural Health 2020; Satti K, Ojugbele O. http://www.ncbi.nlm.nih.gov/pubmed/?term=32845031

65. **Adaptation of contingency management for stimulant use disorder during the COVID-19 pandemic.** J. Subst. Abuse Treat. 2020:108102Zastepa E, Sun JC, Clune J, Mathew N. http://www.ncbi.nlm.nih.gov/pubmed/?term=32854983
66. **Recovery from the pandemic: evidence-based public policy to safeguard health.** Med. J. Aust. 2020; Lo SN, Skarbek A, Capon A. http://www.ncbi.nlm.nih.gov/pubmed/?term=32853400
67. **Snapshot Impact of COVID-19 on Mental Wellness in Nonphysician Otolaryngology Health Care Workers: A National Study.** OTO Open 2020; 4:2473974x20948835Prasad A, Civantos AM, Byrnes Y ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32839747
68. **Trait emotional intelligence and emotional experiences during the COVID-19 pandemic outbreak in Poland: A daily diary study.** Pers. Individ. Dif. 2020:110348Moroń M, Biolik-Moroń M. http://www.ncbi.nlm.nih.gov/pubmed/?term=32843781
69. **Positivity mechanism explains how COVID-19 perceived risk increases death distress and reduces happiness.** Pers. Individ. Dif. 2020:110347Yıldırım M, Güler A. http://www.ncbi.nlm.nih.gov/pubmed/?term=32843780
70. **Psychotherapy in Times of the Covid-19 Pandemic-A Brief Reflection.** PPmP Psychotherapie Psychosomatik Medizinische Psychologie 2020; 70:269-271Zipfel S, Stengel A, Junne F.
71. **"The COVID-19 Pandemic and its Effect on Mental Health in USA - A Review with Some Coping Strategies".** Psychiatr. Q. 2020:1-11Bhattacharjee B, Acharya T. http://www.ncbi.nlm.nih.gov/pubmed/?term=32829449
72. **Mental Health Status in the Community During the COVID-19-Pandemic.** Psychiatr. Prax. 2020; Kuehner C, Schultz K, Gass P ***et al.***
73. **Impact of the COVID-19 pandemic on mental health in the general Chinese population: Changes, predictors and psychosocial correlates.** Psychiatry Res 2020; 293:113396Duan H, Yan L, Ding X ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32861096
74. **Prevalence of psychological morbidities among general population, healthcare workers and COVID-19 patients amidst the COVID-19 pandemic: A systematic review and meta-analysis.** Psychiatry Res 2020; 293:113382Krishnamoorthy Y, Nagarajan R, Saya GK, Menon V. http://www.ncbi.nlm.nih.gov/pubmed/?term=32829073
75. **Mental health during the COVID-19 pandemic: Effects of stay-at-home policies, social distancing behavior, and social resources.** Psychiatry Res 2020; 293:113419Marroquín B, Vine V, Morgan R. http://www.ncbi.nlm.nih.gov/pubmed/?term=32861098
76. **Neurocovid: Pharmacological Recommendations for Delirium Associated With COVID-19.** Psychosomatics 2020; Baller EB, Hogan CS, Fusunyan MA ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32828569
77. **Medical Overuse in the Iranian Healthcare System: A Systematic Scoping Review and Practical Recommendations for Decreasing Medical Overuse During Unexpected COVID-19 Pandemic Opportunity.** Risk Manag. Healthc. Policy 2020; 13:1103-1110Pezeshki MZ, Janati A, Arab-Zozani M. http://www.ncbi.nlm.nih.gov/pubmed/?term=32848487
78. **Interventions to suppress the coronavirus pandemic will increase unemployment and lead to many premature deaths.** Scand J Public Health

2020:1403494820947974Rosén M, Stenbeck M. http://www.ncbi.nlm.nih.gov/pubmed/?term=32842900
79. **The enemy who sealed the world: effects quarantine due to the COVID-19 on sleep quality, anxiety, and psychological distress in the Italian population.** Sleep Med. 2020; 75:12-20Casagrande M, Favieri F, Tambelli R, Forte G. http://www.ncbi.nlm.nih.gov/pubmed/?term=32853913
80. **Sleep quality in times of Covid-19 pandemic.** Sleep Med. 2020; 74:81-85Pinto J, van Zeller M, Amorim P ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32841849
81. **Sleep disturbances among Chinese residents during the Coronavirus Disease 2019 outbreak and associated factors.** Sleep Med. 2020; 74:199-203Wang J, Gong Y, Chen Z ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32861011
82. **Impact on mental health care and on mental health service users of the COVID-19 pandemic: a mixed methods survey of UK mental health care staff.** Soc. Psychiatry Psychiatr. Epidemiol. 2020; Johnson S, Dalton-Locke C, Vera San Juan N ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32857218
83. **Does thinking about coronavirus impact insight and analytical reasoning?** Think Skills Creat 2020; 38:100715Karwowski M, Groyecka-Bernard A, Kowal M, Sorokowski P. http://www.ncbi.nlm.nih.gov/pubmed/?term=32843905
84. **The neglected role of Faith-based Organizations in prevention and control of COVID-19 in Africa.** Trans. R. Soc. Trop. Med. Hyg. 2020; Vilakati PN, Villa S, Alagna R ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32853360

Meta-analyses - systematic reviews (7 articles)

1. **Systematic review with meta-analysis: SARS-CoV-2 stool testing and the potential for faecal-oral transmission.** Aliment. Pharmacol. Ther. 2020; van Doorn AS, Meijer B, Frampton CMA ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32852082
2. **Cardio-Cerebrovascular Disease is Associated With Severity and Mortality of COVID-19: A Systematic Review and Meta-Analysis.** Biol. Res. Nurs. 2020:1099800420951984Yu JN, Wu BB, Yang J ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32851851
3. **Incidence of Venous Thromboembolism in Hospitalized Coronavirus Disease 2019 Patients: A Systematic Review and Meta-Analysis.** Front Cardiovasc Med 2020; 7:151Zhang C, Shen L, Le KJ ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32850990
4. **Efficacy and Safety of Anti-malarial Drugs (Chloroquine and Hydroxy-Chloroquine) in Treatment of COVID-19 Infection: A Systematic Review and Meta-Analysis.** Front Med (Lausanne) 2020; 7:482Das RR, Jaiswal N, Dev N ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32850924
5. **Safety and Efficacy of Hydroxychloroquine in COVID-19: A Systematic Review and Meta-Analysis.** J. Clin. Med. Res. 2020; 12:483-491Ullah W, H MA, Roomi S ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32849936
6. **Interleukin-6 in Covid-19: A systematic review and meta-analysis.** Rev Med Virol 2020:e2141Coomes EA, Haghbayan H. http://www.ncbi.nlm.nih.gov/pubmed/?term=32845568
7. **Venous thromboembolism in patients with COVID-19: Systematic review and meta-analysis.** Thromb Res 2020; 196:67-74Porfidia A, Valeriani E, Pola R ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32853978

Mortality (14 articles)

1. **Postmortem imaging of the lung in cases of COVID-19 deaths.** Der Radiologe 2020; Kniep I, Lutter M, Ron A ***et al.***
2. **Fasting Plasma Glucose Level Independently Predicts the Mortality of Patients with Coronavirus Disease 2019 Infection: A Multicenter, Retrospective Cohort Study.** Endocrinol Metab (Seoul) 2020; Chang MC, Hwang JM, Jeon JH ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32842719
3. **Population-level COVID-19 mortality risk for non-elderly individuals overall and for non-elderly individuals without underlying diseases in pandemic epicenters.** Environ. Res. 2020; 188:109890Ioannidis JPA, Axfors C, Contopoulos-Ioannidis DG. http://www.ncbi.nlm.nih.gov/pubmed/?term=32846654
4. **Excess all-cause mortality during the first wave of the COVID-19 epidemic in France, March to May 2020.** Euro Surveill 2020; 25Fouillet A, Pontais I, Caserio-Schönemann C. http://www.ncbi.nlm.nih.gov/pubmed/?term=32856584
5. **Timely monitoring of total mortality associated with COVID-19: informing public health and the public.** Euro Surveill 2020; 25Vestergaard LS, Mølbak K. http://www.ncbi.nlm.nih.gov/pubmed/?term=32856586
6. **Coronavirus (SARS-CoV-2) and Mortality Rate in India: The Winning Edge.** Front Public Health 2020; 8:397Chaubey G. http://www.ncbi.nlm.nih.gov/pubmed/?term=32850604
7. **A Predicting Nomogram for Mortality in Patients With COVID-19.** Front Public Health 2020; 8:461Pan D, Cheng D, Cao Y ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32850612
8. **Disease progression patterns and risk factors associated with mortality in deceased patients with COVID-19 in Hubei Province, China.** Immun Inflamm Dis 2020; Chen L, Liu S, Tian J ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32857453
9. **Risk factors for Covid-19 severity and fatality: a structured literature review.** Infection 2020; Wolff D, Nee S, Hickey NS, Marschollek M. http://www.ncbi.nlm.nih.gov/pubmed/?term=32860214
10. **Low-dose Hydroxychloroquine Therapy and Mortality in Hospitalized Patients with COVID-19: A Nationwide Observational Study of 8075 Participants.** Int J Antimicrob Agents 2020:106144Catteau L, Dauby N, Montourcy M ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32853673
11. **The FIB-4 Index Is Associated with Need for Mechanical Ventilation and 30-day Mortality in Patients Admitted with COVID-19.** J Infect Dis 2020; Sterling RK, Oakes T, Gal TS ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32856702
12. **An initial report from the French SOT COVID Registry suggests high mortality due to Covid-19 in recipients of kidney transplants.** Kidney Int 2020; Caillard S, Anglicheau D, Matignon M ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32853631
13. **Fatal COVID-19 in an MS patient on natalizumab: A case report.** Mult Scler J Exp Transl Clin 2020; 6:2055217320942931Rimmer K, Farber R, Thakur K ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32850133
14. **Risk factors for in-hospital mortality in patients with acute myocardial infarction during the COVID-19 outbreak.** Rev Esp Cardiol (Engl Ed) 2020; Solano-López J, Zamorano JL, Pardo Sanz A ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32839121

Online – IT – Apps (20 articles)

1. **[Management of Rheumatic Diseases during the COVID-19 Pandemic: Beyond Telehealth Services].** Acta Med Port 2020; Fernandes AL, Silva C, Miranda LC. http://www.ncbi.nlm.nih.gov/pubmed/?term=32840207
2. **Using social media for telemedicine during the COVID-19 epidemic.** Am J Emerg Med 2020; Li Y, Zhang K. http://www.ncbi.nlm.nih.gov/pubmed/?term=32839054
3. **Proficiency of virtual follow-up amongst tinnitus patients who underwent intratympanic steroid therapy amidst COVID 19 pandemic.** Am. J. Otolaryngol. 2020; 41:102680Vijayasundaram S, Karthikeyan P, Mehta SD. http://www.ncbi.nlm.nih.gov/pubmed/?term=32861124
4. **To tele- or not to telehealth? Ongoing COVID-19 challenges for private psychiatry in Australia.** Australas Psychiatry 2020:1039856220950081Looi JC, Pring W. http://www.ncbi.nlm.nih.gov/pubmed/?term=32847378
5. **How People Emotionally Respond to the News on COVID-19: An Online Survey.** Basic Clin Neurosci 2020; 11:171-178Hamidein Z, Hatami J, Rezapour T. http://www.ncbi.nlm.nih.gov/pubmed/?term=32855776
6. **The sudden transition to synchronized online learning during the COVID-19 pandemic in Saudi Arabia: a qualitative study exploring medical students' perspectives.** BMC Med. Educ. 2020; 20:285Khalil R, Mansour AE, Fadda WA ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32859188
7. **Telemental health for child trauma treatment during and post-COVID-19: Limitations and considerations.** Child Abuse Negl. 2020:104698Racine N, Hartwick C, Collin-Vézina D, Madigan S. http://www.ncbi.nlm.nih.gov/pubmed/?term=32839022
8. **Knowledge, perception, and practices towards COVID-19 pandemic among general public of India: A cross-sectional online survey.** Curr Med Res Pract 2020; 10:153-159Narayana G, Pradeepkumar B, Ramaiah JD ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32839725
9. **#Coronavirus: Monitoring the Belgian Twitter Discourse on the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic.** Cyberpsychol Behav Soc Netw 2020; Kurten S, Beullens K. http://www.ncbi.nlm.nih.gov/pubmed/?term=32857607
10. **A first public dataset from Brazilian twitter and news on COVID-19 in Portuguese.** Data Brief 2020; 32:106179de Melo T, Figueiredo CMS. http://www.ncbi.nlm.nih.gov/pubmed/?term=32844106
11. **Alcohol industry arguments for putting profit before health in the midst of a pandemic: The Western Australian experience.** Drug Alcohol Rev 2020; Keric D, Stafford J. http://www.ncbi.nlm.nih.gov/pubmed/?term=32853408
12. **COVID-19 what have we learned? The rise of social machines and connected devices in pandemic management following the concepts of predictive, preventive and personalized medicine.** Epma j 2020; 11:311-332Radanliev P, De Roure D, Walton R ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32839666
13. **Effectiveness and influencing factors of online education for caregivers of patients with eating disorders during COVID-19 pandemic in China.** Eur Eat Disord Rev 2020; Guo L, Wu M, Zhu Z ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32852142
14. **Teleoncology or telemedicine for oncology patients during the COVID-19 pandemic: the new normal for breast cancer survivors?** Future Oncol 2020;

Yildiz F, Oksuzoglu B. http://www.ncbi.nlm.nih.gov/pubmed/?term=32857603

15. **AI4COVID-19: AI enabled preliminary diagnosis for COVID-19 from cough samples via an app.** Inform Med Unlocked 2020; 20:100378Imran A, Posokhova I, Qureshi HN ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32839734
16. **Inpatient Cardiac Monitoring Using a Patch-Based Mobile Cardiac Telemetry System During the COVID-19 Pandemic.** J Cardiovasc Electrophysiol 2020; Braunstein ED, Reynbakh O, Krumerman A ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32852868
17. **The effective use of an e-dentistry service during the COVID-19 crisis.** J. Orthod. 2020:1465312520949557Crawford E, Taylor N. http://www.ncbi.nlm.nih.gov/pubmed/?term=32854562
18. **Lessons Learned: Pediatric Tele-Mental Health in a Rural Medical Center in the Age of SARS-CoV-2.** J Rural Health 2020; Satti K, Ojugbele O. http://www.ncbi.nlm.nih.gov/pubmed/?term=32845031
19. **Teledermatologie in den Zeiten von COVID-19 – ein systematisches Review.** JDDG - Journal of the German Society of Dermatology 2020; 18:841-847Elsner P.
20. **A COVID-19 screening tool for oncology telephone triage.** Support. Care Cancer 2020; Elkin E, Viele C, Schumacher K ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32856214

Other – Miscellaneous (83 articles)

1. **H″IT″ting the Barriers for Exercising during Social Isolation.** Biology (Basel) 2020; 9Souza D, Coswig V, de Lira CAB, Gentil P. http://www.ncbi.nlm.nih.gov/pubmed/?term=32847134
2. **Impact of COVID-19 pandemic and the lockdown on invasive meningococcal disease.** BMC Res. Notes 2020; 13:399Taha MK, Deghmane AE. http://www.ncbi.nlm.nih.gov/pubmed/?term=32854773
3. **Nutritional status, diet and viral respiratory infections: perspectives for SARS-CoV-2.** Br. J. Nutr. 2020:1-32Morais AHA, Aquino JS, Silva-Maia JKD ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32843118
4. **COVID-19 has inspired global healthcare innovation.** Can. J. Public Health. 2020; Palanica A, Fossat Y. http://www.ncbi.nlm.nih.gov/pubmed/?term=32860103
5. **Soft contact lens wearers' compliance during the COVID-19 pandemic.** Cont Lens Anterior Eye 2020; Vianya-Estopa M, Wolffsohn JS, Beukes E ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32839091
6. **Fight against Novel Coronavirus and hunger in India.** Curr Med Res Pract 2020; 10:198-200Yadav AK. http://www.ncbi.nlm.nih.gov/pubmed/?term=32839731
7. **Let us not forget the importance of a face to face consultation in the Covid-19 era, a dermatology perspective.** Dermatol Ther 2020; Hussain K, Borysiewicz C. http://www.ncbi.nlm.nih.gov/pubmed/?term=32860337
8. **To dispense or not to dispense: Lessons to be learnt from ethical challenges faced by pharmacists in the COVID-19 pandemic.** Dev World Bioeth 2020; Cox S. http://www.ncbi.nlm.nih.gov/pubmed/?term=32844516
9. **Allocation of scarce resources in Africa during COVID-19: Utility and justice for the bottom of the pyramid?** Dev World Bioeth 2020; Moodley K, Rennie S, Behets F ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32845575
10. **Alcohol industry arguments for putting profit before health in the midst of a pandemic: The Western Australian experience.** Drug Alcohol Rev 2020; Keric D,

Stafford J. http://www.ncbi.nlm.nih.gov/pubmed/?term=32853408

11. **Analysis of mobility trends during the COVID-19 coronavirus pandemic: Exploring the impacts on global aviation and travel in selected cities.** Energy Res Soc Sci 2020; 68:101693Abu-Rayash A, Dincer I. http://www.ncbi.nlm.nih.gov/pubmed/?term=32839706
12. **Analysis of the electricity demand trends amidst the COVID-19 coronavirus pandemic.** Energy Res Soc Sci 2020; 68:101682Abu-Rayash A, Dincer I. http://www.ncbi.nlm.nih.gov/pubmed/?term=32839701
13. **COVID-19 energy sector responses in Africa: A review of preliminary government interventions.** Energy Res Soc Sci 2020; 68:101681Akrofi MM, Antwi SH. http://www.ncbi.nlm.nih.gov/pubmed/?term=32839700
14. **The impact of different COVID-19 containment measures on electricity consumption in Europe.** Energy Res Soc Sci 2020; 68:101683Bahmanyar A, Estebsari A, Ernst D. http://www.ncbi.nlm.nih.gov/pubmed/?term=32839702
15. **The energy crises revealed by COVID: Intersections of Indigeneity, inequity, and health.** Energy Res Soc Sci 2020; 68:101661Brosemer K, Schelly C, Gagnon V ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32839694
16. **Coronavirus comes home? Energy use, home energy management, and the social-psychological factors of COVID-19.** Energy Res Soc Sci 2020; 68:101688Chen CF, Zarazua de Rubens G, Xu X, Li J. http://www.ncbi.nlm.nih.gov/pubmed/?term=32839705
17. **Validity of energy social research during and after COVID-19: challenges, considerations, and responses.** Energy Res Soc Sci 2020; 68:101646Fell MJ, Pagel L, Chen CF ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32839692
18. **COVID-19 and energy access: An opportunity or a challenge for the African continent?** Energy Res Soc Sci 2020; 68:101677Gebreslassie MG. http://www.ncbi.nlm.nih.gov/pubmed/?term=32839698
19. **What opportunities could the COVID-19 outbreak offer for sustainability transitions research on electricity and mobility?** Energy Res Soc Sci 2020; 68:101666Kanda W, Kivimaa P. http://www.ncbi.nlm.nih.gov/pubmed/?term=32839695
20. **Covid-19 and the politics of sustainable energy transitions.** Energy Res Soc Sci 2020; 68:101685Kuzemko C, Bradshaw M, Bridge G ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32839704
21. **Emergency measures to protect energy consumers during the Covid-19 pandemic: A global review and critical analysis.** Energy Res Soc Sci 2020; 68:101678Mastropietro P, Rodilla P, Batlle C. http://www.ncbi.nlm.nih.gov/pubmed/?term=32839699
22. **When pandemics impact economies and climate change: Exploring the impacts of COVID-19 on oil and electricity demand in China.** Energy Res Soc Sci 2020; 68:101654Norouzi N, Zarazua de Rubens G, Choupanpiesheh S, Enevoldsen P. http://www.ncbi.nlm.nih.gov/pubmed/?term=32839693
23. **Contextualizing the Covid-19 pandemic for a carbon-constrained world: Insights for sustainability transitions, energy justice, and research methodology.** Energy Res Soc Sci 2020; 68:101701Sovacool BK, Furszyfer Del Rio D, Griffiths S. http://www.ncbi.nlm.nih.gov/pubmed/?term=32844087
24. **The influence of COVID-19 on grid parity of China's photovoltaic industry.** Environ. Geochem. Health 2020; Song Y, Liu T, Li Y, Ye B. http://www.ncbi.nlm.nih.gov/pubmed/?term=32857234

25. **The role of air pollution (PM and NO(2)) in COVID-19 spread and lethality: a systematic review.** Environ. Res. 2020:110129Copat C, Cristaldi A, Fiore M ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32853663
26. **An ecological analysis of long-term exposure to PM(2.5) and incidence of COVID-19 in Canadian Health Regions.** Environ. Res. 2020:110052Stieb DM, Evans GJ, To TM ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32860780
27. **COVID-19 lockdowns, stimulus packages, travel bans, and stock returns.** Financ Res Lett 2020:101732Narayan PK, Phan DHB, Liu G. http://www.ncbi.nlm.nih.gov/pubmed/?term=32843886
28. **Healthcare Transformation in the Post-Coronavirus Pandemic Era.** Front Med (Lausanne) 2020; 7:429Jazieh AR, Kozlakidis Z. http://www.ncbi.nlm.nih.gov/pubmed/?term=32850915
29. **COVID-19: Looking Into the Overlooked.** Front Mol Biosci 2020; 7:165Petersen FC, Dahle UR, Nicolau B, Casals-Pascual C. http://www.ncbi.nlm.nih.gov/pubmed/?term=32850958
30. **COVID-19: Can this crisis be transformative for global health?** Glob Public Health 2020:1-13Casale M. http://www.ncbi.nlm.nih.gov/pubmed/?term=32841091
31. **Policing in pandemics: A systematic review and best practices for police response to COVID-19.** Int J Disaster Risk Reduct 2020; 51:101812Laufs J, Waseem Z. http://www.ncbi.nlm.nih.gov/pubmed/?term=32839687
32. **Sedentary Behaviors and Physical Activity of Italian Undergraduate Students during Lockdown at the Time of CoViD-19 Pandemic.** Int J Environ Res Public Health 2020; 17Gallè F, Sabella EA, Ferracuti S ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32854414
33. **Ultra Long-Haul: An emerging business model accelerated by COVID-19.** J Air Transp Manag 2020; 89:101901Bauer LB, Bloch D, Merkert R. http://www.ncbi.nlm.nih.gov/pubmed/?term=32839647
34. **Air carrier's liability for the safety of passengers during COVID-19 pandemic.** J Air Transp Manag 2020:101896Naboush E, Alnimer R. http://www.ncbi.nlm.nih.gov/pubmed/?term=32839646
35. **Accelerating the De-Personalization of Medicine: The Ethical Toxicities of COVID-19.** J. Bioeth. Inq. 2020; Arnold M, Kerridge I. http://www.ncbi.nlm.nih.gov/pubmed/?term=32840851
36. **Clever COVID-19, Clever Citizens-98: Critical and Creative Reflections from Tehran, Toronto, and Sydney.** J. Bioeth. Inq. 2020; Bisaillon L, Khosravi M, Jahandoost B, Briskman L. http://www.ncbi.nlm.nih.gov/pubmed/?term=32840857
37. **"We" Are In This Together, But We Are Not One and the Same.** J. Bioeth. Inq. 2020; Braidotti R. http://www.ncbi.nlm.nih.gov/pubmed/?term=32840844
38. **Antibodies as Currency: COVID-19's Golden Passport.** J. Bioeth. Inq. 2020; Bramstedt KA. http://www.ncbi.nlm.nih.gov/pubmed/?term=32840824
39. **Systems of Care in Crisis: The Changing Nature of Palliative Care During COVID-19.** J. Bioeth. Inq. 2020; Chapman M, Russell B, Philip J. http://www.ncbi.nlm.nih.gov/pubmed/?term=32840836
40. **COVID-19-Extending Surveillance and the Panopticon.** J. Bioeth. Inq. 2020; Couch DL, Robinson P, Komesaroff PA. http://www.ncbi.nlm.nih.gov/pubmed/?term=32840859
41. **The Phenomenology of Contagion.** J. Bioeth. Inq. 2020; Dahiya A. http://www.ncbi.nlm.nih.gov/pubmed/?term=32840826

42. **Building an Ethics Framework for COVID-19 Resource Allocation: The How and the Why.** J. Bioeth. Inq. 2020; Dawson A. http://www.ncbi.nlm.nih.gov/pubmed/?term=32840848
43. **An Ethics Framework for Making Resource Allocation Decisions Within Clinical Care: Responding to COVID-19.** J. Bioeth. Inq. 2020; Dawson A, Isaacs D, Jansen M ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32840833
44. **Rethinking the Central Role of Equity in the Global Governance of Pandemic Response.** J. Bioeth. Inq. 2020; Eyawo O, Viens AM. http://www.ncbi.nlm.nih.gov/pubmed/?term=32840828
45. **COVID-19 Ethics-Looking Down the Muzzle.** J. Bioeth. Inq. 2020; Gillett G. http://www.ncbi.nlm.nih.gov/pubmed/?term=32840854
46. **Pandemic Surveillance and Racialized Subpopulations: Mitigating Vulnerabilities in COVID-19 Apps.** J. Bioeth. Inq. 2020; Hendl T, Chung R, Wild V. http://www.ncbi.nlm.nih.gov/pubmed/?term=32840858
47. **Coronavirus Human Infection Challenge Studies: Assessing Potential Benefits and Risks.** J. Bioeth. Inq. 2020; Jamrozik E, Heriot GS, Selgelid MJ. http://www.ncbi.nlm.nih.gov/pubmed/?term=32840856
48. **Advancing Global Health Equity in the COVID-19 Response: Beyond Solidarity.** J. Bioeth. Inq. 2020; Johnson SB. http://www.ncbi.nlm.nih.gov/pubmed/?term=32840837
49. **Dignity, Autonomy, and Allocation of Scarce Medical Resources During COVID-19.** J. Bioeth. Inq. 2020; Kirchhoffer DG. http://www.ncbi.nlm.nih.gov/pubmed/?term=32840827
50. **Not all Bad: Sparks of Hope in a Global Disaster.** J. Bioeth. Inq. 2020; Komesaroff PA. http://www.ncbi.nlm.nih.gov/pubmed/?term=32840834
51. **Lead Essay-Inside the Pandemic.** J. Bioeth. Inq. 2020; Komesaroff PA, Chapman M, Kerridge I, Upshur REG. http://www.ncbi.nlm.nih.gov/pubmed/?term=32845462
52. **Science at Warp Speed: Medical Research, Publication, and Translation During the COVID-19 Pandemic.** J. Bioeth. Inq. 2020; Lipworth W, Gentgall M, Kerridge I, Stewart C. http://www.ncbi.nlm.nih.gov/pubmed/?term=32840838
53. **Hope and Optimism: A Spinozist Perspective on COVID-19.** J. Bioeth. Inq. 2020; Lloyd G. http://www.ncbi.nlm.nih.gov/pubmed/?term=32840855
54. **COVID-19 and Contact Tracing Apps: Ethical Challenges for a Social Experiment on a Global Scale.** J. Bioeth. Inq. 2020; Lucivero F, Hallowell N, Johnson S ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32840842
55. **Gambling with COVID-19 Makes More Sense: Ethical and Practical Challenges in COVID-19 Responses in Communalistic Resource-Limited Africa.** J. Bioeth. Inq. 2020; Nderitu D, Kamaara E. http://www.ncbi.nlm.nih.gov/pubmed/?term=32840829
56. **In the Shadow of Biological Warfare: Conspiracy Theories on the Origins of COVID-19 and Enhancing Global Governance of Biosafety as a Matter of Urgency.** J. Bioeth. Inq. 2020; Nie JB. http://www.ncbi.nlm.nih.gov/pubmed/?term=32840850
57. **Humiliating Whistle-Blowers: Li Wenliang, the Response to Covid-19, and the Call for a Decent Society.** J. Bioeth. Inq. 2020; Nie JB, Elliott C. http://www.ncbi.nlm.nih.gov/pubmed/?term=32840823
58. **Fairness, Ethnicity, and COVID-19 Ethics : A Discussion of How the Focus on Fairness in Ethical Guidance During the Pandemic Discriminates Against**

People From Ethnic Minority Backgrounds. J. Bioeth. Inq. 2020; Paton A. http://www.ncbi.nlm.nih.gov/pubmed/?term=32840825
59. **Disability, Disablism, and COVID-19 Pandemic Triage.** J. Bioeth. Inq. 2020; Scully JL. http://www.ncbi.nlm.nih.gov/pubmed/?term=32840832
60. **Understanding Ethical and Legal Obligations in a Pandemic: A Taxonomy of "Duty" for Health Practitioners.** J. Bioeth. Inq. 2020; Sheahan L, Lamont S. http://www.ncbi.nlm.nih.gov/pubmed/?term=32840830
61. **Learning Lessons from COVID-19 Requires Recognizing Moral Failures.** J. Bioeth. Inq. 2020; Smith MJ, Upshur REG. http://www.ncbi.nlm.nih.gov/pubmed/?term=32840847
62. **The Rejuvenation of the Withering Nation State and Bio-power: The New Dynamics of Human Interaction.** J. Bioeth. Inq. 2020; Suri AW. http://www.ncbi.nlm.nih.gov/pubmed/?term=32840845
63. **Family Presence for Patients and Separated Relatives During COVID-19: Physical, Virtual, and Surrogate.** J. Bioeth. Inq. 2020; Voo TC, Senguttuvan M, Tam CC. http://www.ncbi.nlm.nih.gov/pubmed/?term=32840835
64. **Knowing How to Act Well in Time.** J. Bioeth. Inq. 2020; Wagner P. http://www.ncbi.nlm.nih.gov/pubmed/?term=32840843
65. **The Appointment in Samarra: A New Use for Some Old Jokes.** J. Bioeth. Inq. 2020; Žižek S. http://www.ncbi.nlm.nih.gov/pubmed/?term=32840846
66. **Care of traditional patients in the campaign against COVID-19: casualties of friendly fire.** J Community Hosp Intern Med Perspect 2020; 10:299-300Srivastava MC. http://www.ncbi.nlm.nih.gov/pubmed/?term=32850083
67. **Lost Touch? Implications of Physical Touch for Physical Health.** J. Gerontol. B Psychol. Sci. Soc. Sci. 2020; Thomas PA, Kim S. http://www.ncbi.nlm.nih.gov/pubmed/?term=32845008
68. **COVID-19 immunity certificates: science, ethics, policy, and law.** J Law Biosci 2020; 7:lsaa035Greely HT. http://www.ncbi.nlm.nih.gov/pubmed/?term=32839671
69. **Caeteris paribus: In search of the "Silent Professional Identity" of filipino radiologic technologists during the COVID-19 pandemic.** J Med Imaging Radiat Sci 2020; de Guzman AB, Angcahan DZ. http://www.ncbi.nlm.nih.gov/pubmed/?term=32847721
70. **COVID-19 outbreak, social response, and early economic effects: a global VAR analysis of cross-country interdependencies.** J Popul Econ 2020:1-30Milani F. http://www.ncbi.nlm.nih.gov/pubmed/?term=32839640
71. **What Will Travel Medicine Look Like in the COVID-19 Pandemic Era?** J Travel Med 2020; Shlim DR, Connor BA, Taylor DN. http://www.ncbi.nlm.nih.gov/pubmed/?term=32856040
72. **Application of Additive manufacturing in challenges posed by COVID-19.** Mater Today Proc 2020; Arora PK, Arora R, Haleem A, Kumar H. http://www.ncbi.nlm.nih.gov/pubmed/?term=32844088
73. **Nurses' ethical challenges caring for people with COVID-19: A qualitative study.** Nurs. Ethics 2020:969733020944453Jia Y, Chen O, Xiao Z ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32856534
74. **Use of the ADKAR® and CLARC ® Change Models to Navigate staffing model changes during the COVID-19 pandemic.** Nurse Lead 2020; Balluck J, Asturi E, Brockman V. http://www.ncbi.nlm.nih.gov/pubmed/?term=32843885
75. **Ethics Trade-Off Between Hazards Prevention and the Safeguard of Death Dignity During COVID-19.** Omega (Westport) 2020:30222820950890Logar S,

Leese M. http://www.ncbi.nlm.nih.gov/pubmed/?term=32842881

76. **This section comprises references that occur in the reference list but not in the body of the text. Please position each reference in the text or, alternatively, delete it.Impact of COVID-19 on Household Waste Flows, Diversion and Reuse: The Case of Multi-residential Buildings in Toronto, Canada.** Resour Conserv Recycl 2020:105111Ikiz E, Maclaren VW, Alfred E, Sivanesan S. http://www.ncbi.nlm.nih.gov/pubmed/?term=32839638
77. **Changes in air pollution levels after COVID-19 outbreak in Korea.** Sci Total Environ 2020; 750:141521Ju MJ, Oh J, Choi YH. http://www.ncbi.nlm.nih.gov/pubmed/?term=32829258
78. **Correlation of ambient temperature and COVID-19 incidence in Canada.** Sci Total Environ 2020; 750:141484To T, Zhang K, Maguire B ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32829260
79. **Particulate matter and SARS-CoV-2: A possible model of COVID-19 transmission.** Sci Total Environ 2020; 750:141532Tung NT, Cheng PC, Chi KH ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32858292
80. **Rising home values and Covid-19 case rates in Massachusetts.** Soc. Sci. Med. 2020:113290Arcaya MC, Nidam Y, Binet A ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32843186
81. **Assessment of Turkish oncology nurses' knowledge regarding COVID-19 during the current outbreak in Turkey.** Support. Care Cancer 2020:1-8Semerci R, Kudubes AA, Eşref F. http://www.ncbi.nlm.nih.gov/pubmed/?term=32829464
82. **Neglecting the effect of COVID-19 on neglected tropical diseases: the Ethiopian perspective.** Trans. R. Soc. Trop. Med. Hyg. 2020; Abdela SG, van Griensven J, Seife F, Enbiale W. http://www.ncbi.nlm.nih.gov/pubmed/?term=32853370
83. **Response to Letter by Rallis and Tejerina.** Trends Cancer 2020; Shirke MM, Shaikh SA, Harky A. http://www.ncbi.nlm.nih.gov/pubmed/?term=32855098

Pathology (2 articles)

1. **Recording COVID-19 consultations: review of symptoms, risk factors, and proposed SNOMED CT terms.** BJGP Open 2020; Jani BD, Pell JP, McGagh D ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32843331
2. **Anticoagulation, Mortality, Bleeding and Pathology Among Patients Hospitalized with COVID-19: A Single Health System Study.** J Am Coll Cardiol 2020; Nadkarni GN, Lala A, Bagiella E ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32860872

Protection (23 articles)

1. **Evaluation of disinfection procedures in a designated hospital for COVID-19.** Am. J. Infect. Control 2020; Ge T, Lu Y, Zheng S ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32841686
2. **There is no intraocular affection on a SARS-CoV-2 - Infected ocular surface.** Am J Ophthalmol Case Rep 2020:100884Lauermann P, Storch M, Weig M ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32839739
3. **The impact of COVID-19 on food systems, safety, and security-a symposium report.** Ann. N. Y. Acad. Sci. 2020; Cable J, Jaykus LA, Hoelzer K ***et al.***

http://www.ncbi.nlm.nih.gov/pubmed/?term=32860255
4. **Face Mask Policies in South Korea in Response to COVID-19.** Asia Pac. J. Public Health 2020:1010539520951397Yu S, Kim S, Kang J. http://www.ncbi.nlm.nih.gov/pubmed/?term=32844677
5. **Protecting healthcare providers from COVID-19 through a large simulation training programme.** Br J Anaesth 2020; Buléon C, Minehart RD, Fischer MO. http://www.ncbi.nlm.nih.gov/pubmed/?term=32828493
6. **Pre-procedural screening for COVID-19 with nasopharyngeal polymerase chain reaction testing.** Br J Anaesth 2020; Gershengorn HB, Warde PR, Nguyen DM ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32859362
7. **Distanced-based dynamic behaviour of aerosol particles during aerosol-generating medical procedures.** Br J Anaesth 2020; Tsui BCH, Pan S. http://www.ncbi.nlm.nih.gov/pubmed/?term=32828494
8. **Use of mouthwashes against COVID-19 in dentistry.** Br. J. Oral Maxillofac. Surg. 2020; Vergara-Buenaventura A, Castro-Ruiz C. http://www.ncbi.nlm.nih.gov/pubmed/?term=32859459
9. **Child safety, protection, and safeguarding in the time of COVID-19 in Great Britain: Proposing a conceptual framework.** Child Abuse Negl. 2020:104668Levine DT, Morton J, O'Reilly M. http://www.ncbi.nlm.nih.gov/pubmed/?term=32828561
10. **Transmission of SARS-CoV-2 through the air.** Curr Med Res Pract 2020; 10:196-197Thaper R. http://www.ncbi.nlm.nih.gov/pubmed/?term=32839730
11. **Food Safety During and After the Era of COVID-19 Pandemic.** Front. Microbiol. 2020; 11:1854Olaimat AN, Shahbaz HM, Fatima N ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32849446
12. **Healthcare Worker Infection with SARS-CoV-2 and Test-Based Return to Work.** Infect Control Hosp Epidemiol 2020:1-11Shenoy ES, West LR, Hooper DC ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32843110
13. **Rapid Review of SARS-CoV-1 and SARS-CoV-2 Viability, Susceptibility to Treatment, and the Disinfection and Reuse of PPE, Particularly Filtering Facepiece Respirators.** Int J Environ Res Public Health 2020; 17Derraik JGB, Anderson WA, Connelly EA, Anderson YC. http://www.ncbi.nlm.nih.gov/pubmed/?term=32842655
14. **Airborne Transmission of Covid-19: Implications for Irish Hospitals.** Ir Med J 2020; 113:126Humphreys H, Fitzpatrick F. http://www.ncbi.nlm.nih.gov/pubmed/?term=32846080
15. **Anesthesiologist behavior and anesthesia machine use in the operating room during the COVID-19 pandemic: awareness and changes to cope with the risk of infection transmission.** J. Anesth. 2020; Obara S. http://www.ncbi.nlm.nih.gov/pubmed/?term=32856167
16. **Environmental contamination in the isolation rooms of COVID-19 patients with severe pneumonia requiring mechanical ventilation or high-flow oxygen therapy.** J Hosp Infect 2020; Ahn JY, An S, Sohn Y ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32828864
17. **Transmission of infection from non-isolated patients with COVID-19 to health care workers.** J Hosp Infect 2020; Basso T, Nordbø SA, Sundqvist E ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32828865
18. **Microwave- and Heat-Based Decontamination of N95 Filtering Facepiece Respirators: A Systematic Review.** J Hosp Infect 2020; Gertsman S, Agarwal A,

O'Hearn K ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32841704

19. **Easy-to-use electrocautery smoke evacuation device for open surgery under the risk of the COVID-19 pandemic.** J. Int. Med. Res. 2020; 48:300060520949772Ekci B. http://www.ncbi.nlm.nih.gov/pubmed/?term=32844707
20. **COVID-19 After Effects: Concerns for Singers.** J. Voice 2020; Helding L, Carroll TL, Nix J ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32839055
21. **Video Section-Operative Nuances: Step by Step - Donning and Doffing in Neurosurgical Operating Room.** Neurol. India 2020; 68:796-799Verma SK, Dharanipathy S, Suri A ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32859815
22. **Environmental disinfection against COVID-19 in different areas of health care facilities: a review.** Rev. Environ. Health 2020; Sharafi SM, Ebrahimpour K, Nafez A. http://www.ncbi.nlm.nih.gov/pubmed/?term=32845869
23. **Sunlight ultraviolet radiation dose is negatively correlated with the percent positive of SARS-CoV-2 and four other common human coronaviruses in the U.S.** Sci Total Environ 2020; 751:141816Tang L, Liu M, Ren B ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32861186

Pulmonary disease (11 articles)

1. **Respiratory epidemics and older people.** Age Ageing 2020; Doraiswamy S, Mamtani R, Ameduri M ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32857159
2. **COVID-19 Versus non-COVID-19-related Acute Respiratory Distress Syndrome: Differences and Similarities.** Am J Respir Crit Care Med 2020; Brault C, Zerbib Y, Kontar L ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32857595
3. **Pre-HCT lung computed tomography as an alternative to PFT during the COVID-19 Pandemic.** Biol Blood Marrow Transplant 2020; Tamaki M, Nakasone H, Aikawa T ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32860909
4. **Respiratory physiology of COVID-19-induced respiratory failure compared to ARDS of other etiologies.** Crit Care 2020; 24:529Grieco DL, Bongiovanni F, Chen L ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32859264
5. **Lung and kidney perfusion deficits diagnosed by dual-energy computed tomography in patients with COVID-19-related systemic microangiopathy.** Eur Radiol 2020; Idilman IS, Telli Dizman G, Ardali Duzgun S ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32860146
6. **First report on clinical and radiological features of COVID-19 pneumonitis in a Caucasian population: factors predicting fibrotic evolution.** Int J Infect Dis 2020; Marvisi M, Ferrozzi F, Balzarini L ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32841688
7. **Pulmonary Rehabilitation: Time for an Upgrade.** J Clin Med 2020; 9Sebio-García R. http://www.ncbi.nlm.nih.gov/pubmed/?term=32854317
8. **Disproportionate decline in admissions for exacerbated COPD during the COVID-19 pandemic.** Respir. Med. 2020:106120Berghaus TM, Karschnia P, Haberl S, Schwaiblmair M. http://www.ncbi.nlm.nih.gov/pubmed/?term=32839072
9. **Chronic obstructive pulmonary disease and the COVID-19 pandemic: Reciprocal challenges.** Respir Med Res 2020; 78:100764Deslée G, Zysman M, Burgel PR ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32841820
10. **Letter from New Zealand.** Respirology 2020; Hancox RJ. http://www.ncbi.nlm.nih.gov/pubmed/?term=32829510

11. **Interstitial pneumonitis in the COVID-19 era: a difficult differential diagnosis in patients with lung cancer.** Tumori 2020:300891620951863Catania C, Stati V, Spitaleri G. http://www.ncbi.nlm.nih.gov/pubmed/?term=32842909

Renal disease (13 articles)

1. **COVID-19 and the kidney: A matter of concern.** Curr Med Res Pract 2020; 10:165-168Meena P, Bhargava V, Rana DS ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32839726
2. **The impact of COVID-19 pandemic on the care of patients with kidney diseases in Duhok City, Kurdistan Region of Iraq.** Diabetes Metab Syndr 2020; 14:1551-1553Hussein NR, ZS MS, Ibrahim N ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32846367
3. **Lung and kidney perfusion deficits diagnosed by dual-energy computed tomography in patients with COVID-19-related systemic microangiopathy.** Eur Radiol 2020; Idilman IS, Telli Dizman G, Ardali Duzgun S ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32860146
4. **Identify the Risk Factors of COVID-19-Related Acute Kidney Injury: A Single-Center, Retrospective Cohort Study.** Front Med (Lausanne) 2020; 7:436Wang J, Wang Z, Zhu Y ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32850917
5. **COVID-19 Infection in Kidney Transplant Recipients: Disease Incidence and Clinical Outcomes.** J Am Soc Nephrol 2020; Elias M, Pievani D, Randoux C ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32847984
6. **Severe Coronavirus disease 2019 pneumonia patients showed signs of aggravated renal impairment.** J. Clin. Lab. Anal. 2020:e23535Gao M, Wang Q, Wei J ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32840917
7. **An initial report from the French SOT COVID Registry suggests high mortality due to Covid-19 in recipients of kidney transplants.** Kidney Int 2020; Caillard S, Anglicheau D, Matignon M ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32853631
8. **IgA Vasculitis with Nephritis (Henoch-Schönlein purpura) in a COVID-19 patient.** Kidney Int Rep 2020; Suso AS, Mon C, Alonso IO ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32839743
9. **De Novo ANCA-associated Vasculitis with Glomerulonephritis in COVID-19.** Kidney Int Rep 2020; Uppal NN, Kello N, Shah HH ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32839744
10. **COVID-19 associated with onset nephrotic syndrome in a pediatric patient: coincidence or related conditions?** Pediatr. Nephrol. 2020; Alvarado A, Franceschi G, Resplandor E ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32852576
11. **Be aware of acute kidney injury in critically ill children with COVID-19.** Pediatr. Nephrol. 2020; Wang X, Chen X, Tang F ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32844290
12. **COVID-19 & Chronic Renal Disease: Clinical characteristics & prognosis.** QJM 2020; Yang D, Xiao Y, Chen J ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32840579
13. **Neutropenic fever in COVID-19 in kidney transplant patient.** Rev Med Virol 2020:e2156Al-Makki A, Taber T. http://www.ncbi.nlm.nih.gov/pubmed/?term=32856324

Reviews (48 articles)

1. **COVID-19 Testing.** Am J Clin Pathol 2020; Brooks ZC, Das S. http://www.ncbi.nlm.nih.gov/pubmed/?term=32857119
2. **Utility of D-dimer as a Prognostic Factor in SARS CoV2 Infection: A Review.** Am J Med Case Rep 2020; 8:337-340Kariyanna PT, Aurora L, Jayarangaiah A ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32851129
3. **Transmission of SARS-CoV-2 through breast milk and breastfeeding: a living systematic review.** Ann. N. Y. Acad. Sci. 2020; Centeno-Tablante E, Medina-Rivera M, Finkelstein JL ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32860259
4. **People with disabilities and other forms of vulnerability to the COVID-19 pandemic: Study protocol for a scoping review and thematic analysis.** Arch Rehabil Res Clin Transl 2020:100079Jesus TS, Kamalakannan S, Bhattacharjya S ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32839757
5. **Fear, Loss, Social Isolation, and Incomplete Grief Due to COVID-19: A Recipe for a Psychiatric Pandemic.** Basic Clin Neurosci 2020; 11:225-232Mortazavi SS, Assari S, Alimohamadi A ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32855782
6. **COVID-19 infection in children and adolescents.** Br. J. Hosp. Med. (Lond.) 2020; 81:1-10Naja M, Wedderburn L, Ciurtin C. http://www.ncbi.nlm.nih.gov/pubmed/?term=32845750
7. **Systematic review of COVID-19 related myocarditis: Insights on management and outcome.** Cardiovasc. Revasc. Med. 2020; Sawalha K, Abozenah M, Kadado AJ ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32847728
8. **Emerging Pandemic Diseases: How We Got to COVID-19.** Cell 2020; Morens DM, Fauci AS. http://www.ncbi.nlm.nih.gov/pubmed/?term=32846157
9. **Unpuzzling COVID-19 Prothrombotic State: Are Preexisting Thrombophilic Risk Profiles Responsible for Heterogenous Thrombotic Events?** Clin. Appl. Thromb. Hemost. 2020; 26:1076029620952884Burlacu A, Genovesi S, Popa IV, Crisan-Dabija R. http://www.ncbi.nlm.nih.gov/pubmed/?term=32842771
10. **Seizures Related to Coronavirus Disease (COVID-19): Case Series and Literature Review.** Cureus 2020; 12:e9378Ashraf M, Sajed S. http://www.ncbi.nlm.nih.gov/pubmed/?term=32850246
11. **COVID-19 manifestations in children.** Curr Med Res Pract 2020; 10:186-188Kachru S, Kaul D. http://www.ncbi.nlm.nih.gov/pubmed/?term=32839729
12. **Do we have serological evidences that chilblain-like lesions are related to SARS-CoV-2? A review of the literature.** Dermatol Ther 2020:e14229Balestri R, Magnano M, Rizzoli L, Rech G. http://www.ncbi.nlm.nih.gov/pubmed/?term=32844512
13. **COVID-19: Where are we now?** Deutsche Medizinische Wochenschrift 2020; 145:1019Von Bergwelt-Baildon M, Addo M.
14. **Clinical profile and outcomes in COVID-19 patients with diabetic ketoacidosis: A systematic review of literature.** Diabetes Metab Syndr 2020; 14:1563-1569Pal R, Banerjee M, Yadav U, Bhattacharjee S. http://www.ncbi.nlm.nih.gov/pubmed/?term=32853901
15. **Biomedical application, Drug Delivery and Metabolic Pathway of Antiviral Nanotherapeutics for combating viral Pandemic: A Review.** Environ. Res. 2020:110119Mukherjee S, Mazumder P, Joshi M ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32846177

16. **Multimodality imaging of COVID-19 pneumonia: from diagnosis to follow-up. Acomprehensive review.** Eur J Radiol 2020; 131:109217Larici AR, Cicchetti G, Marano R ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32861174
17. **Azithromycin in the treatment of COVID-19: a review.** Expert Rev. Anti Infect. Ther. 2020; Echeverría-Esnal D, Martin-Ontiyuelo C, Navarrete-Rouco ME ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32853038
18. **Renin-Angiotensin System and Coronavirus Disease 2019: A Narrative Review.** Front Cardiovasc Med 2020; 7:143Mascolo A, Scavone C, Rafaniello C ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32850989
19. **Will Hydroxychloroquine Still Be a Game-Changer for COVID-19 by Combining Azithromycin?** Front. Immunol. 2020; 11:1969Li C, Cheng G. http://www.ncbi.nlm.nih.gov/pubmed/?term=32849658
20. **Treatment Options for COVID-19: A Review.** Front Med (Lausanne) 2020; 7:480Ali MJ, Hanif M, Haider MA ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32850922
21. **Single Virus Targeting Multiple Organs: What We Know and Where We Are Heading?** Front Med (Lausanne) 2020; 7:370Prasad A, Prasad M. http://www.ncbi.nlm.nih.gov/pubmed/?term=32850890
22. **Cellular and Molecular Pathways of COVID-19 and Potential Points of Therapeutic Intervention.** Front. Pharmacol. 2020; 11:1169Hussman JP. http://www.ncbi.nlm.nih.gov/pubmed/?term=32848776
23. **COVID-19 Therapeutic Options Under Investigation.** Front. Pharmacol. 2020; 11:1196Kaddoura M, AlIbrahim M, Hijazi G ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32848795
24. **The Enigma of Endothelium in COVID-19.** Front. Physiol. 2020; 11:989Kaur S, Tripathi DM, Yadav A. http://www.ncbi.nlm.nih.gov/pubmed/?term=32848893
25. **COVID-19: A Multidisciplinary Review.** Front Public Health 2020; 8:383Chams N, Chams S, Badran R ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32850602
26. **Involvement of the digestive system in covid-19. A review.** Gastroenterol. Hepatol. 2020; Sanz Segura P, Arguedas Lázaro Y, Mostacero Tapia S ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32859408
27. **Ethical Considerations for safeguarding human participants in pandemic research: a rapid review protocol.** HRB Open Res 2020; 3:22O'Sullivan L, Killeen RP, Doran P, Crowley RK. http://www.ncbi.nlm.nih.gov/pubmed/?term=32832851
28. **Neurological manifestations of COVID-19: A brief review.** Indian J Med Res 2020; Sachdev K, Agrawal S, Ish P ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32859864
29. **COVID-19 (Coronavirus Disease 2019): A New Coronavirus Disease.** Infect Drug Resist 2020; 13:2819-2828Sadeghi Dousari A, Taati Moghadam M, Satarzadeh N. http://www.ncbi.nlm.nih.gov/pubmed/?term=32848431
30. **Risk factors for Covid-19 severity and fatality: a structured literature review.** Infection 2020; Wolff D, Nee S, Hickey NS, Marschollek M. http://www.ncbi.nlm.nih.gov/pubmed/?term=32860214
31. **Policing in pandemics: A systematic review and best practices for police response to COVID-19.** Int J Disaster Risk Reduct 2020; 51:101812Laufs J, Waseem Z. http://www.ncbi.nlm.nih.gov/pubmed/?term=32839687
32. **Rapid Review of SARS-CoV-1 and SARS-CoV-2 Viability, Susceptibility to Treatment, and the Disinfection and Reuse of PPE, Particularly Filtering Facepiece Respirators.** Int J Environ Res Public Health 2020; 17Derraik JGB,

Anderson WA, Connelly EA, Anderson YC. http://www.ncbi.nlm.nih.gov/pubmed/?term=32842655

33. **Coronavirus Disease 2019 (COVID-19) in Children: Prevalence, Diagnosis, Clinical Symptoms, and Treatment.** Int. J. Gen. Med. 2020; 13:477-482Zare-Zardini H, Soltaninejad H, Ferdosian F ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32848446
34. **Clinical features of neonates born to mothers with coronavirus disease-2019: A systematic review of 105 neonates.** J Microbiol Immunol Infect 2020; Chi H, Chiu NC, Tai YL ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32847748
35. **Guillain-Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases.** J. Neurol. 2020; Abu-Rumeileh S, Abdelhak A, Foschi M ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32840686
36. **Teledermatologie in den Zeiten von COVID-19 – ein systematisches Review.** JDDG - Journal of the German Society of Dermatology 2020; 18:841-847Elsner P.
37. **COVID-19 und Immunregulation – von grundlegenden und translationalen Aspekten zu klinischen Implikationen.** JDDG - Journal of the German Society of Dermatology 2020; 18:795-809Schön MP, Berking C, Biedermann T ***et al.***
38. **Smell disorders at COVID-19 - The current level of knowledge.** Laryngo- Rhino-Otologie 2020; 99:531-535Otte MS, Kluβmann JP, Luers JC.
39. **Pharmacological treatment of COVID-19: Narrative review of the Working Group in Infectious Diseases and Sepsis (GTEIS) and the Working Groups in Transfusions and Blood Products (GTTH).** Med. Intensiva 2020; Díaz E, Amézaga Menéndez R, Vidal Cortés P ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32854988
40. **The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.** Med. Res. Rev. 2020; Pillaiyar T, Wendt LL, Manickam M, Easwaran M. http://www.ncbi.nlm.nih.gov/pubmed/?term=32852058
41. **Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a newly emerged pathogen: an overview.** Pathog Dis 2020; Rathore JS, Ghosh C. http://www.ncbi.nlm.nih.gov/pubmed/?term=32840560
42. **Prevention and treatment of COVID-19 using Traditional Chinese Medicine: A review.** Phytomedicine 2020:153308Zhao Z, Li Y, Zhou L ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32843234
43. **A systematic review on recent trends in transmission, diagnosis, prevention and imaging features of COVID-19.** Process Biochem. 2020; Manigandan S, Wu MT, Ponnusamy VK ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32843849
44. **The Interplay Between Coagulation and Inflammation Pathways in COVID-19-Associated Respiratory Failure: A Narrative Review.** Pulm Ther 2020; Bhattacharyya R, Iyer P, Phua GC, Lee JH. http://www.ncbi.nlm.nih.gov/pubmed/?term=32844302
45. **Predictors of COVID-19 severity: A literature review.** Rev Med Virol 2020:e2146Gallo Marin B, Aghagoli G, Lavine K ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32845042
46. **Viral, host and environmental factors that favor anthropozoonotic spillover of coronaviruses: An opinionated review, focusing on SARS-CoV, MERS-CoV and SARS-CoV-2.** Sci Total Environ 2020; 750:141483da Silva PG, Mesquita JR, de São José Nascimento M, Ferreira VAM. http://www.ncbi.nlm.nih.gov/pubmed/?term=32829257

47. **Urinary stone management during the COVID-19 pandemic: a suggested approach and review of literature.** Ther. Adv. Urol. 2020; 12:1756287220939513Fakhr Yasseri A, Aghamir SMK. http://www.ncbi.nlm.nih.gov/pubmed/?term=32849913
48. **HIV and Human Coronavirus Coinfections: A Historical Perspective.** Viruses 2020; 12Makoti P, Fielding BC. http://www.ncbi.nlm.nih.gov/pubmed/?term=32858801

Risk factors (51 articles)

1. **Red Blood Cell Distribution Is a Significant Predictor of Severe Illness in Coronavirus Disease 2019.** Acta Haematol. 2020:1-5Lippi G, Henry BM, Sanchis-Gomar F. http://www.ncbi.nlm.nih.gov/pubmed/?term=32841949
2. **Early coagulation tests predict risk stratification and prognosis of COVID-19.** Aging (Albany NY) 2020; 12Luo L, Xu M, Du M ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32860672
3. **The Importance of Redox Status in the Frame of Lifestyle Approaches and the Genetics of the Lung Innate Immune Molecules, SP-A1 and SP-A2, on Differential Outcomes of COVID-19 Infection.** Antioxidants (Basel) 2020; 9Tekos F, Skaperda Z, Goutzourelas N ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32854247
4. **ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19.** Biomed. Pharmacother. 2020; 131:110678Dong M, Zhang J, Ma X ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32861070
5. **Epigenetic susceptibility to severe respiratory viral infections: pathogenic and therapeutic implications: a narrative review.** Br J Anaesth 2020; Crimi E, Benincasa G, Figueroa-Marrero N ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32828489
6. **Risk factors for COVID-19 death in a population cohort study from the Western Cape Province, South Africa.** Clin Infect Dis 2020; Boulle A, Davies MA, Hussey H ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32860699
7. **Reduced vitamin K status as a potentially modifiable risk factor of severe COVID-19.** Clin Infect Dis 2020; Dofferhoff ASM, Piscaer I, Schurgers LJ ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32852539
8. **SARS-CoV-2 RNA in serum as predictor of severe outcome in COVID-19: a retrospective cohort study.** Clin Infect Dis 2020; Hagman K, Hedenstierna M, Gille-Johnson P ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32856036
9. **Association between Body Mass Index and Risk of COVID-19: A Nationwide Case-Control Study in South Korea.** Clin Infect Dis 2020; Jung CY, Park H, Kim DW ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32841322
10. **Antibody Responses and Clinical Outcomes in Adults Hospitalized with Severe COVID-19: A Post hoc Analysis of LOTUS China Trial.** Clin Infect Dis 2020; Ren L, Fan G, Wu W ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32840287
11. **Viral dynamics and immune correlates of COVID-19 disease severity.** Clin Infect Dis 2020; Young BE, Ong SWX, Ng LFP ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32856707
12. **Longitudinal changes of inflammatory parameters and their correlation with disease severity and outcomes in patients with COVID-19 from Wuhan, China.**

Crit Care 2020; 24:525Zeng Z, Yu H, Chen H ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32854750

13. **Predictive value of neutrophil to lymphocyte and platelet to lymphocyte ratio in COVID-19.** Crit Care 2020; 24:532Zhu S, Dong L, Cai W. http://www.ncbi.nlm.nih.gov/pubmed/?term=32859254
14. **Hemoglobin A1C is a Predictor of COVID-19 Severity in Patients with Diabetes.** Diabetes Metab Res Rev 2020:e3398Merzon E, Green I, Shpigelman M ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32852883
15. **Hyperglycemia and COVID-19: what was known and what is really new?** Diabetes Res Clin Pract 2020:108383Ceriello A. http://www.ncbi.nlm.nih.gov/pubmed/?term=32853690
16. **The association of diabetes and the prognosis of COVID-19 patients: a retrospective study.** Diabetes Res Clin Pract 2020:108386Liu Z, Bai X, Han X ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32853685
17. **J-shaped Association Between Fasting Blood Glucose Levels and COVID-19 Severity in Patients without Diabetes.** Diabetes Res Clin Pract 2020:108381Zhu B, Jin S, Wu L ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32853687
18. **Risk factors for developing into critical COVID-19 patients in Wuhan, China: A multicenter, retrospective, cohort study.** EClinicalMedicine 2020:100471Liu D, Cui P, Zeng S ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32840491
19. **Fasting Plasma Glucose Level Independently Predicts the Mortality of Patients with Coronavirus Disease 2019 Infection: A Multicenter, Retrospective Cohort Study.** Endocrinol Metab (Seoul) 2020; Chang MC, Hwang JM, Jeon JH ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32842719
20. **Is periodontal disease a risk factor for developing severe Covid-19 infection? The potential role of Galectin-3.** Exp. Biol. Med. (Maywood) 2020:1535370220953771Kara C, Çelen K, Dede F ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32838557
21. **Identify the Risk Factors of COVID-19-Related Acute Kidney Injury: A Single-Center, Retrospective Cohort Study.** Front Med (Lausanne) 2020; 7:436Wang J, Wang Z, Zhu Y ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32850917
22. **Global and Temporal COVID-19 Risk Evaluation.** Front Public Health 2020; 8:440Arsalan M, Mubin O, Alnajjar F ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32850611
23. **A Predicting Nomogram for Mortality in Patients With COVID-19.** Front Public Health 2020; 8:461Pan D, Cheng D, Cao Y ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32850612
24. **Blood pressure control and adverse outcomes of COVID-19 infection in patients with concomitant hypertension in Wuhan, China.** Hypertens. Res. 2020; Ran J, Song Y, Zhuang Z ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32855527
25. **A public health perspective of aging: do hyper-inflammatory syndromes such as COVID-19, SARS, ARDS, cytokine storm syndrome, and post-ICU syndrome accelerate short- and long-term inflammaging?** Immun. Ageing 2020; 17:23Bektas A, Schurman SH, Franceschi C, Ferrucci L. http://www.ncbi.nlm.nih.gov/pubmed/?term=32849908
26. **Disease progression patterns and risk factors associated with mortality in deceased patients with COVID-19 in Hubei Province, China.** Immun Inflamm Dis

2020; Chen L, Liu S, Tian J ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32857453

27. **A five-compartment model of age-specific transmissibility of SARS-CoV-2.** Infect Dis Poverty 2020; 9:117Zhao ZY, Zhu YZ, Xu JW ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32843094
28. **A survey of genetic variants in SARS-CoV-2 interacting domains of ACE2, TMPRSS2 and TLR3/7/8 across populations.** Infect Genet Evol 2020:104507Lee IH, Lee JW, Kong SW. http://www.ncbi.nlm.nih.gov/pubmed/?term=32858233
29. **Differences of inflammatory and non-inflammatory indicators in Coronavirus disease-19 (COVID-19) with different severity.** Infect Genet Evol 2020:104511Wang M, Zhu Q, Fu J ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32858231
30. **Risk factors for Covid-19 severity and fatality: a structured literature review.** Infection 2020; Wolff D, Nee S, Hickey NS, Marschollek M. http://www.ncbi.nlm.nih.gov/pubmed/?term=32860214
31. **Lung ultrasound predicts clinical course and outcomes in COVID-19 patients.** Intensive Care Med 2020; Lichter Y, Topilsky Y, Taieb P ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32860069
32. **Clinical features and potential risk factors for discerning the critical cases and predicting the outcome of patients with COVID-19.** J. Clin. Lab. Anal. 2020:e23547Wang W, Zhao Z, Liu X ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32860454
33. **High body mass index and night shift work are associated with COVID-19 in health care workers.** J. Endocrinol. Invest. 2020; Rizza S, Coppeta L, Grelli S ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32852704
34. **Characterizing COVID-19 severity, epidemiology and SARS-CoV-2 genotypes in a regional business hub of China.** J Infect 2020; Yan Y, Liu B, Ding H ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32853601
35. **Evaluation of seventeen patients with COVID-19 pneumonia treated with anakinra according to HScore, SOFA, MuLBSTA and Brescia-COVID respiratory severity scale (BCRSS) scoring systems.** J Med Virol 2020; Erden A, Ozdemir B, Karakas O ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32860431
36. **The prognostic role of neopterin in COVID-19 patients.** J Med Virol 2020; Ozger HS, Dizbay M, Corbacioglu SK ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32860465
37. **Management of SARS-CoV-2 Pneumonia.** J Med Virol 2020; Sagnelli C, Celia B, Monari C ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32856728
38. **Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors.** J. Oncol. Pharm. Pract. 2020:1078155220953198Başcı S, Ata N, Altuntaş F ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32854573
39. **Assessing SARS-CoV-2 RNA levels and lymphocyte/T cell counts in COVID-19 patients revealed initial immune status as a major determinant of disease severity.** Med. Microbiol. Immunol. 2020; Han M, Xu M, Zhang Y ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32860073
40. **Decreased prealbumin level is associated with increased risk for mortality in elderly hospitalized patients with COVID-19.** Nutrition 2020; 78:110930Zuo P, Tong S, Yan Q ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32854020
41. **Individuals with obesity and COVID-19: A global perspective on the epidemiology and biological relationships.** Obes Rev 2020; Popkin BM, Du S,

Green WD ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32845580
42. **The Correlation Between Clinical Features and Viral RNA Shedding in Outpatients With COVID-19.** Open Forum Infect Dis 2020; 7:ofaa331Liao T, Yin Z, Xu J ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32851112
43. **COVID-19 and Comorbid Hypertension: Is ACE2 the Culprit?** Prehosp. Disaster Med. 2020:1-6Zhang T, Zhong S, Cao W. http://www.ncbi.nlm.nih.gov/pubmed/?term=32838828
44. **US racial inequality may be as deadly as COVID-19.** Proc Natl Acad Sci U S A 2020; Wrigley-Field E. http://www.ncbi.nlm.nih.gov/pubmed/?term=32839337
45. **Risk factors for in-hospital mortality in patients with acute myocardial infarction during the COVID-19 outbreak.** Rev Esp Cardiol (Engl Ed) 2020; Solano-López J, Zamorano JL, Pardo Sanz A ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32839121
46. **Alpha-1-antitrypsin: A possible host protective factor against Covid-19.** Rev Med Virol 2020:e2157de Loyola MB, Dos Reis TTA, de Oliveira G ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32844538
47. **Predictors of COVID-19 severity: A literature review.** Rev Med Virol 2020:e2146Gallo Marin B, Aghagoli G, Lavine K ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32845042
48. **Particulate matter and SARS-CoV-2: A possible model of COVID-19 transmission.** Sci Total Environ 2020; 750:141532Tung NT, Cheng PC, Chi KH ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32858292
49. **Admission D-dimer levels, D-dimer trends, and outcomes in COVID-19.** Thromb Res 2020; 196:99-105Naymagon L, Zubizarreta N, Feld J ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32853982
50. **Lung Ultrasound Score in Evaluating the Severity of Coronavirus Disease 2019 (COVID-19) Pneumonia.** Ultrasound Med. Biol. 2020; Zhao L, Yu K, Zhao Q ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32828577
51. **[Prognostic value of myocardial injury in patients with COVID-19].** Zhonghua Xin Xue Guan Bing Za Zhi 2020; 48:461-466Wang L, He WB, Yu XM ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32842255

Safety (9 articles)

1. **Drug Interactions of Psychiatric and COVID-19 Medications.** Basic Clin Neurosci 2020; 11:185-200Mohebbi N, Talebi A, Moghadamnia M ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32855778
2. **Angiotensin-converting enzyme 2: a double-edged sword in COVID-19 patients with an increased risk of heart failure.** Heart Fail. Rev. 2020; Razeghian-Jahromi I, Zibaeenezhad MJ, Lu Z ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32844337
3. **Plasma Angiotensin Peptide Profiling and ACE2-Activity in COVID-19 Patients treated with Pharmacological Blockers of the Renin Angiotensin System.** Hypertension 2020; Kintscher U, Slagman A, Domenig O ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32851897
4. **Predictive factors for cardiac conduction abnormalities with hydroxychloroquine-containing combinations for COVID-19.** Int J Antimicrob Agents 2020:106142Padilla S, Telenti G, Guillén L ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32853675

5. **Anticoagulation, Mortality, Bleeding and Pathology Among Patients Hospitalized with COVID-19: A Single Health System Study.** J Am Coll Cardiol 2020; Nadkarni GN, Lala A, Bagiella E ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32860872
6. **What we have to know about corticosteroids use during Sars-Cov-2 infection.** J. Endocrinol. Invest. 2020; Ferraù F, Ceccato F, Cannavò S, Scaroni C. http://www.ncbi.nlm.nih.gov/pubmed/?term=32860209
7. **Systemische Immunsuppression in Zeiten von COVID-19: Müssen wir umdenken?** JDDG - Journal of the German Society of Dermatology 2020; 18:810-814Grabbe S, Beissert S, Enk A.
8. **Hydroxychloroquine and azithromycin tolerance in haemodialysis patients during COVID-19 infection.** Nephrol Dial Transplant 2020; Giaime P, Guenoun M, Pedinielli N ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32844224
9. **COVID-19 and NSAIDs: Primum non nocere.** Therapie 2020; Micallef J, Soeiro T, Jonville-Béra AP. http://www.ncbi.nlm.nih.gov/pubmed/?term=32839015

Treatment options (86 articles)

1. **Nicotinamide Adenine Dinucleotide: Biosynthesis, Consumption, and Therapeutic Role in Cardiac Diseases.** Acta Physiol. (Oxf.) 2020; Tannous C, Booz GW, Altara R ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32853469
2. **Azithromycin Downregulates Gene Expression of IL-1β and Pathways Involving TMPRSS2 and TMPRSS11D Required by SARS-CoV-2.** Am. J. Respir. Cell Mol. Biol. 2020; Renteria AE, Endam Mfuna L, Adam D ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32857620
3. **SARS-CoV-2 E protein is a potential ion channel that can be inhibited by Gliclazide and Memantine.** Biochem. Biophys. Res. Commun. 2020; 530:10-14Singh Tomar PP, Arkin IT. http://www.ncbi.nlm.nih.gov/pubmed/?term=32828269
4. **Immune Dysfunction and Multiple Treatment Modalities for the SARS-CoV-2 Pandemic: Races of Uncontrolled Running Sweat?** Biology (Basel) 2020; 9Kothari A, Singh V, Nath UK ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32846906
5. **Drug repurposing of anti-infective clinical drugs: Discovery of two potential anti-cytokine storm agents.** Biomed. Pharmacother. 2020; 131:110643Su L, Tu Y, Kong DP ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32846329
6. **Promising role for mesenchymal stromal cells in coronavirus infectious disease-19 (COVID-19)-related severe acute respiratory syndrome?** Blood Rev. 2020:100742Hamdan H, Hashmi SK, Lazarus H ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32854985
7. **Reverse takotsubo cardiomyopathy in fulminant COVID-19 associated with cytokine release syndrome and resolution following therapeutic plasma exchange: a case-report.** BMC Cardiovasc. Disord. 2020; 20:389Faqihi F, Alharthy A, Alshaya R ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32842957
8. **Low level laser therapy as a modality to attenuate cytokine storm at multiple levels, enhance recovery, and reduce the use of ventilators in COVID-19.** Can J Respir Ther 2020; 56:25-31Mokmeli S, Vetrici M. http://www.ncbi.nlm.nih.gov/pubmed/?term=32844112
9. **Autophagy Augmentation to Alleviate Immune Response Dysfunction, and Resolve Respiratory and COVID-19 Exacerbations.** Cells 2020; 9Pehote G, Vij N. http://www.ncbi.nlm.nih.gov/pubmed/?term=32847034

10. **Patient Characteristics and Outcomes of 11,721 Patients with COVID19 Hospitalized Across the United States.** Clin Infect Dis 2020; Fried MW, Crawford JM, Mospan AR ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32856034
11. **Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19).** Clin Microbiol Infect 2020; Rodríguez-Baño J, Pachón J, Carratalà J ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32860964
12. **The Antiviral and Antimalarial Drug Repurposing in Quest of Chemotherapeutics to Combat COVID-19 Utilizing Structure-Based Molecular Docking.** Comb. Chem. High Throughput Screen. 2020; Nandi S, Kumar M, Saxena M, Saxena AK. http://www.ncbi.nlm.nih.gov/pubmed/?term=32838713
13. **Efficacy of tocilizumab treatment in severely ill COVID-19 patients.** Crit Care 2020; 24:524Zhao J, Cui W, Tian BP. http://www.ncbi.nlm.nih.gov/pubmed/?term=32854738
14. **Nanocarriers in the delivery of hydroxychloroquine to the respiratory system: An alternative to COVID-19?** Curr Drug Deliv 2020; Cavalcanti IDL, de Fátima Ramos Dos Santos Medeiros SM, Dos Santos Macêdo DC ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32860358
15. **Comparing outcomes of hospitalized patients with moderate and severe COVID-19 following treatment with hydroxychloroquine plus atazanavir/ritonavir.** Daru 2020; Rahmani H, Davoudi-Monfared E, Nourian A ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32857301
16. **Finding the Best Antiviral Regimen for COVID-19: A Double-Center Retrospective Cohort Study of 207 Cases in Hunan, China.** Dose Response 2020; 18:1559325820949740Hu X, Hu C, Zhong P ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32855629
17. **Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19.** Environ. Res. 2020; 188:109858Angelopoulou A, Alexandris N, Konstantinou E ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32846644
18. **Biomedical application, Drug Delivery and Metabolic Pathway of Antiviral Nanotherapeutics for combating viral Pandemic: A Review.** Environ. Res. 2020:110119Mukherjee S, Mazumder P, Joshi M ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32846177
19. **A novel approach to managing COVID-19 patients; results of lopinavir plus doxycycline cohort.** Eur J Clin Microbiol Infect Dis 2020; Cag Y, Icten S, Isik-Goren B ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32856202
20. **Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study.** Eur J Intern Med 2020; Castelnuovo AD, Costanzo S, Antinori A ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32859477
21. **How to follow-up a patient who received tocilizumab in severe COVID-19: a case report.** Eur. J. Med. Res. 2020; 25:37Podlasin RB, Kowalska JD, Pihowicz A ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32854774
22. **Vitamin D and COVID-19 infection and mortality in UK Biobank.** Eur. J. Nutr. 2020; Hastie CE, Pell JP, Sattar N. http://www.ncbi.nlm.nih.gov/pubmed/?term=32851419
23. **Azithromycin in the treatment of COVID-19: a review.** Expert Rev. Anti Infect. Ther. 2020; Echeverría-Esnal D, Martin-Ontiyuelo C, Navarrete-Rouco ME ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32853038

24. **Prospects for RNAi Therapy of COVID-19.** Front Bioeng Biotechnol 2020; 8:916Uludağ H, Parent K, Aliabadi HM, Haddadi A. http://www.ncbi.nlm.nih.gov/pubmed/?term=32850752
25. **Construction of SARS-CoV-2 Virus-Like Particles by Mammalian Expression System.** Front Bioeng Biotechnol 2020; 8:862Xu R, Shi M, Li J ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32850726
26. **Mucosal-Associated Invariant T Cells as a Possible Target to Suppress Secondary Infections at COVID-19.** Front. Immunol. 2020; 11:1896Akasov RA, Khaydukov EV. http://www.ncbi.nlm.nih.gov/pubmed/?term=32849648
27. **Impact of Hydroxychloroquine on Antibody Responses to the SARS-CoV-2 Coronavirus.** Front. Immunol. 2020; 11:1739de Miranda Santos IKF, Costa CHN. http://www.ncbi.nlm.nih.gov/pubmed/?term=32849619
28. **Can Drinking Microfiltered Raw Immune Milk From Cows Immunized Against SARS-CoV-2 Provide Short-Term Protection Against COVID-19?** Front. Immunol. 2020; 11:1888Jawhara S. http://www.ncbi.nlm.nih.gov/pubmed/?term=32849647
29. **Will Hydroxychloroquine Still Be a Game-Changer for COVID-19 by Combining Azithromycin?** Front. Immunol. 2020; 11:1969Li C, Cheng G. http://www.ncbi.nlm.nih.gov/pubmed/?term=32849658
30. **Treatment Options for COVID-19: A Review.** Front Med (Lausanne) 2020; 7:480Ali MJ, Hanif M, Haider MA ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32850922
31. **Plants Metabolites: Possibility of Natural Therapeutics Against the COVID-19 Pandemic.** Front Med (Lausanne) 2020; 7:444Bhuiyan FR, Howlader S, Raihan T, Hasan M. http://www.ncbi.nlm.nih.gov/pubmed/?term=32850918
32. **Spironolactone: An Anti-androgenic and Anti-hypertensive Drug That May Provide Protection Against the Novel Coronavirus (SARS-CoV-2) Induced Acute Respiratory Distress Syndrome (ARDS) in COVID-19.** Front Med (Lausanne) 2020; 7:453Cadegiani FA, Wambier CG, Goren A. http://www.ncbi.nlm.nih.gov/pubmed/?term=32850920
33. **Ruxolitinib Rapidly Reduces Acute Respiratory Distress Syndrome in COVID-19 Disease. Analysis of Data Collection From RESPIRE Protocol.** Front Med (Lausanne) 2020; 7:466Capochiani E, Frediani B, Iervasi G ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32850921
34. **Efficacy and Safety of Anti-malarial Drugs (Chloroquine and Hydroxy-Chloroquine) in Treatment of COVID-19 Infection: A Systematic Review and Meta-Analysis.** Front Med (Lausanne) 2020; 7:482Das RR, Jaiswal N, Dev N ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32850924
35. **Treatment of COVID-19: Perspective on Convalescent Plasma Transfusion.** Front Med (Lausanne) 2020; 7:435Farhat RM, Mousa MA, Daas EJ, Glassberg MK. http://www.ncbi.nlm.nih.gov/pubmed/?term=32850916
36. **Directly Acting Antivirals for COVID-19: Where Do We Stand?** Front. Microbiol. 2020; 11:1857Teoh SL, Lim YH, Lai NM, Lee SWH. http://www.ncbi.nlm.nih.gov/pubmed/?term=32849448
37. **Molecular Pathogenesis, Immunopathogenesis and Novel Therapeutic Strategy Against COVID-19.** Front Mol Biosci 2020; 7:196Chatterjee SK, Saha S, Munoz MNM. http://www.ncbi.nlm.nih.gov/pubmed/?term=32850977
38. **Combination Therapy Using Inhalable GapmeR and Recombinant ACE2 for COVID-19.** Front Mol Biosci 2020; 7:197Verma NK, Fazil M, Duggan SP, Kelleher D.

http://www.ncbi.nlm.nih.gov/pubmed/?term=32850978
39. **Medicinal Plants as Sources of Active Molecules Against COVID-19.** Front. Pharmacol. 2020; 11:1189Benarba B, Pandiella A. http://www.ncbi.nlm.nih.gov/pubmed/?term=32848790
40. **Research Progress of Chloroquine and Hydroxychloroquine on the COVID-19 and Their Potential Risks in Clinic Use.** Front. Pharmacol. 2020; 11:1167Chen Y, Shen T, Zhong L ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32848774
41. **A Novel Strategy to Mitigate the Hyperinflammatory Response to COVID-19 by Targeting Leukotrienes.** Front. Pharmacol. 2020; 11:1214Funk CD, Ardakani A. http://www.ncbi.nlm.nih.gov/pubmed/?term=32848802
42. **Cellular and Molecular Pathways of COVID-19 and Potential Points of Therapeutic Intervention.** Front. Pharmacol. 2020; 11:1169Hussman JP. http://www.ncbi.nlm.nih.gov/pubmed/?term=32848776
43. **COVID-19 Therapeutic Options Under Investigation.** Front. Pharmacol. 2020; 11:1196Kaddoura M, AlIbrahim M, Hijazi G ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32848795
44. **Rationale for Considering Oral Idasanutlin as a Therapeutic Option for COVID-19 Patients.** Front. Pharmacol. 2020; 11:1156Zauli G, Tisato V, Secchiero P. http://www.ncbi.nlm.nih.gov/pubmed/?term=32848765
45. **Chinese Patent Medicines in the Treatment of Coronavirus Disease 2019 (COVID-19) in China.** Front. Pharmacol. 2020; 11:1066Zhuang W, Fan Z, Chu Y ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32848729
46. **Improving Non-specific Immunity to Coronavirus Disease (COVID-19) by the Novelty, Diversity, and Quantity of Antigen.** Front Public Health 2020; 8:393Boucher P, Boucher R. http://www.ncbi.nlm.nih.gov/pubmed/?term=32850603
47. **Low-dose Hydroxychloroquine Therapy and Mortality in Hospitalized Patients with COVID-19: A Nationwide Observational Study of 8075 Participants.** Int J Antimicrob Agents 2020:106144Catteau L, Dauby N, Montourcy M ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32853673
48. **Predictive factors for cardiac conduction abnormalities with hydroxychloroquine-containing combinations for COVID-19.** Int J Antimicrob Agents 2020:106142Padilla S, Telenti G, Guillén L ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32853675
49. **NSafety and Effectiveness of Azithromycin in Patients with COVID-19: an open-label randomized trial.** Int J Antimicrob Agents 2020:106143Sekhavati E, Jafari F, SeyedAlinaghi S ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32853672
50. **CORTICOSTEROIDS IN THE TREATMENT OF SEVERE COVID-19 LUNG DISEASE: THE PULMONOLOGY PERSPECTIVE FROM THE FIRST UNITED STATES EPICENTER.** Int J Infect Dis 2020; Macauley P, Martin A, Epelbaum O. http://www.ncbi.nlm.nih.gov/pubmed/?term=32829047
51. **Case studies of SARS-CoV-2 treated with favipiravir among patients in critical or severe condition.** Int J Infect Dis 2020; Takahashi H, Iwasaki Y, Watanabe T ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32829044
52. **Emerging Treatment Options of Regenerative Medicine in Severe Corona Virus/COVID 19 Infections.** Int J Stem Cells 2020; Kumar A, Ghosh SB. http://www.ncbi.nlm.nih.gov/pubmed/?term=32840231
53. **High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-**

19 patients. J Autoimmun 2020:102537Julián EI, Veloso ML, de la Torre Ferrera N ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32843231

54. **Targeting COVID-19 (SARS-CoV-2) main protease through active phytochemicals of ayurvedic medicinal plants - Withania somnifera (Ashwagandha), Tinospora cordifolia (Giloy) and Ocimum sanctum (Tulsi) - a molecular docking study.** J Biomol Struct Dyn 2020:1-14Shree P, Mishra P, Selvaraj C ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32851919
55. **Could Mesenchymal Stem Cell-Derived Exosomes Be a Therapeutic Option for Critically Ill COVID-19 Patients?** J Clin Med 2020; 9Gardin C, Ferroni L, Chachques JC, Zavan B. http://www.ncbi.nlm.nih.gov/pubmed/?term=32858940
56. **Exploring Repurposing Potential of Existing Drugs in the Management of COVID-19 Epidemic: A Critical Review.** J. Clin. Med. Res. 2020; 12:463-471Chakraborty D, Debnath F, Biswas S ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32849934
57. **Safety and Efficacy of Hydroxychloroquine in COVID-19: A Systematic Review and Meta-Analysis.** J. Clin. Med. Res. 2020; 12:483-491Ullah W, H MA, Roomi S ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32849936
58. **Neutrophil elastase inhibitor (sivelestat) may be a promising therapeutic option for management of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19.** J. Clin. Pharm. Ther. 2020; Sahebnasagh A, Saghafi F, Safdari M ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32860252
59. **A comprehensive strategy for the early treatment of COVID-19 with azithromycin/hydroxychloroquine and/or corticosteroids: results of a retrospective observational study in the French overseas department of Reunion Island.** J Glob Antimicrob Resist 2020; Dubernet A, Larsen K, Masse L ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32828896
60. **Investigating the potential antiviral activity drugs against SARS-CoV-2 by molecular docking simulation.** J. Mol. Liq. 2020; 318:113968El-Hoshoudy AN. http://www.ncbi.nlm.nih.gov/pubmed/?term=32839634
61. **Laser irradiated phenothiazines: New potential treatment for COVID-19 explored by molecular docking.** J. Photochem. Photobiol. B 2020; 211:111997Udrea AM, Avram S, Nistorescu S ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32829256
62. **Azithromycin: The First Broad-spectrum Therapeutic.** J Transl Autoimmun 2020:100062Kruger D, Prathapan P. http://www.ncbi.nlm.nih.gov/pubmed/?term=32839756
63. **The importance of vitamin d metabolism as a potential prophylactic, immunoregulatory and neuroprotective treatment for COVID-19.** J Transl Med 2020; 18:322Xu Y, Baylink DJ, Chen CS ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32847594
64. **COVID-19: Pathophysiology, treatment options, nanotechnology approaches, and research agenda to combating the SARS-CoV2 pandemic.** Life Sci 2020:118336Bhavana V, Thakor P, Singh SB, Mehra NK. http://www.ncbi.nlm.nih.gov/pubmed/?term=32846164
65. **Pharmacological treatment of COVID-19: Narrative review of the Working Group in Infectious Diseases and Sepsis (GTEIS) and the Working Groups in Transfusions and Blood Products (GTTH).** Med. Intensiva 2020; Díaz E,

Amézaga Menéndez R, Vidal Cortés P ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32854988

66. **Drug Discovery by Drug Repurposing: Combating COVID-19 in the 21st Century.** Mini Rev. Med. Chem. 2020; Sanghai N, Shafiq K, Tranmer GK. http://www.ncbi.nlm.nih.gov/pubmed/?term=32838716
67. **In Silico Identification of Potential Natural Product Inhibitors of Human Proteases Key to SARS-CoV-2 Infection.** Molecules 2020; 25Vivek-Ananth RP, Rana A, Rajan N ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32842606
68. **Hydroxychloroquine and azithromycin tolerance in haemodialysis patients during COVID-19 infection.** Nephrol Dial Transplant 2020; Giaime P, Guenoun M, Pedinielli N ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32844224
69. **Clinical Trials for Use of Melatonin to Fight against COVID-19 Are Urgently Needed.** Nutrients 2020; 12Kleszczyński K, Slominski AT, Steinbrink K, Reiter RJ. http://www.ncbi.nlm.nih.gov/pubmed/?term=32847033
70. **Metformin use is associated with reduced mortality rate from coronavirus disease 2019 (COVID-19) infection.** Obes Med 2020; 19:100290Hariyanto TI, Kurniawan A. http://www.ncbi.nlm.nih.gov/pubmed/?term=32844132
71. **Coronavirus Disease-2019 Treatment Strategies Targeting Interleukin-6 Signaling and Herbal Medicine.** OMICS 2020; Dzobo K, Chiririwa H, Dandara C, Dzobo W. http://www.ncbi.nlm.nih.gov/pubmed/?term=32857671
72. **Opaganib: Anticancer drug against COVID-19.** Pharm. Ztg. 2020; 165:18Gräfe VKA.
73. **COVID-19: How is the current standard therapy?** Pharm. Ztg. 2020; 165:12-14Hüttemann VD.
74. **COVID-19 studies: Hydroxychloroquine brings no benefit.** Pharm. Ztg. 2020; 165:16Hüttemann VD.
75. **COVID-19: Colchicine in clinical trials.** Pharm. Ztg. 2020; 165:19Siebenand VS.
76. **Fight against COVID-19: Remdesivir on the rise.** Pharm. Ztg. 2020; 165:10Tebroke VE.
77. **Prevention and treatment of COVID-19 using Traditional Chinese Medicine: A review.** Phytomedicine 2020:153308Zhao Z, Li Y, Zhou L ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32843234
78. **Vitamin D and Covid-19: From potential therapeutic effects to unanswered questions.** Rev Med Virol 2020:e2159Teymoori-Rad M, Marashi SM. http://www.ncbi.nlm.nih.gov/pubmed/?term=32856339
79. **Extending the identification of structural features responsible for anti-SARS-CoV activity of peptide-type compounds using QSAR modelling.** SAR QSAR Environ. Res. 2020:1-12Masand VH, Rastija V, Patil MK ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32847369
80. **Regen med therapeutic opportunities for fighting COVID-19.** Stem Cells Transl Med 2020; Atala A, Henn A, Lundberg M ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32856432
81. **An industry update: the latest developments in therapeutic delivery covering May 2020.** Ther. Deliv. 2020; Steinbach OC. http://www.ncbi.nlm.nih.gov/pubmed/?term=32840177
82. **Supply and demand for plasma-derived medicinal products - a critical re-assessment amidst the COVID-19 pandemic.** Transfusion 2020; Hartmann J, Klein HG. http://www.ncbi.nlm.nih.gov/pubmed/?term=32856742

83. **High dose dexamethasone treatment for Acute Respiratory Distress Syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial.** Trials 2020; 21:743Maskin LP, Olarte GL, Palizas F, Jr. ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32843098
84. **Hydroxychloroquine for post-exposure prophylaxis of COVID-19 among naval personnel in Sri Lanka: study protocol for a randomized, controlled trial.** Trials 2020; 21:748Niriella MA, Ediriweera DS, De Silva AP ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32854751
85. **Viral Vectors Applied for RNAi-Based Antiviral Therapy.** Viruses 2020; 12Lundstrom K. http://www.ncbi.nlm.nih.gov/pubmed/?term=32842491
86. **Convalescent plasma therapy in a pregnant COVID-19 patient with a dramatic clinical and imaging response: A case report.** World J Radiol 2020; 12:137-141Jafari R, Jonaidi-Jafari N, Dehghanpoor F, Saburi A. http://www.ncbi.nlm.nih.gov/pubmed/?term=32850016

Trials (9 articles)

1. **Drug Interactions of Psychiatric and COVID-19 Medications.** Basic Clin Neurosci 2020; 11:185-200Mohebbi N, Talebi A, Moghadamnia M ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32855778
2. **Angiotensin-converting enzyme 2: a double-edged sword in COVID-19 patients with an increased risk of heart failure.** Heart Fail. Rev. 2020; Razeghian-Jahromi I, Zibaeenezhad MJ, Lu Z ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32844337
3. **Plasma Angiotensin Peptide Profiling and ACE2-Activity in COVID-19 Patients treated with Pharmacological Blockers of the Renin Angiotensin System.** Hypertension 2020; Kintscher U, Slagman A, Domenig O ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32851897
4. **Predictive factors for cardiac conduction abnormalities with hydroxychloroquine-containing combinations for COVID-19.** Int J Antimicrob Agents 2020:106142Padilla S, Telenti G, Guillén L ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32853675
5. **Anticoagulation, Mortality, Bleeding and Pathology Among Patients Hospitalized with COVID-19: A Single Health System Study.** J Am Coll Cardiol 2020; Nadkarni GN, Lala A, Bagiella E ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32860872
6. **What we have to know about corticosteroids use during Sars-Cov-2 infection.** J. Endocrinol. Invest. 2020; Ferraù F, Ceccato F, Cannavò S, Scaroni C. http://www.ncbi.nlm.nih.gov/pubmed/?term=32860209
7. **Systemische Immunsuppression in Zeiten von COVID-19: Müssen wir umdenken?** JDDG - Journal of the German Society of Dermatology 2020; 18:810-814Grabbe S, Beissert S, Enk A.
8. **Hydroxychloroquine and azithromycin tolerance in haemodialysis patients during COVID-19 infection.** Nephrol Dial Transplant 2020; Giaime P, Guenoun M, Pedinielli N ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32844224
9. **COVID-19 and NSAIDs: Primum non nocere.** Therapie 2020; Micallef J, Soeiro T, Jonville-Béra AP. http://www.ncbi.nlm.nih.gov/pubmed/?term=32839015

Vaccines (16 articles)

1. **BCG vaccination in infancy does not protect against COVID-19. Evidence from a natural experiment in Sweden.** Clin Infect Dis 2020; de Chaisemartin C, de Chaisemartin L. http://www.ncbi.nlm.nih.gov/pubmed/?term=32829400
2. **Timelines of COVID-19 vaccines.** Curr Med Res Pract 2020; 10:137-138Chugh T. http://www.ncbi.nlm.nih.gov/pubmed/?term=32839724
3. **COVID-19 vaccines: ethical framework concerning human challenge studies.** Daru 2020; Calina D, Hartung T, Docea AO ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32851596
4. **Vaccination against SARS-CoV-2 and disease enhancement - knowns and unknowns.** Expert Rev Vaccines 2020:1-8Zellweger RM, Wartel TA, Marks F ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32838605
5. **Development of vaccines for SARS-CoV-2.** F1000Res 2020; 9Ng WH, Liu X, Mahalingam S. http://www.ncbi.nlm.nih.gov/pubmed/?term=32850116
6. **Contriving Multi-Epitope Subunit of Vaccine for COVID-19: Immunoinformatics Approaches.** Front. Immunol. 2020; 11:1784Dong R, Chu Z, Yu F, Zha Y. http://www.ncbi.nlm.nih.gov/pubmed/?term=32849643
7. **Combating COVID-19: MVA Vector Vaccines Applied to the Respiratory Tract as Promising Approach Toward Protective Immunity in the Lung.** Front. Immunol. 2020; 11:1959Förster R, Fleige H, Sutter G. http://www.ncbi.nlm.nih.gov/pubmed/?term=32849655
8. **Child Healthcare and Immunizations in Sub-Saharan Africa During the COVID-19 Pandemic.** Front Pediatr 2020; 8:517Buonsenso D, Cinicola B, Kallon MN, Iodice F. http://www.ncbi.nlm.nih.gov/pubmed/?term=32850565
9. **Recent advances in therapeutic modalities and vaccines to counter COVID-19/SARS-CoV-2.** Hum Vaccin Immunother 2020:1-9Bilal M, Iqbal HMN. http://www.ncbi.nlm.nih.gov/pubmed/?term=32845742
10. **Vaccines and routine immunization strategies during the COVID-19 pandemic.** Hum Vaccin Immunother 2020:1-8Dinleyici EC, Borrow R, Safadi MAP ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32845739
11. **Role of antibody-dependent enhancement (ADE) in the virulence of SARS-CoV-2 and its mitigation strategies for the development of vaccines and immunotherapies to counter COVID-19.** Hum Vaccin Immunother 2020:1-6Karthik K, Senthilkumar TMA, Udhayavel S, Raj GD. http://www.ncbi.nlm.nih.gov/pubmed/?term=32845733
12. **The Association between Influenza and Pneumococcal Vaccinations and SARS-Cov-2 Infection: Data from the EPICOVID19 Web-Based Survey.** Vaccines (Basel) 2020; 8Noale M, Trevisan C, Maggi S ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32842505
13. **Current Clinical Trials Protocols and the Global Effort for Immunization against SARS-CoV-2.** Vaccines (Basel) 2020; 8Rego GNA, Nucci MP, Alves AH ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32854391
14. **A Scalable Topical Vectored Vaccine Candidate against SARS-CoV-2.** Vaccines (Basel) 2020; 8Rohaim MA, Munir M. http://www.ncbi.nlm.nih.gov/pubmed/?term=32846910
15. **Is There a Rationale for Using Bacillus Calmette-Guerin Vaccine in Coronavirus Infection?** Viral Immunol 2020; Maheshwari N, Jain A. http://www.ncbi.nlm.nih.gov/pubmed/?term=32857679
16. **Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development.** Virus Res. 2020:198141Samrat SK, Tharappel AM, Li Z,

Li H. http://www.ncbi.nlm.nih.gov/pubmed/?term=32846196

Women – pregnancy (21 articles)

1. **Preparing the Burns Unit to Accommodate Vaginal Delivery and Cesarean Section for Pregnant Women with COVID-19: A Successful Experience from Jordan.** Adv Ther 2020; Altal O, Bani Hani D, Aleshawi A ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32852673
2. **Expression of SARS-CoV-2 cell entry genes, ACE2 and TMPRSS2, in the placenta across gestation and at the maternal-fetal interface in pregnancies complicated by preterm birth or preeclampsia.** Am J Obstet Gynecol 2020; Bloise E, Zhang J, Nakpu J ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32853537
3. **Transmission of SARS-CoV-2 through breast milk and breastfeeding: a living systematic review.** Ann. N. Y. Acad. Sci. 2020; Centeno-Tablante E, Medina-Rivera M, Finkelstein JL ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32860259
4. **Patients With COVID-19 Undergoing Cesarean Deliveries: Adapting the OR Suite and Perioperative Care to Prevent Transmission.** AORN J. 2020; 112:217-224Zou K, Chen H, Liu Y. http://www.ncbi.nlm.nih.gov/pubmed/?term=32857402
5. **Rapid establishment of a COVID-19 perinatal biorepository: early lessons from the first 100 women enrolled.** BMC Med. Res. Methodol. 2020; 20:215Shook LL, Shui JE, Boatin AA ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32842979
6. **Intraoperative coagulopathy during cesarean section as an unsuspected initial presentation of COVID-19: a case report.** BMC Pregnancy Childbirth 2020; 20:481Kinsey KE, Ganz E, Khalil S, Brustman L. http://www.ncbi.nlm.nih.gov/pubmed/?term=32838744
7. **Potential Effect of COVID-19 on Maternal and Infant Outcome: Lesson From SARS.** Front Pediatr 2020; 8:511Wang Y, Wang Y, Han X ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32850564
8. **Effect of delayed obstetric labor care during the COVID-19 pandemic on perinatal outcomes.** Int J Gynaecol Obstet 2020; Sun SY, Guazzelli CAF, de Morais LR ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32860437
9. **A Case Report of Newborn Infant with Severe COVID-19 in Mexico: Detection of SARS-CoV-2 in Human Breast Milk and Stool.** Int J Infect Dis 2020; Hinojosa-Velasco A, de Oca PVB, García-Sosa LE ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32860950
10. **No intrauterine vertical transmission in pregnancy with COVID-19: A case report.** J Infect Chemother 2020; Lv Y, Gu B, Chen Y ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32859496
11. **Clinical features of neonates born to mothers with coronavirus disease-2019: A systematic review of 105 neonates.** J Microbiol Immunol Infect 2020; Chi H, Chiu NC, Tai YL ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32847748
12. **Psychometric properties of the Pandemic-Related Pregnancy Stress Scale (PREPS).** J. Psychosom. Obstet. Gynaecol. 2020; 41:191-197Preis H, Mahaffey B, Lobel M. http://www.ncbi.nlm.nih.gov/pubmed/?term=32838629
13. **Beliefs related to sexual intimacy, pregnancy and breastfeeding in the public during COVID-19 era: a web-based survey from India.** J. Psychosom. Obstet. Gynaecol. 2020:1-8Sahoo S, Pattnaik JI, Mehra A ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32851889

14. **COVID-19 Coagulopathy in Pregnancy: Critical Review, Preliminary Recommendations and ISTH Registry - Communication from the ISTH SSC for Women's Health.** J Thromb Haemost 2020; Kadir RA, Kobayashi T, Iba T ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32846051
15. **Clinical Features and Outcome of SARS-CoV-2 Infection in Neonates: A Systematic Review.** J. Trop. Pediatr. 2020; Dhir SK, Kumar J, Meena J, Kumar P. http://www.ncbi.nlm.nih.gov/pubmed/?term=32856065
16. **Fetal Surgery in the era of SARS-CoV-2 pandemic: A single institution review.** Mayo Clin Proc Innov Qual Outcomes 2020; Narang K, Elrefaei A, Wyatt MA ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32839753
17. **Lessons from past epidemics and pandemics and a way forward for pregnant women, midwives and nurses during COVID-19 and beyond: A meta-synthesis.** Midwifery 2020; 90:102821Shorey S, Chan V. http://www.ncbi.nlm.nih.gov/pubmed/?term=32847770
18. **Single-cell RNA expression profiling of ACE2 and TMPRSS2 in the human trophectoderm and placenta.** Ultrasound Obstet Gynecol 2020; Cui D, Liu Y, Jiang X ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32851697
19. **COVID-19 during pregnancy: non-reassuring fetal heart rate, placental pathology and coagulopathy.** Ultrasound Obstet Gynecol 2020; Mongula JE, Frenken MWE, van Lijnschoten G ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32853442
20. **Neonates With Complex Cardiac Malformation and Congenital Diaphragmatic Hernia Born to SARS-CoV-2 Positive Women-A Single Center Experience.** World J Pediatr Congenit Heart Surg 2020:2150135120950256Goldshtrom N, Vargas D, Vasquez A ***et al.*** http://www.ncbi.nlm.nih.gov/pubmed/?term=32851931
21. **Convalescent plasma therapy in a pregnant COVID-19 patient with a dramatic clinical and imaging response: A case report.** World J Radiol 2020; 12:137-141Jafari R, Jonaidi-Jafari N, Dehghanpoor F, Saburi A. http://www.ncbi.nlm.nih.gov/pubmed/?term=32850016
